<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=us-ascii">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>Adcetris, INN-brentuximab vedotin</title>
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Helvetica;
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Courier;
	panose-1:2 7 4 9 2 2 5 2 4 4;}
@font-face
	{font-family:"Tms Rmn";
	panose-1:2 2 6 3 4 5 5 2 3 4;}
@font-face
	{font-family:Helv;
	panose-1:2 11 6 4 2 2 2 3 2 4;}
@font-face
	{font-family:"New York";
	panose-1:2 4 5 3 6 5 6 2 3 4;}
@font-face
	{font-family:System;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:Batang;
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:PMingLiU;
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:Dotum;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimHei;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:MingLiU;
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:Mincho;
	panose-1:2 2 6 9 4 3 5 8 3 5;}
@font-face
	{font-family:Gulim;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:Century;
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:"Angsana New";
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"Cordia New";
	panose-1:2 11 3 4 2 2 2 2 2 4;}
@font-face
	{font-family:Mangal;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Latha;
	panose-1:2 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sylfaen;
	panose-1:1 10 5 2 5 3 6 3 3 3;}
@font-face
	{font-family:Vrinda;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Raavi;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Shruti;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sendnya;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Gautami;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Tunga;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Estrangelo Edessa";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:DengXian;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Calibri Light";
	panose-1:2 15 3 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Palatino Linotype";
	panose-1:2 4 5 2 5 5 5 3 3 4;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Segoe UI Emoji";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Cambria;
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Segoe UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Segoe UI Symbol";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:BISansCond;}
@font-face
	{font-family:Marlett;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Black";
	panose-1:2 11 10 4 2 1 2 2 2 4;}
@font-face
	{font-family:"Bahnschrift Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Bahnschrift;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight SemiConde";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold SemiConden";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Candara;
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Candara Light";
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Comic Sans MS";
	panose-1:3 15 7 2 3 3 2 2 2 4;}
@font-face
	{font-family:Consolas;
	panose-1:2 11 6 9 2 2 4 3 2 4;}
@font-face
	{font-family:Constantia;
	panose-1:2 3 6 2 5 3 6 3 3 3;}
@font-face
	{font-family:Corbel;
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"Corbel Light";
	panose-1:2 11 3 3 2 2 4 2 2 4;}
@font-face
	{font-family:Ebrima;
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Franklin Gothic Medium";
	panose-1:2 11 6 3 2 1 2 2 2 4;}
@font-face
	{font-family:Gabriola;
	panose-1:4 4 6 5 5 16 2 2 13 2;}
@font-face
	{font-family:Gadugi;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Georgia;
	panose-1:2 4 5 2 5 4 5 2 3 3;}
@font-face
	{font-family:Impact;
	panose-1:2 11 8 6 3 9 2 5 2 4;}
@font-face
	{font-family:"Ink Free";
	panose-1:3 8 4 2 0 5 0 0 0 0;}
@font-face
	{font-family:"Javanese Text";
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Leelawadee UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Leelawadee UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Lucida Console";
	panose-1:2 11 6 9 4 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Unicode";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Malgun Gothic";
	panose-1:2 11 5 3 2 0 0 2 0 4;}
@font-face
	{font-family:"\@Malgun Gothic";}
@font-face
	{font-family:"Malgun Gothic Semilight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Malgun Gothic Semilight";}
@font-face
	{font-family:"Microsoft Himalaya";
	panose-1:1 1 1 0 1 1 1 1 1 1;}
@font-face
	{font-family:"Microsoft JhengHei";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei";}
@font-face
	{font-family:"Microsoft JhengHei UI";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI";}
@font-face
	{font-family:"Microsoft JhengHei Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei Light";}
@font-face
	{font-family:"Microsoft JhengHei UI Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI Light";}
@font-face
	{font-family:"Microsoft New Tai Lue";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft PhagsPa";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft Sans Serif";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Microsoft Tai Le";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft YaHei";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei";}
@font-face
	{font-family:"Microsoft YaHei UI";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei UI";}
@font-face
	{font-family:"Microsoft YaHei Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei Light";}
@font-face
	{font-family:"Microsoft YaHei UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei UI Light";}
@font-face
	{font-family:"Microsoft Yi Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:MingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU-ExtB";}
@font-face
	{font-family:PMingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@PMingLiU-ExtB";}
@font-face
	{font-family:MingLiU_HKSCS-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU_HKSCS-ExtB";}
@font-face
	{font-family:"Mongolian Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:"MS UI Gothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS UI Gothic";}
@font-face
	{font-family:"MS PGothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS PGothic";}
@font-face
	{font-family:"MV Boli";
	panose-1:2 0 5 0 3 2 0 9 0 0;}
@font-face
	{font-family:"Myanmar Text";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Segoe Print";
	panose-1:2 0 6 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Segoe Script";
	panose-1:3 11 5 4 2 0 0 0 0 3;}
@font-face
	{font-family:"Segoe UI Black";
	panose-1:2 11 10 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Historic";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semibold";
	panose-1:2 11 7 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@SimSun";
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:NSimSun;
	panose-1:2 1 6 9 3 1 1 1 1 1;}
@font-face
	{font-family:"\@NSimSun";}
@font-face
	{font-family:SimSun-ExtB;
	panose-1:2 1 6 9 6 1 1 1 1 1;}
@font-face
	{font-family:"\@SimSun-ExtB";}
@font-face
	{font-family:"Sitka Small";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Text";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Subheading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Heading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Display";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Banner";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Trebuchet MS";
	panose-1:2 11 6 3 2 2 2 2 2 4;}
@font-face
	{font-family:Webdings;
	panose-1:5 3 1 2 1 5 9 6 7 3;}
@font-face
	{font-family:"\@Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Yu Gothic UI";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI";}
@font-face
	{font-family:"Yu Gothic UI Semibold";
	panose-1:2 11 7 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semibold";}
@font-face
	{font-family:"Yu Gothic Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Light";}
@font-face
	{font-family:"Yu Gothic UI Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Light";}
@font-face
	{font-family:"Yu Gothic Medium";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Medium";}
@font-face
	{font-family:"Yu Gothic UI Semilight";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semilight";}
@font-face
	{font-family:"HoloLens MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Agency FB";
	panose-1:2 11 5 3 2 2 2 2 2 4;}
@font-face
	{font-family:Algerian;
	panose-1:4 2 7 5 4 10 2 6 7 2;}
@font-face
	{font-family:"Book Antiqua";
	panose-1:2 4 6 2 5 3 5 3 3 4;}
@font-face
	{font-family:"Arial Narrow";
	panose-1:2 11 6 6 2 2 2 3 2 4;}
@font-face
	{font-family:"Arial Rounded MT Bold";
	panose-1:2 15 7 4 3 5 4 3 2 4;}
@font-face
	{font-family:"Baskerville Old Face";
	panose-1:2 2 6 2 8 5 5 2 3 3;}
@font-face
	{font-family:"Bauhaus 93";
	panose-1:4 3 9 5 2 11 2 2 12 2;}
@font-face
	{font-family:"Bell MT";
	panose-1:2 2 5 3 6 3 5 2 3 3;}
@font-face
	{font-family:"Bernard MT Condensed";
	panose-1:2 5 8 6 6 9 5 2 4 4;}
@font-face
	{font-family:"Bodoni MT";
	panose-1:2 7 6 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Black";
	panose-1:2 7 10 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Condensed";
	panose-1:2 7 6 6 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Poster Compressed";
	panose-1:2 7 7 6 8 6 1 5 2 4;}
@font-face
	{font-family:"Bookman Old Style";
	panose-1:2 5 6 4 5 5 5 2 2 4;}
@font-face
	{font-family:"Bradley Hand ITC";
	panose-1:3 7 4 2 5 3 2 3 2 3;}
@font-face
	{font-family:"Britannic Bold";
	panose-1:2 11 9 3 6 7 3 2 2 4;}
@font-face
	{font-family:"Berlin Sans FB";
	panose-1:2 14 6 2 2 5 2 2 3 6;}
@font-face
	{font-family:"Berlin Sans FB Demi";
	panose-1:2 14 8 2 2 5 2 2 3 6;}
@font-face
	{font-family:Broadway;
	panose-1:4 4 9 5 8 11 2 2 5 2;}
@font-face
	{font-family:"Brush Script MT";
	panose-1:3 6 8 2 4 4 6 7 3 4;}
@font-face
	{font-family:"Bookshelf Symbol 7";
	panose-1:5 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Californian FB";
	panose-1:2 7 4 3 6 8 11 3 2 4;}
@font-face
	{font-family:"Calisto MT";
	panose-1:2 4 6 3 5 5 5 3 3 4;}
@font-face
	{font-family:Castellar;
	panose-1:2 10 4 2 6 4 6 1 3 1;}
@font-face
	{font-family:"Century Schoolbook";
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:Centaur;
	panose-1:2 3 5 4 5 2 5 2 3 4;}
@font-face
	{font-family:Chiller;
	panose-1:4 2 4 4 3 16 7 2 6 2;}
@font-face
	{font-family:"Colonna MT";
	panose-1:4 2 8 5 6 2 2 3 2 3;}
@font-face
	{font-family:"Cooper Black";
	panose-1:2 8 9 4 4 3 11 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Bold";
	panose-1:2 14 7 5 2 2 6 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Light";
	panose-1:2 14 5 7 2 2 6 2 4 4;}
@font-face
	{font-family:"Curlz MT";
	panose-1:4 4 4 4 5 7 2 2 2 2;}
@font-face
	{font-family:Dubai;
	panose-1:2 11 5 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Light";
	panose-1:2 11 3 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Medium";
	panose-1:2 11 6 3 3 4 3 3 2 4;}
@font-face
	{font-family:Elephant;
	panose-1:2 2 9 4 9 5 5 2 3 3;}
@font-face
	{font-family:"Engravers MT";
	panose-1:2 9 7 7 8 5 5 2 3 4;}
@font-face
	{font-family:"Eras Bold ITC";
	panose-1:2 11 9 7 3 5 4 2 2 4;}
@font-face
	{font-family:"Eras Demi ITC";
	panose-1:2 11 8 5 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Light ITC";
	panose-1:2 11 4 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Medium ITC";
	panose-1:2 11 6 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Felix Titling";
	panose-1:4 6 5 5 6 2 2 2 10 4;}
@font-face
	{font-family:Forte;
	panose-1:3 6 9 2 4 5 2 7 2 3;}
@font-face
	{font-family:"Franklin Gothic Book";
	panose-1:2 11 5 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi";
	panose-1:2 11 7 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi Cond";
	panose-1:2 11 7 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Heavy";
	panose-1:2 11 9 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Medium Cond";
	panose-1:2 11 6 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Freestyle Script";
	panose-1:3 8 4 2 3 2 5 11 4 4;}
@font-face
	{font-family:"French Script MT";
	panose-1:3 2 4 2 4 6 7 4 6 5;}
@font-face
	{font-family:"Footlight MT Light";
	panose-1:2 4 6 2 6 3 10 2 3 4;}
@font-face
	{font-family:Garamond;
	panose-1:2 2 4 4 3 3 1 1 8 3;}
@font-face
	{font-family:Gigi;
	panose-1:4 4 5 4 6 16 7 2 13 2;}
@font-face
	{font-family:"Gill Sans MT";
	panose-1:2 11 5 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans MT Condensed";
	panose-1:2 11 5 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold Condensed";
	panose-1:2 11 10 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold";
	panose-1:2 11 10 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gloucester MT Extra Condensed";
	panose-1:2 3 8 8 2 6 1 1 1 1;}
@font-face
	{font-family:"Gill Sans MT Ext Condensed Bold";
	panose-1:2 11 9 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Century Gothic";
	panose-1:2 11 5 2 2 2 2 2 2 4;}
@font-face
	{font-family:"Goudy Old Style";
	panose-1:2 2 5 2 5 3 5 2 3 3;}
@font-face
	{font-family:"Goudy Stout";
	panose-1:2 2 9 4 7 3 11 2 4 1;}
@font-face
	{font-family:"Harlow Solid Italic";
	panose-1:4 3 6 4 2 15 2 2 13 2;}
@font-face
	{font-family:Harrington;
	panose-1:4 4 5 5 5 10 2 2 7 2;}
@font-face
	{font-family:Haettenschweiler;
	panose-1:2 11 7 6 4 9 2 6 2 4;}
@font-face
	{font-family:"High Tower Text";
	panose-1:2 4 5 2 5 5 6 3 3 3;}
@font-face
	{font-family:"Imprint MT Shadow";
	panose-1:4 2 6 5 6 3 3 3 2 2;}
@font-face
	{font-family:"Informal Roman";
	panose-1:3 6 4 2 3 4 6 11 2 4;}
@font-face
	{font-family:"Blackadder ITC";
	panose-1:4 2 5 5 5 16 7 2 13 2;}
@font-face
	{font-family:"Edwardian Script ITC";
	panose-1:3 3 3 2 4 7 7 13 8 4;}
@font-face
	{font-family:"Kristen ITC";
	panose-1:3 5 5 2 4 2 2 3 2 2;}
@font-face
	{font-family:Jokerman;
	panose-1:4 9 6 5 6 13 6 2 7 2;}
@font-face
	{font-family:"Juice ITC";
	panose-1:4 4 4 3 4 10 2 2 2 2;}
@font-face
	{font-family:"Kunstler Script";
	panose-1:3 3 4 2 2 6 7 13 13 6;}
@font-face
	{font-family:"Wide Latin";
	panose-1:2 10 10 7 5 5 5 2 4 4;}
@font-face
	{font-family:"Lucida Bright";
	panose-1:2 4 6 2 5 5 5 2 3 4;}
@font-face
	{font-family:"Lucida Calligraphy";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Fax";
	panose-1:2 6 6 2 5 5 5 2 2 4;}
@font-face
	{font-family:"Lucida Handwriting";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Sans";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Typewriter";
	panose-1:2 11 5 9 3 5 4 3 2 4;}
@font-face
	{font-family:Magneto;
	panose-1:4 3 8 5 5 8 2 2 13 2;}
@font-face
	{font-family:"Maiandra GD";
	panose-1:2 14 5 2 3 3 8 2 2 4;}
@font-face
	{font-family:"Matura MT Script Capitals";
	panose-1:3 2 8 2 6 6 2 7 2 2;}
@font-face
	{font-family:Mistral;
	panose-1:3 9 7 2 3 4 7 2 4 3;}
@font-face
	{font-family:"Modern No\. 20";
	panose-1:2 7 7 4 7 5 5 2 3 3;}
@font-face
	{font-family:"Monotype Corsiva";
	panose-1:3 1 1 1 1 2 1 1 1 1;}
@font-face
	{font-family:"Niagara Engraved";
	panose-1:4 2 5 2 7 7 3 3 2 2;}
@font-face
	{font-family:"Niagara Solid";
	panose-1:4 2 5 2 7 7 2 2 2 2;}
@font-face
	{font-family:"OCR A Extended";
	panose-1:2 1 5 9 2 1 2 1 3 3;}
@font-face
	{font-family:"Old English Text MT";
	panose-1:3 4 9 2 4 5 8 3 8 6;}
@font-face
	{font-family:Onyx;
	panose-1:4 5 6 2 8 7 2 2 2 3;}
@font-face
	{font-family:"MS Outlook";
	panose-1:5 1 1 0 1 0 0 0 0 0;}
@font-face
	{font-family:"Palace Script MT";
	panose-1:3 3 3 2 2 6 7 12 11 5;}
@font-face
	{font-family:Papyrus;
	panose-1:3 7 5 2 6 5 2 3 2 5;}
@font-face
	{font-family:Parchment;
	panose-1:3 4 6 2 4 7 8 4 8 4;}
@font-face
	{font-family:Perpetua;
	panose-1:2 2 5 2 6 4 1 2 3 3;}
@font-face
	{font-family:"Perpetua Titling MT";
	panose-1:2 2 5 2 6 5 5 2 8 4;}
@font-face
	{font-family:Playbill;
	panose-1:4 5 6 3 10 6 2 2 2 2;}
@font-face
	{font-family:"Poor Richard";
	panose-1:2 8 5 2 5 5 5 2 7 2;}
@font-face
	{font-family:Pristina;
	panose-1:3 6 4 2 4 4 6 8 2 4;}
@font-face
	{font-family:"Rage Italic";
	panose-1:3 7 5 2 4 5 7 7 3 4;}
@font-face
	{font-family:Ravie;
	panose-1:4 4 8 5 5 8 9 2 6 2;}
@font-face
	{font-family:"MS Reference Sans Serif";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"MS Reference Specialty";
	panose-1:5 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Rockwell Condensed";
	panose-1:2 6 6 3 5 4 5 2 1 4;}
@font-face
	{font-family:Rockwell;
	panose-1:2 6 6 3 2 2 5 2 4 3;}
@font-face
	{font-family:"Rockwell Extra Bold";
	panose-1:2 6 9 3 4 5 5 2 4 3;}
@font-face
	{font-family:"Script MT Bold";
	panose-1:3 4 6 2 4 6 7 8 9 4;}
@font-face
	{font-family:"Showcard Gothic";
	panose-1:4 2 9 4 2 1 2 2 6 4;}
@font-face
	{font-family:"Snap ITC";
	panose-1:4 4 10 7 6 10 2 2 2 2;}
@font-face
	{font-family:Stencil;
	panose-1:4 4 9 5 13 8 2 2 4 4;}
@font-face
	{font-family:"Tw Cen MT";
	panose-1:2 11 6 2 2 1 4 2 6 3;}
@font-face
	{font-family:"Tw Cen MT Condensed";
	panose-1:2 11 6 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Tw Cen MT Condensed Extra Bold";
	panose-1:2 11 8 3 2 2 2 2 2 4;}
@font-face
	{font-family:"Tempus Sans ITC";
	panose-1:4 2 4 4 3 13 7 2 2 2;}
@font-face
	{font-family:"Viner Hand ITC";
	panose-1:3 7 5 2 3 5 2 2 2 3;}
@font-face
	{font-family:Vivaldi;
	panose-1:3 2 6 2 5 5 6 9 8 4;}
@font-face
	{font-family:"Vladimir Script";
	panose-1:3 5 4 2 4 4 7 7 3 5;}
@font-face
	{font-family:"Wingdings 2";
	panose-1:5 2 1 2 1 5 7 7 7 7;}
@font-face
	{font-family:"Wingdings 3";
	panose-1:5 4 1 2 1 8 7 7 7 7;}
@font-face
	{font-family:AngsanaUPC;}
@font-face
	{font-family:CordiaUPC;}
@font-face
	{font-family:Abadi;}
@font-face
	{font-family:"Abadi Extra Light";}
@font-face
	{font-family:Aharoni;}
@font-face
	{font-family:Aldhabi;}
@font-face
	{font-family:Aparajita;}
@font-face
	{font-family:"Arabic Typesetting";}
@font-face
	{font-family:"Arial Nova";}
@font-face
	{font-family:"Arial Nova Cond";}
@font-face
	{font-family:"Arial Nova Cond Light";}
@font-face
	{font-family:"Arial Nova Light";}
@font-face
	{font-family:"Avenir Next LT Pro";}
@font-face
	{font-family:"Avenir Next LT Pro Light";}
@font-face
	{font-family:BatangChe;}
@font-face
	{font-family:Bembo;}
@font-face
	{font-family:Biome;}
@font-face
	{font-family:"Biome Light";}
@font-face
	{font-family:"Browallia New";}
@font-face
	{font-family:BrowalliaUPC;}
@font-face
	{font-family:Cavolini;}
@font-face
	{font-family:Dante;}
@font-face
	{font-family:DaunPenh;}
@font-face
	{font-family:David;}
@font-face
	{font-family:Daytona;}
@font-face
	{font-family:"Daytona Condensed";}
@font-face
	{font-family:"Daytona Condensed Light";}
@font-face
	{font-family:"Daytona Light";}
@font-face
	{font-family:"DengXian Light";}
@font-face
	{font-family:DilleniaUPC;}
@font-face
	{font-family:DokChampa;}
@font-face
	{font-family:DotumChe;}
@font-face
	{font-family:"Elephant Pro";}
@font-face
	{font-family:EucrosiaUPC;}
@font-face
	{font-family:Euphemia;}
@font-face
	{font-family:FangSong;}
@font-face
	{font-family:FrankRuehl;}
@font-face
	{font-family:FreesiaUPC;}
@font-face
	{font-family:"Georgia Pro";}
@font-face
	{font-family:"Georgia Pro Black";}
@font-face
	{font-family:"Georgia Pro Cond";}
@font-face
	{font-family:"Georgia Pro Cond Black";}
@font-face
	{font-family:"Georgia Pro Cond Light";}
@font-face
	{font-family:"Georgia Pro Cond Semibold";}
@font-face
	{font-family:"Georgia Pro Light";}
@font-face
	{font-family:"Georgia Pro Semibold";}
@font-face
	{font-family:"Gill Sans Nova";}
@font-face
	{font-family:"Gill Sans Nova Cond";}
@font-face
	{font-family:"Gill Sans Nova Cond Lt";}
@font-face
	{font-family:"Gill Sans Nova Cond Ultra Bold";}
@font-face
	{font-family:"Gill Sans Nova Cond XBd";}
@font-face
	{font-family:"Gill Sans Nova Light";}
@font-face
	{font-family:"Gill Sans Nova Ultra Bold";}
@font-face
	{font-family:Gisha;}
@font-face
	{font-family:Grotesque;}
@font-face
	{font-family:"Grotesque Light";}
@font-face
	{font-family:GulimChe;}
@font-face
	{font-family:Gungsuh;}
@font-face
	{font-family:GungsuhChe;}
@font-face
	{font-family:"Hadassah Friedlaender";}
@font-face
	{font-family:HGGothicE;}
@font-face
	{font-family:HGMaruGothicMPRO;}
@font-face
	{font-family:HGMinchoE;}
@font-face
	{font-family:HGPGothicE;}
@font-face
	{font-family:HGPMinchoE;}
@font-face
	{font-family:HGPSoeiKakugothicUB;}
@font-face
	{font-family:HGSGothicE;}
@font-face
	{font-family:HGSMinchoE;}
@font-face
	{font-family:HGSoeiKakugothicUB;}
@font-face
	{font-family:HGSSoeiKakugothicUB;}
@font-face
	{font-family:IrisUPC;}
@font-face
	{font-family:"Iskoola Pota";}
@font-face
	{font-family:JasmineUPC;}
@font-face
	{font-family:KaiTi;}
@font-face
	{font-family:Kalinga;}
@font-face
	{font-family:Kartika;}
@font-face
	{font-family:"Khmer UI";}
@font-face
	{font-family:Kigelia;}
@font-face
	{font-family:"Kigelia Arabic";}
@font-face
	{font-family:"Kigelia Arabic Light";}
@font-face
	{font-family:"Kigelia Light";}
@font-face
	{font-family:KodchiangUPC;}
@font-face
	{font-family:Kokila;}
@font-face
	{font-family:"Lao UI";}
@font-face
	{font-family:Leelawadee;}
@font-face
	{font-family:"Levenim MT";}
@font-face
	{font-family:LilyUPC;}
@font-face
	{font-family:"Mangal Pro";}
@font-face
	{font-family:Meiryo;}
@font-face
	{font-family:"Meiryo UI";}
@font-face
	{font-family:"Microsoft GothicNeo";}
@font-face
	{font-family:"Microsoft GothicNeo Light";}
@font-face
	{font-family:"Microsoft Uighur";}
@font-face
	{font-family:MingLiU_HKSCS;}
@font-face
	{font-family:Miriam;}
@font-face
	{font-family:"Miriam Fixed";}
@font-face
	{font-family:"Modern Love";}
@font-face
	{font-family:"Modern Love Caps";}
@font-face
	{font-family:"Modern Love Grunge";}
@font-face
	{font-family:MoolBoran;}
@font-face
	{font-family:"MS PMincho";}
@font-face
	{font-family:"MT Extra";}
@font-face
	{font-family:Narkisim;}
@font-face
	{font-family:"Neue Haas Grotesk Text Pro";}
@font-face
	{font-family:"News Gothic MT";}
@font-face
	{font-family:Nyala;}
@font-face
	{font-family:OCRB;}
@font-face
	{font-family:"Plantagenet Cherokee";}
@font-face
	{font-family:Posterama;}
@font-face
	{font-family:"Quire Sans";}
@font-face
	{font-family:"Quire Sans Light";}
@font-face
	{font-family:"Quire Sans Pro Light";}
@font-face
	{font-family:"Rockwell Light";}
@font-face
	{font-family:"Rockwell Nova";}
@font-face
	{font-family:"Rockwell Nova Cond";}
@font-face
	{font-family:"Rockwell Nova Cond Light";}
@font-face
	{font-family:"Rockwell Nova Extra Bold";}
@font-face
	{font-family:"Rockwell Nova Light";}
@font-face
	{font-family:Rod;}
@font-face
	{font-family:"Sabon Next LT";}
@font-face
	{font-family:"Sagona Book";}
@font-face
	{font-family:"Sagona ExtraLight";}
@font-face
	{font-family:"Sakkal Majalla";}
@font-face
	{font-family:"Sanskrit Text";}
@font-face
	{font-family:Selawik;}
@font-face
	{font-family:"Selawik Light";}
@font-face
	{font-family:"Selawik Semibold";}
@font-face
	{font-family:"Shonar Bangla";}
@font-face
	{font-family:"Simplified Arabic";}
@font-face
	{font-family:"Simplified Arabic Fixed";}
@font-face
	{font-family:"Sitka Banner Semibold";}
@font-face
	{font-family:"Sitka Display Semibold";}
@font-face
	{font-family:"Sitka Heading Semibold";}
@font-face
	{font-family:"Sitka Small Semibold";}
@font-face
	{font-family:"Sitka Subheading Semibold";}
@font-face
	{font-family:"Sitka Text Semibold";}
@font-face
	{font-family:"Source Sans Pro";}
@font-face
	{font-family:"Source Sans Pro Black";}
@font-face
	{font-family:"Source Sans Pro ExtraLight";}
@font-face
	{font-family:"Source Sans Pro Light";}
@font-face
	{font-family:"Source Sans Pro SemiBold";}
@font-face
	{font-family:"Speak Pro";}
@font-face
	{font-family:"Speak Pro Light";}
@font-face
	{font-family:STCaiyun;}
@font-face
	{font-family:STFangsong;}
@font-face
	{font-family:STHupo;}
@font-face
	{font-family:STKaiti;}
@font-face
	{font-family:STXihei;}
@font-face
	{font-family:STXingkai;}
@font-face
	{font-family:STXinwei;}
@font-face
	{font-family:STZhongsong;}
@font-face
	{font-family:"TH SarabunPSK";}
@font-face
	{font-family:"The Hand";}
@font-face
	{font-family:"The Hand Black";}
@font-face
	{font-family:"The Hand Extrablack";}
@font-face
	{font-family:"The Hand Light";}
@font-face
	{font-family:"The Serif Hand";}
@font-face
	{font-family:"The Serif Hand Black";}
@font-face
	{font-family:"The Serif Hand Extrablack";}
@font-face
	{font-family:"The Serif Hand Light";}
@font-face
	{font-family:"Tisa Offc Serif Pro";}
@font-face
	{font-family:"Tisa Offc Serif Pro Thin";}
@font-face
	{font-family:"Trade Gothic Next";}
@font-face
	{font-family:"Trade Gothic Next Cond";}
@font-face
	{font-family:"Trade Gothic Next Cond Hv";}
@font-face
	{font-family:"Trade Gothic Next Heavy";}
@font-face
	{font-family:"Trade Gothic Next Light";}
@font-face
	{font-family:"Traditional Arabic";}
@font-face
	{font-family:"UD Digi Kyokasho N-B";}
@font-face
	{font-family:"UD Digi Kyokasho N-R";}
@font-face
	{font-family:"UD Digi Kyokasho NK-B";}
@font-face
	{font-family:"UD Digi Kyokasho NK-R";}
@font-face
	{font-family:"UD Digi Kyokasho NP-B";}
@font-face
	{font-family:"UD Digi Kyokasho NP-R";}
@font-face
	{font-family:Univers;}
@font-face
	{font-family:"Univers Condensed";}
@font-face
	{font-family:"Univers Condensed Light";}
@font-face
	{font-family:"Univers Light";}
@font-face
	{font-family:"Urdu Typesetting";}
@font-face
	{font-family:Utsaah;}
@font-face
	{font-family:Vani;}
@font-face
	{font-family:"Verdana Pro";}
@font-face
	{font-family:"Verdana Pro Black";}
@font-face
	{font-family:"Verdana Pro Cond";}
@font-face
	{font-family:"Verdana Pro Cond Black";}
@font-face
	{font-family:"Verdana Pro Cond Light";}
@font-face
	{font-family:"Verdana Pro Cond SemiBold";}
@font-face
	{font-family:"Verdana Pro Light";}
@font-face
	{font-family:"Verdana Pro SemiBold";}
@font-face
	{font-family:Vijaya;}
@font-face
	{font-family:"Walbaum Display";}
@font-face
	{font-family:"Walbaum Display Heavy";}
@font-face
	{font-family:"Walbaum Display Light";}
@font-face
	{font-family:"Walbaum Display SemiBold";}
@font-face
	{font-family:"Walbaum Heading";}
@font-face
	{font-family:"Walbaum Text";}
@font-face
	{font-family:"Yu Mincho";}
@font-face
	{font-family:"Yu Mincho Demibold";}
@font-face
	{font-family:"Yu Mincho Light";}
@font-face
	{font-family:"TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRomanPSMT;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Times New Roman Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:PraxisCom-Regular;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:EUAlbertina;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Times;
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"\@TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Arial\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:"\@Batang";
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@BatangChe";}
@font-face
	{font-family:"\@Gungsuh";}
@font-face
	{font-family:"\@GungsuhChe";}
@font-face
	{font-family:"\@DengXian Light";}
@font-face
	{font-family:"\@Gulim";
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@GulimChe";}
@font-face
	{font-family:"\@Dotum";
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@DotumChe";}
@font-face
	{font-family:"\@Meiryo";}
@font-face
	{font-family:"\@Meiryo UI";}
@font-face
	{font-family:"\@MingLiU";
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:"\@PMingLiU";
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"\@MingLiU_HKSCS";}
@font-face
	{font-family:"\@MS PMincho";}
@font-face
	{font-family:"\@STXingkai";}
@font-face
	{font-family:"\@STZhongsong";}
@font-face
	{font-family:"\@Yu Mincho";}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
h1
	{mso-style-link:"Heading 1 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-align:center;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;
	text-transform:uppercase;
	font-weight:bold;}
h2
	{mso-style-link:"Heading 2 Char";
	margin:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman Bold",serif;
	color:windowtext;
	text-transform:uppercase;
	font-weight:bold;}
h3
	{mso-style-link:"Heading 3 Char";
	margin:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;
	font-weight:bold;}
h4
	{mso-style-link:"Heading 4 Char";
	margin:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;
	font-weight:normal;
	text-decoration:underline;}
h5
	{mso-style-link:"Heading 5 Char";
	margin:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;
	font-weight:normal;
	font-style:italic;}
h6
	{mso-style-link:"Heading 6 Char";
	margin-top:0in;
	margin-right:17.85pt;
	margin-bottom:0in;
	margin-left:0in;
	text-align:center;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;
	font-weight:bold;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{mso-style-link:"Heading 7 Char";
	margin-top:0in;
	margin-right:17.65pt;
	margin-bottom:0in;
	margin-left:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;
	font-weight:bold;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{mso-style-link:"Heading 8 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-28.35pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Calibri",sans-serif;
	color:windowtext;
	font-style:italic;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{mso-style-link:"Heading 9 Char";
	margin:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Cambria",serif;
	color:windowtext;}
p.MsoIndex1, li.MsoIndex1, div.MsoIndex1
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoIndex2, li.MsoIndex2, div.MsoIndex2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:22.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoIndex3, li.MsoIndex3, div.MsoIndex3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:33.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoIndex4, li.MsoIndex4, div.MsoIndex4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:44.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoIndex5, li.MsoIndex5, div.MsoIndex5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:55.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoIndex6, li.MsoIndex6, div.MsoIndex6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:66.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoIndex7, li.MsoIndex7, div.MsoIndex7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:77.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoIndex8, li.MsoIndex8, div.MsoIndex8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:88.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoIndex9, li.MsoIndex9, div.MsoIndex9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:99.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoToc1, li.MsoToc1, div.MsoToc1
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoToc2, li.MsoToc2, div.MsoToc2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoToc3, li.MsoToc3, div.MsoToc3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:22.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoToc4, li.MsoToc4, div.MsoToc4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:33.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoToc5, li.MsoToc5, div.MsoToc5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:44.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoToc6, li.MsoToc6, div.MsoToc6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:55.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoToc7, li.MsoToc7, div.MsoToc7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:66.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoToc8, li.MsoToc8, div.MsoToc8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:77.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoToc9, li.MsoToc9, div.MsoToc9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:88.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoNormalIndent, li.MsoNormalIndent, div.MsoNormalIndent
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoFootnoteText, li.MsoFootnoteText, div.MsoFootnoteText
	{mso-style-link:"Footnote Text Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-name:"Comment Text\, Car17\, Char Char Char\, Char Char1\,Annotationtext\,Char\,Char Char Char\,Comment Text Char Char\,Comment Text Char Char Char Char\,Comment Text Char Char1 Char\,Comment Text Char1\,Comment Text Char1 Char Char\,Comment Text Char2 Ch";
	mso-style-link:"Comment Text Char2\, Car17 Char1\, Char Char Char Char1\, Char Char1 Char1\,Annotationtext Char1\,Char Char Char Char1\,Char Char2\,Comment Text Char Char Char Char Char\,Comment Text Char Char Char1\,Comment Text Char Char1 Char Char\,Comment Text Char1 Char1";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{mso-style-link:"Header Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{mso-style-link:"Footer Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoIndexHeading, li.MsoIndexHeading, div.MsoIndexHeading
	{margin:0in;
	font-size:11.0pt;
	font-family:"Cambria",serif;
	color:black;
	font-weight:bold;}
p.MsoCaption, li.MsoCaption, div.MsoCaption
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:1.0in;
	text-indent:-1.0in;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Arial Bold",serif;
	color:black;
	font-weight:bold;}
p.MsoTof, li.MsoTof, div.MsoTof
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoEnvelopeAddress, li.MsoEnvelopeAddress, div.MsoEnvelopeAddress
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:2.0in;
	font-size:12.0pt;
	font-family:"Cambria",serif;
	color:black;}
p.MsoEnvelopeReturn, li.MsoEnvelopeReturn, div.MsoEnvelopeReturn
	{margin:0in;
	font-size:10.0pt;
	font-family:"Cambria",serif;
	color:black;}
span.MsoCommentReference
	{font-family:"Times New Roman",serif;}
span.MsoLineNumber
	{font-family:"Times New Roman",serif;}
span.MsoPageNumber
	{font-family:"Times New Roman",serif;}
span.MsoEndnoteReference
	{vertical-align:super;}
p.MsoEndnoteText, li.MsoEndnoteText, div.MsoEndnoteText
	{mso-style-link:"Endnote Text Char1";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoToa, li.MsoToa, div.MsoToa
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoMacroText, li.MsoMacroText, div.MsoMacroText
	{mso-style-link:"Macro Text Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Courier New";
	color:windowtext;}
p.MsoToaHeading, li.MsoToaHeading, div.MsoToaHeading
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Cambria",serif;
	color:black;
	font-weight:bold;}
p.MsoList, li.MsoList, div.MsoList
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListCxSpFirst, li.MsoListCxSpFirst, div.MsoListCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListCxSpMiddle, li.MsoListCxSpMiddle, div.MsoListCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListCxSpLast, li.MsoListCxSpLast, div.MsoListCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListBullet, li.MsoListBullet, div.MsoListBullet
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListNumber, li.MsoListNumber, div.MsoListNumber
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListNumberCxSpFirst, li.MsoListNumberCxSpFirst, div.MsoListNumberCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListNumberCxSpMiddle, li.MsoListNumberCxSpMiddle, div.MsoListNumberCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListNumberCxSpLast, li.MsoListNumberCxSpLast, div.MsoListNumberCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoList2, li.MsoList2, div.MsoList2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoList2CxSpFirst, li.MsoList2CxSpFirst, div.MsoList2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoList2CxSpMiddle, li.MsoList2CxSpMiddle, div.MsoList2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoList2CxSpLast, li.MsoList2CxSpLast, div.MsoList2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoList3, li.MsoList3, div.MsoList3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoList3CxSpFirst, li.MsoList3CxSpFirst, div.MsoList3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoList3CxSpMiddle, li.MsoList3CxSpMiddle, div.MsoList3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoList3CxSpLast, li.MsoList3CxSpLast, div.MsoList3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoList4, li.MsoList4, div.MsoList4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoList4CxSpFirst, li.MsoList4CxSpFirst, div.MsoList4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoList4CxSpMiddle, li.MsoList4CxSpMiddle, div.MsoList4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoList4CxSpLast, li.MsoList4CxSpLast, div.MsoList4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoList5, li.MsoList5, div.MsoList5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoList5CxSpFirst, li.MsoList5CxSpFirst, div.MsoList5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoList5CxSpMiddle, li.MsoList5CxSpMiddle, div.MsoList5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoList5CxSpLast, li.MsoList5CxSpLast, div.MsoList5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListBullet2, li.MsoListBullet2, div.MsoListBullet2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListBullet2CxSpFirst, li.MsoListBullet2CxSpFirst, div.MsoListBullet2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListBullet2CxSpMiddle, li.MsoListBullet2CxSpMiddle, div.MsoListBullet2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListBullet2CxSpLast, li.MsoListBullet2CxSpLast, div.MsoListBullet2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListBullet3, li.MsoListBullet3, div.MsoListBullet3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListBullet3CxSpFirst, li.MsoListBullet3CxSpFirst, div.MsoListBullet3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListBullet3CxSpMiddle, li.MsoListBullet3CxSpMiddle, div.MsoListBullet3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListBullet3CxSpLast, li.MsoListBullet3CxSpLast, div.MsoListBullet3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListBullet4, li.MsoListBullet4, div.MsoListBullet4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListBullet4CxSpFirst, li.MsoListBullet4CxSpFirst, div.MsoListBullet4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListBullet4CxSpMiddle, li.MsoListBullet4CxSpMiddle, div.MsoListBullet4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListBullet4CxSpLast, li.MsoListBullet4CxSpLast, div.MsoListBullet4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListBullet5, li.MsoListBullet5, div.MsoListBullet5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListBullet5CxSpFirst, li.MsoListBullet5CxSpFirst, div.MsoListBullet5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListBullet5CxSpMiddle, li.MsoListBullet5CxSpMiddle, div.MsoListBullet5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListBullet5CxSpLast, li.MsoListBullet5CxSpLast, div.MsoListBullet5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListNumber2, li.MsoListNumber2, div.MsoListNumber2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	color:black;}
p.MsoListNumber3, li.MsoListNumber3, div.MsoListNumber3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListNumber3CxSpFirst, li.MsoListNumber3CxSpFirst, div.MsoListNumber3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListNumber3CxSpMiddle, li.MsoListNumber3CxSpMiddle, div.MsoListNumber3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListNumber3CxSpLast, li.MsoListNumber3CxSpLast, div.MsoListNumber3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListNumber4, li.MsoListNumber4, div.MsoListNumber4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListNumber4CxSpFirst, li.MsoListNumber4CxSpFirst, div.MsoListNumber4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListNumber4CxSpMiddle, li.MsoListNumber4CxSpMiddle, div.MsoListNumber4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListNumber4CxSpLast, li.MsoListNumber4CxSpLast, div.MsoListNumber4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListNumber5, li.MsoListNumber5, div.MsoListNumber5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListNumber5CxSpFirst, li.MsoListNumber5CxSpFirst, div.MsoListNumber5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListNumber5CxSpMiddle, li.MsoListNumber5CxSpMiddle, div.MsoListNumber5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListNumber5CxSpLast, li.MsoListNumber5CxSpLast, div.MsoListNumber5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoTitle, li.MsoTitle, div.MsoTitle
	{mso-style-link:"Title Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	font-size:16.0pt;
	font-family:"Cambria",serif;
	color:windowtext;
	font-weight:bold;}
p.MsoClosing, li.MsoClosing, div.MsoClosing
	{mso-style-link:"Closing Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:3.0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoSignature, li.MsoSignature, div.MsoSignature
	{mso-style-link:"Signature Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:3.0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{mso-style-link:"Body Text Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoBodyTextIndent, li.MsoBodyTextIndent, div.MsoBodyTextIndent
	{mso-style-link:"Body Text Indent Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-align:justify;
	text-justify:inter-ideograph;
	text-autospace:none;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListContinue, li.MsoListContinue, div.MsoListContinue
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListContinueCxSpFirst, li.MsoListContinueCxSpFirst, div.MsoListContinueCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListContinueCxSpMiddle, li.MsoListContinueCxSpMiddle, div.MsoListContinueCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListContinueCxSpLast, li.MsoListContinueCxSpLast, div.MsoListContinueCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListContinue2, li.MsoListContinue2, div.MsoListContinue2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListContinue2CxSpFirst, li.MsoListContinue2CxSpFirst, div.MsoListContinue2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListContinue2CxSpMiddle, li.MsoListContinue2CxSpMiddle, div.MsoListContinue2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListContinue2CxSpLast, li.MsoListContinue2CxSpLast, div.MsoListContinue2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListContinue3, li.MsoListContinue3, div.MsoListContinue3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.75in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListContinue3CxSpFirst, li.MsoListContinue3CxSpFirst, div.MsoListContinue3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListContinue3CxSpMiddle, li.MsoListContinue3CxSpMiddle, div.MsoListContinue3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListContinue3CxSpLast, li.MsoListContinue3CxSpLast, div.MsoListContinue3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.75in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListContinue4, li.MsoListContinue4, div.MsoListContinue4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:1.0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListContinue4CxSpFirst, li.MsoListContinue4CxSpFirst, div.MsoListContinue4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListContinue4CxSpMiddle, li.MsoListContinue4CxSpMiddle, div.MsoListContinue4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListContinue4CxSpLast, li.MsoListContinue4CxSpLast, div.MsoListContinue4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:1.0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListContinue5, li.MsoListContinue5, div.MsoListContinue5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:1.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListContinue5CxSpFirst, li.MsoListContinue5CxSpFirst, div.MsoListContinue5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListContinue5CxSpMiddle, li.MsoListContinue5CxSpMiddle, div.MsoListContinue5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListContinue5CxSpLast, li.MsoListContinue5CxSpLast, div.MsoListContinue5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:1.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoMessageHeader, li.MsoMessageHeader, div.MsoMessageHeader
	{mso-style-link:"Message Header Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.75in;
	background:#CCCCCC;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Cambria",serif;
	color:windowtext;}
p.MsoSubtitle, li.MsoSubtitle, div.MsoSubtitle
	{mso-style-link:"Subtitle Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Cambria",serif;
	color:windowtext;}
p.MsoSalutation, li.MsoSalutation, div.MsoSalutation
	{mso-style-link:"Salutation Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoDate, li.MsoDate, div.MsoDate
	{mso-style-link:"Date Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoBodyTextFirstIndent, li.MsoBodyTextFirstIndent, div.MsoBodyTextFirstIndent
	{mso-style-link:"Body Text First Indent Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-indent:10.5pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoBodyTextFirstIndent2, li.MsoBodyTextFirstIndent2, div.MsoBodyTextFirstIndent2
	{mso-style-link:"Body Text First Indent 2 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.25in;
	text-indent:10.5pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoNoteHeading, li.MsoNoteHeading, div.MsoNoteHeading
	{mso-style-link:"Note Heading Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2
	{mso-style-link:"Body Text 2 Char";
	margin:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	text-autospace:none;
	border:none;
	padding:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoBodyText3, li.MsoBodyText3, div.MsoBodyText3
	{mso-style-link:"Body Text 3 Char";
	margin:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	text-autospace:none;
	font-size:8.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoBodyTextIndent2, li.MsoBodyTextIndent2, div.MsoBodyTextIndent2
	{mso-style-link:"Body Text Indent 2 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.7pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-autospace:none;
	border:none;
	padding:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoBodyTextIndent3, li.MsoBodyTextIndent3, div.MsoBodyTextIndent3
	{mso-style-link:"Body Text Indent 3 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:31.65pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-autospace:none;
	font-size:8.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoBlockText, li.MsoBlockText, div.MsoBlockText
	{margin-top:0in;
	margin-right:1.0in;
	margin-bottom:6.0pt;
	margin-left:1.0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
a:link, span.MsoHyperlink
	{font-family:"Times New Roman",serif;
	color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{font-family:"Times New Roman",serif;
	color:purple;
	text-decoration:underline;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{mso-style-link:"Document Map Char";
	margin:0in;
	background:navy;
	font-size:1.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoPlainText, li.MsoPlainText, div.MsoPlainText
	{mso-style-link:"Plain Text Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Courier New";
	color:windowtext;}
p.MsoAutoSig, li.MsoAutoSig, div.MsoAutoSig
	{mso-style-link:"E-mail Signature Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p
	{margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Arial Unicode MS",serif;
	color:black;}
address
	{mso-style-link:"HTML Address Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;
	font-style:italic;}
pre
	{mso-style-link:"HTML Preformatted Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Courier New";
	color:windowtext;}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{mso-style-link:"Comment Subject Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-link:"Balloon Text Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoNoSpacing, li.MsoNoSpacing, div.MsoNoSpacing
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoRMPane, li.MsoRMPane, div.MsoRMPane
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoQuote, li.MsoQuote, div.MsoQuote
	{mso-style-link:"Quote Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;
	font-style:italic;}
p.MsoIntenseQuote, li.MsoIntenseQuote, div.MsoIntenseQuote
	{mso-style-link:"Intense Quote Char";
	margin-top:10.0pt;
	margin-right:.65in;
	margin-bottom:14.0pt;
	margin-left:.65in;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:#4F81BD;
	font-weight:bold;
	font-style:italic;}
p.MsoBibliography, li.MsoBibliography, div.MsoBibliography
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoTocHeading, li.MsoTocHeading, div.MsoTocHeading
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:16.0pt;
	font-family:"Cambria",serif;
	color:windowtext;
	font-weight:bold;}
span.Heading1Char
	{mso-style-name:"Heading 1 Char";
	mso-style-link:"Heading 1";
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
span.Heading2Char
	{mso-style-name:"Heading 2 Char";
	mso-style-link:"Heading 2";
	font-family:"Times New Roman Bold",serif;
	text-transform:uppercase;
	font-weight:bold;}
span.Heading3Char
	{mso-style-name:"Heading 3 Char";
	mso-style-link:"Heading 3";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.Heading4Char
	{mso-style-name:"Heading 4 Char";
	mso-style-link:"Heading 4";
	font-family:"Times New Roman",serif;
	text-decoration:underline;}
span.Heading5Char
	{mso-style-name:"Heading 5 Char";
	mso-style-link:"Heading 5";
	font-family:"Times New Roman",serif;
	font-style:italic;}
span.Heading6Char
	{mso-style-name:"Heading 6 Char";
	mso-style-link:"Heading 6";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.Heading7Char
	{mso-style-name:"Heading 7 Char";
	mso-style-link:"Heading 7";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.Heading8Char
	{mso-style-name:"Heading 8 Char";
	mso-style-link:"Heading 8";
	font-family:"Calibri",sans-serif;
	font-style:italic;}
span.Heading9Char
	{mso-style-name:"Heading 9 Char";
	mso-style-link:"Heading 9";
	font-family:"Cambria",serif;}
span.HeaderChar
	{mso-style-name:"Header Char";
	mso-style-link:Header;
	font-family:"Times New Roman",serif;}
span.FooterChar
	{mso-style-name:"Footer Char";
	mso-style-link:Footer;
	font-family:"Times New Roman",serif;}
span.BodyTextIndentChar
	{mso-style-name:"Body Text Indent Char";
	mso-style-link:"Body Text Indent";
	font-family:"Times New Roman",serif;}
span.BodyText3Char
	{mso-style-name:"Body Text 3 Char";
	mso-style-link:"Body Text 3";
	font-family:"Times New Roman",serif;}
span.BodyTextIndent2Char
	{mso-style-name:"Body Text Indent 2 Char";
	mso-style-link:"Body Text Indent 2";
	font-family:"Times New Roman",serif;}
span.BodyTextChar
	{mso-style-name:"Body Text Char";
	mso-style-link:"Body Text";
	font-family:"Times New Roman",serif;}
span.BodyText2Char
	{mso-style-name:"Body Text 2 Char";
	mso-style-link:"Body Text 2";
	font-family:"Times New Roman",serif;}
span.CommentTextChar2
	{mso-style-name:"Comment Text Char2\, Car17 Char1\, Char Char Char Char1\, Char Char1 Char1\,Annotationtext Char1\,Char Char Char Char1\,Char Char2\,Comment Text Char Char Char Char Char\,Comment Text Char Char Char1\,Comment Text Char Char1 Char Char\,Comment Text Char1 Char1";
	mso-style-link:"Comment Text\, Car17\, Char Char Char\, Char Char1\,Annotationtext\,Char\,Char Char Char\,Comment Text Char Char\,Comment Text Char Char Char Char\,Comment Text Char Char1 Char\,Comment Text Char1\,Comment Text Char1 Char Char\,Comment Text Char2 Ch";
	font-family:"Times New Roman",serif;}
p.EMEAEnBodyText, li.EMEAEnBodyText, div.EMEAEnBodyText
	{mso-style-name:"EMEA En Body Text";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
span.DocumentMapChar
	{mso-style-name:"Document Map Char";
	mso-style-link:"Document Map";
	font-family:"Times New Roman",serif;}
p.AHeader1, li.AHeader1, div.AHeader1
	{mso-style-name:"AHeader 1";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.2pt;
	text-indent:-14.2pt;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	color:black;
	font-weight:bold;}
p.AHeader2, li.AHeader2, div.AHeader2
	{mso-style-name:"AHeader 2";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:35.45pt;
	text-indent:-21.25pt;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	color:black;
	font-weight:bold;}
p.AHeader3, li.AHeader3, div.AHeader3
	{mso-style-name:"AHeader 3";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:63.8pt;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	color:black;
	font-weight:bold;}
p.AHeader2abc, li.AHeader2abc, div.AHeader2abc
	{mso-style-name:"AHeader 2 abc";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.5in;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-.5in;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	color:black;}
p.AHeader3abc, li.AHeader3abc, div.AHeader3abc
	{mso-style-name:"AHeader 3 abc";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:85.05pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-21.25pt;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	color:black;}
span.BodyTextIndent3Char
	{mso-style-name:"Body Text Indent 3 Char";
	mso-style-link:"Body Text Indent 3";
	font-family:"Times New Roman",serif;}
span.BalloonTextChar
	{mso-style-name:"Balloon Text Char";
	mso-style-link:"Balloon Text";}
p.Default, li.Default, div.Default
	{mso-style-name:Default;
	margin:0in;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
span.CommentSubjectChar
	{mso-style-name:"Comment Subject Char";
	mso-style-link:"Comment Subject";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.Paragraph, li.Paragraph, div.Paragraph
	{mso-style-name:Paragraph;
	mso-style-link:"Paragraph Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:12.0pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.default0, li.default0, div.default0
	{mso-style-name:default;
	margin:0in;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.default1, li.default1, div.default1
	{mso-style-name:default1;
	margin:0in;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.paragraph0, li.paragraph0, div.paragraph0
	{mso-style-name:paragraph0;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:12.0pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.ReferenceText, li.ReferenceText, div.ReferenceText
	{mso-style-name:"Reference Text";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:1.15in;
	font-size:12.0pt;
	font-family:"Times New Roman Bold",serif;
	color:windowtext;
	font-weight:bold;}
span.ParagraphChar
	{mso-style-name:"Paragraph Char";
	mso-style-link:Paragraph;}
p.ReferenceHeading2, li.ReferenceHeading2, div.ReferenceHeading2
	{mso-style-name:"Reference Heading 2";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:42.5pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-42.5pt;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	color:black;
	text-transform:uppercase;
	font-weight:bold;}
p.ReferenceHeading3, li.ReferenceHeading3, div.ReferenceHeading3
	{mso-style-name:"Reference Heading 3";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:.5in;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-.5in;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	color:black;
	font-weight:bold;}
p.ListEnd, li.ListEnd, div.ListEnd
	{mso-style-name:"List End";
	margin:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
span.Instructions
	{mso-style-name:Instructions;
	color:teal;
	display:none;
	font-style:italic;}
p.TableFootnote, li.TableFootnote, div.TableFootnote
	{mso-style-name:"Table Footnote";
	mso-style-link:"Table Footnote Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:9.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
span.TableFootnoteChar
	{mso-style-name:"Table Footnote Char";
	mso-style-link:"Table Footnote";
	font-family:"Times New Roman",serif;}
span.PlainTextChar
	{mso-style-name:"Plain Text Char";
	mso-style-link:"Plain Text";
	font-family:"Courier New";}
span.DateChar
	{mso-style-name:"Date Char";
	mso-style-link:Date;
	font-family:"Times New Roman",serif;}
span.CharChar1
	{mso-style-name:"Char Char1";
	font-family:"Times New Roman",serif;}
p.BodytextAgency, li.BodytextAgency, div.BodytextAgency
	{mso-style-name:"Body text \(Agency\)";
	mso-style-link:"Body text \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	color:windowtext;}
span.BodytextAgencyChar
	{mso-style-name:"Body text \(Agency\) Char";
	mso-style-link:"Body text \(Agency\)";
	font-family:"Verdana",sans-serif;}
p.Lijstalinea1, li.Lijstalinea1, div.Lijstalinea1
	{mso-style-name:Lijstalinea1;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.Lijstalinea1CxSpFirst, li.Lijstalinea1CxSpFirst, div.Lijstalinea1CxSpFirst
	{mso-style-name:Lijstalinea1CxSpFirst;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.Lijstalinea1CxSpMiddle, li.Lijstalinea1CxSpMiddle, div.Lijstalinea1CxSpMiddle
	{mso-style-name:Lijstalinea1CxSpMiddle;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.Lijstalinea1CxSpLast, li.Lijstalinea1CxSpLast, div.Lijstalinea1CxSpLast
	{mso-style-name:Lijstalinea1CxSpLast;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.FooterAgency, li.FooterAgency, div.FooterAgency
	{mso-style-name:"Footer \(Agency\)";
	mso-style-link:"Footer \(Agency\) Char Char";
	margin:0in;
	font-size:7.0pt;
	font-family:"Verdana",sans-serif;
	color:#6D6F71;}
span.FooterAgencyCharChar
	{mso-style-name:"Footer \(Agency\) Char Char";
	mso-style-link:"Footer \(Agency\)";
	font-family:"Verdana",sans-serif;
	color:#6D6F71;}
p.DraftingNotesAgency, li.DraftingNotesAgency, div.DraftingNotesAgency
	{mso-style-name:"Drafting Notes \(Agency\)";
	mso-style-link:"Drafting Notes \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:11.0pt;
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
p.No-numheading3Agency, li.No-numheading3Agency, div.No-numheading3Agency
	{mso-style-name:"No-num heading 3 \(Agency\)";
	mso-style-link:"No-num heading 3 \(Agency\) Char";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Verdana",sans-serif;
	color:windowtext;
	font-weight:bold;}
p.NormalAgency, li.NormalAgency, div.NormalAgency
	{mso-style-name:"Normal \(Agency\)";
	mso-style-link:"Normal \(Agency\) Char";
	margin:0in;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	color:windowtext;}
span.NormalAgencyChar
	{mso-style-name:"Normal \(Agency\) Char";
	mso-style-link:"Normal \(Agency\)";
	font-family:"Verdana",sans-serif;}
span.DraftingNotesAgencyChar
	{mso-style-name:"Drafting Notes \(Agency\) Char";
	mso-style-link:"Drafting Notes \(Agency\)";
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
span.No-numheading3AgencyChar
	{mso-style-name:"No-num heading 3 \(Agency\) Char";
	mso-style-link:"No-num heading 3 \(Agency\)";
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.TitleB, li.TitleB, div.TitleB
	{mso-style-name:"Title B";
	margin-top:0in;
	margin-right:28.35pt;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;
	font-weight:bold;}
p.TableheadingrowsAgency, li.TableheadingrowsAgency, div.TableheadingrowsAgency
	{mso-style-name:"Table heading rows \(Agency\)";
	margin:0in;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Verdana",sans-serif;
	color:windowtext;}
p.TitleA, li.TitleA, div.TitleA
	{mso-style-name:"Title A";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-align:center;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;
	text-transform:uppercase;
	font-weight:bold;}
span.BodyTextFirstIndentChar
	{mso-style-name:"Body Text First Indent Char";
	mso-style-link:"Body Text First Indent";
	font-family:"Times New Roman",serif;}
span.BodyTextFirstIndent2Char
	{mso-style-name:"Body Text First Indent 2 Char";
	mso-style-link:"Body Text First Indent 2";
	font-family:"Times New Roman",serif;}
span.ClosingChar
	{mso-style-name:"Closing Char";
	mso-style-link:Closing;}
span.E-mailSignatureChar
	{mso-style-name:"E-mail Signature Char";
	mso-style-link:"E-mail Signature";}
span.EndnoteTextChar1
	{mso-style-name:"Endnote Text Char1";
	mso-style-link:"Endnote Text";}
span.FootnoteTextChar
	{mso-style-name:"Footnote Text Char";
	mso-style-link:"Footnote Text";}
span.HTMLAddressChar
	{mso-style-name:"HTML Address Char";
	mso-style-link:"HTML Address";
	font-style:italic;}
span.HTMLPreformattedChar
	{mso-style-name:"HTML Preformatted Char";
	mso-style-link:"HTML Preformatted";
	font-family:"Courier New";}
span.IntenseQuoteChar
	{mso-style-name:"Intense Quote Char";
	mso-style-link:"Intense Quote";
	color:#4F81BD;
	font-weight:bold;
	font-style:italic;}
span.MacroTextChar
	{mso-style-name:"Macro Text Char";
	mso-style-link:"Macro Text";
	font-family:"Courier New";}
span.MessageHeaderChar
	{mso-style-name:"Message Header Char";
	mso-style-link:"Message Header";
	font-family:"Cambria",serif;
	background:#CCCCCC;}
span.NoteHeadingChar
	{mso-style-name:"Note Heading Char";
	mso-style-link:"Note Heading";}
span.QuoteChar
	{mso-style-name:"Quote Char";
	mso-style-link:Quote;
	color:black;
	font-style:italic;}
span.SalutationChar
	{mso-style-name:"Salutation Char";
	mso-style-link:Salutation;}
span.SignatureChar
	{mso-style-name:"Signature Char";
	mso-style-link:Signature;}
span.SubtitleChar
	{mso-style-name:"Subtitle Char";
	mso-style-link:Subtitle;
	font-family:"Cambria",serif;}
span.TitleChar
	{mso-style-name:"Title Char";
	mso-style-link:Title;
	font-family:"Cambria",serif;
	font-weight:bold;}
p.TableText, li.TableText, div.TableText
	{mso-style-name:"Table\:Text";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
span.CommentTextChar
	{mso-style-name:"Comment Text Char\, Car17 Char\, Char Char Char Char\, Char Char1 Char\,Annotationtext Char\,Char Char\,Char Char Char Char\,Char Char1 Char\,Comment Text Char Char Char\,Comment Text Char1 Char\,Comment Text Char1 Char Char Char\,Comment Text Char2 Char Char";
	font-family:"Times New Roman",serif;}
p.SOPheading, li.SOPheading, div.SOPheading
	{mso-style-name:"SOP heading";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.5in;
	text-indent:-.5in;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	color:windowtext;
	font-weight:bold;
	text-decoration:underline;}
p.TableFootnoteLetter, li.TableFootnoteLetter, div.TableFootnoteLetter
	{mso-style-name:"Table Footnote Letter";
	mso-style-link:"Table Footnote Letter Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:9.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
span.TableFootnoteLetterChar
	{mso-style-name:"Table Footnote Letter Char";
	mso-style-link:"Table Footnote Letter";
	font-family:"Times New Roman",serif;}
p.TableParagraph, li.TableParagraph, div.TableParagraph
	{mso-style-name:"Table Paragraph";
	margin:0in;
	text-align:center;
	line-height:11.35pt;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	color:windowtext;}
span.EndnoteTextChar
	{mso-style-name:"Endnote Text Char";
	font-family:Courier;}
span.UnresolvedMention1
	{mso-style-name:"Unresolved Mention1";
	color:gray;
	background:#E6E6E6;}
p.CM1, li.CM1, div.CM1
	{mso-style-name:CM1;
	margin:0in;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"EUAlbertina",serif;
	color:windowtext;}
p.CM3, li.CM3, div.CM3
	{mso-style-name:CM3;
	margin:0in;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"EUAlbertina",serif;
	color:windowtext;}
span.msoIns
	{mso-style-name:"";
	text-decoration:underline;
	color:teal;}
span.msoDel
	{mso-style-name:"";
	text-decoration:line-through;
	color:red;}
 /* Page Definitions */
 @page WordSection1
	{size:595.35pt 842.0pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US link=blue vlink=purple style='word-wrap:break-word'>

<div class=WordSection1>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<h1><span lang=EN-GB>ANNEX I </span></h1>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=TitleA><span lang=EN-GB>SUMMARY OF PRODUCT CHARACTERISTICS</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:green'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><span lang=EN-GB style='color:windowtext'><img width=21
height=18 id="Picture 1"
src="Adcetris-ema-combined-h-2455-en-IB-SOB-C2500_files/image001.gif"
alt="Description: Description: Description: BT_1000x858px">This medicinal
product is subject to additional monitoring. This will allow quick
identification of new safety information. Healthcare professionals are asked to
report any suspected adverse reactions. See section&nbsp;4.8 for how to report
adverse reactions.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<h2 style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>NAME
OF THE MEDICINAL PRODUCT</span></h2>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>ADCETRIS 50&nbsp;mg powder for concentrate
for solution for infusion.</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<h2><span lang=EN-GB style='font-family:"Times New Roman",serif'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; QUALITATIVE
AND QUANTITATIVE COMPOSITION</span></h2>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each vial contains 50&nbsp;mg of
brentuximab vedotin. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>After reconstitution (see section&nbsp;6.6),
each mL contains 5&nbsp;mg of brentuximab vedotin.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>ADCETRIS is an antibody&#8209;drug
conjugate composed of a CD30&#8209;directed monoclonal antibody (recombinant
chimeric immunoglobulin G1 [IgG1], produced by recombinant DNA technology in
Chinese Hamster ovary cells) that is covalently linked to the antimicrotubule
agent monomethyl auristatin E (MMAE).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Excipient with known effect</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each vial contains approximately
13.2&nbsp;mg of sodium. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For the full list of excipients, see section&nbsp;6.1.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<h2><span lang=EN-GB style='font-family:"Times New Roman",serif'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
form</span></h2>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
page-break-after:avoid;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
text-autospace:none'><span lang=EN-GB>Powder for concentrate for solution for
infusion.</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
text-autospace:none'><span lang=EN-GB>White to off&#8209;white cake or powder. </span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<h2><span lang=EN-GB style='font-family:"Times New Roman",serif'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Clinical
particulars</span></h2>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<h3><span lang=EN-GB>4.1&nbsp;&nbsp;&nbsp;&nbsp; Therapeutic indications</span></h3>

<p class=MsoNormal style='page-break-after:avoid'><a name="OLE_LINK2"></a><a
name="OLE_LINK5"><span lang=EN-GB>&nbsp;</span></a></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Hodgkin
lymphoma</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>ADCETRIS is indicated for adult patients
with previously untreated CD30+ Stage&nbsp;IV Hodgkin lymphoma (HL) in
combination with doxorubicin, vinblastine and dacarbazine (AVD) (see sections&nbsp;4.2&nbsp;and&nbsp;5.1).</span></p>

<p class=MsoPlainText><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=Paragraph style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>ADCETRIS is indicated for the treatment of adult patients with CD30+ HL
at increased risk of relapse or progression following </span><span
style='font-size:11.0pt'>autologous stem cell transplant</span><span
lang=EN-GB style='font-size:11.0pt'> (ASCT) (see section&nbsp;5.1).</span></p>

<p class=Paragraph style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoPlainText><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>ADCETRIS is indicated for the treatment of adult
patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL): </span></p>

<p class=MsoPlainText style='margin-left:66.55pt;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>1.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>following
ASCT, or</span></p>

<p class=MsoPlainText style='margin-left:66.55pt;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>2.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>following
at least two prior therapies when ASCT or multi-agent chemotherapy is not a
treatment option.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=Paragraph style='margin-bottom:0in;page-break-after:avoid'><u><span
lang=EN-GB style='font-size:11.0pt'>Systemic anaplastic large cell lymphoma</span></u></p>

<p class=Paragraph style='margin-bottom:0in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Paragraph style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>ADCETRIS in combination with cyclophosphamide, doxorubicin and
prednisone (CHP) is indicated for adult patients with previously untreated systemic
anaplastic large cell lymphoma (sALCL) (see section&nbsp;5.1).</span></p>

<p class=Paragraph style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=Paragraph style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>ADCETRIS is indicated for the treatment of adult patients with relapsed
or refractory sALCL.</span></p>

<p class=Paragraph style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=Paragraph style='margin-bottom:0in;page-break-after:avoid'><u><span
lang=EN-GB style='font-size:11.0pt'>Cutaneous T&#8209;cell lymphoma </span></u></p>

<p class=Paragraph style='margin-bottom:0in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Paragraph style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>ADCETRIS is indicated for the treatment of adult patients with CD30+
cutaneous T&#8209;cell lymphoma (CTCL) after at least 1 prior systemic therapy (see
section&nbsp;5.1).</span></p>

<p class=Paragraph style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<h3><span lang=EN-GB>4.2&nbsp;&nbsp;&nbsp;&nbsp; Posology and method of
administration</span></h3>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>ADCETRIS should
be administered under the supervision of a physician experienced in the use of
anti&#8209;cancer agents.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><b><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Previously
Untreated HL</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The recommended dose in combination with
chemotherapy (doxorubicin [A], vinblastine [V] and dacarbazine [D] [AVD]) is
1.2&nbsp;mg/kg administered as an intravenous infusion over 30&nbsp;minutes on
days&nbsp;1 and&nbsp;15 of each 28&#8209;day cycle for 6&nbsp;cycles (see section&nbsp;5.1).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Primary prophylaxis with growth factor
support (G-CSF), beginning with the first dose, is recommended for all patients
with previously untreated HL receiving combination therapy (see section&nbsp;4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Refer to the summary of product
characteristics (SmPC) of chemotherapy agents given in combination with
ADCETRIS for patients with previously untreated HL. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>HL at
increased risk of relapse or progression </span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal><span lang=EN-GB>The recommended dose is 1.8&nbsp;mg/kg
administered as an intravenous infusion over 30&nbsp;minutes every 3&nbsp;weeks.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>ADCETRIS treatment should start following
recovery from ASCT based on clinical judgment. These patients should receive up
to 16&nbsp;cycles (see section&nbsp;5.1).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Relapsed
or refractory HL</span></i><span lang=EN-GB> </span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The recommended dose is 1.8&nbsp;mg/kg
administered as an intravenous infusion over 30&nbsp;minutes every
3&nbsp;weeks.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The recommended starting dose for the
retreatment of patients who have previously responded to treatment with
ADCETRIS is 1.8&nbsp;mg/kg administered as an intravenous infusion over
30&nbsp;minutes every 3&nbsp;weeks. Alternatively, treatment may be started at
the last tolerated dose (see section&nbsp;5.1).</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><a name="OLE_LINK6"></a><a name="OLE_LINK7"><span
lang=EN-GB>Treatment should be continued until disease progression or
unacceptable toxicity<sup> </sup>(see section&nbsp;4.4).</span></a></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Patients who achieve stable disease or
better should receive a minimum of 8&nbsp;cycles and </span><span lang=EN-GB>up
to a maximum of 16&nbsp;cycles (approximately 1&nbsp;year) (see section&nbsp;5.1).
</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Previously
untreated sALCL</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The recommended dose in combination with
chemotherapy (cyclophosphamide [C], doxorubicin [H] and prednisone [P] [CHP])
is 1.8&nbsp;mg/kg administered as an intravenous infusion over 30&nbsp;minutes
every 3&nbsp;weeks for 6&nbsp;to 8&nbsp;cycles </span><span lang=EN-GB>(see
section&nbsp;5.1). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Primary prophylaxis with G-CSF, beginning
with the first dose, is recommended for all patients </span><span lang=EN-GB>with
previously untreated sALCL receiving combination therapy (see
section&nbsp;4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Refer to the SmPCs of chemotherapy agents
given in combination with ADCETRIS for patients with previously untreated sALCL.
</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Relapsed
or refractory sALCL</span></i><span lang=EN-GB> </span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The recommended dose is 1.8&nbsp;mg/kg
administered as an intravenous infusion over 30&nbsp;minutes every
3&nbsp;weeks.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The recommended starting dose for the
retreatment of patients who have previously responded to treatment with
ADCETRIS is 1.8&nbsp;mg/kg administered as an intravenous infusion over
30&nbsp;minutes every 3&nbsp;weeks. Alternatively, treatment may be started at
the last tolerated dose (see section&nbsp;5.1).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Treatment should be continued until disease
progression or unacceptable toxicity<sup> </sup>(see section&nbsp;4.4).</span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Patients who achieve stable disease or
better should receive a minimum of 8&nbsp;cycles and up to a maximum of
16&nbsp;cycles (approximately 1&nbsp;year) (see section&nbsp;5.1). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>CTCL</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The recommended dose is 1.8&nbsp;mg/kg
administered as an intravenous infusion over 30&nbsp;minutes every
3&nbsp;weeks.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Patients with CTCL should receive up to 16
cycles (see section&nbsp;5.1).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>General</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>If the
patient&#8217;s weight is more than 100&nbsp;kg, the dose calculation should
use 100&nbsp;kg (see section&nbsp;6.6).</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Complete blood
counts should be monitored prior to administration of each dose of this
treatment (see section&nbsp;4.4). </span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Patients should
be monitored during and after infusion (see section&nbsp;4.4). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Dose
adjustments</span></u></p>

<p class=Default style='page-break-after:avoid'><i><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Neutropenia</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>If
neutropenia develops during treatment it should be managed by dose delays. See
Table&nbsp;1 and Table&nbsp;2 for appropriate dosing recommendations for
monotherapy and combination therapy, respectively (see also section&nbsp;4.4). </span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Table 1:
Dosing recommendations for neutropenia with monotherapy<br>
<br>
</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="99%"
 style='width:99.22%;margin-left:5.4pt;border-collapse:collapse;border:none'>
 <tr>
  <td width="37%" valign=top style='width:37.12%;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><a name="_Hlk8891520"><b><span lang=EN-GB>Severity grade of
  neutropenia</span></b></a></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>(signs and symptoms </span></b><span lang=EN-GB>[abbreviated
  description of CTCAE<sup>a</sup>])</span></p>
  </td>
  <td width="62%" valign=top style='width:62.88%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Modification of dosing schedule</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="37%" valign=top style='width:37.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=SV>Grade 1
  (&lt;&nbsp;LLN&#8209;1500/mm<sup>3</sup></span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=SV>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  &nbsp;&nbsp;&nbsp;&lt;&nbsp;LLN&#8209;1.5 x 10<sup>9</sup>/L) or</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Grade 2
  (&lt;&nbsp;1500&#8209;1000/mm<sup>3</sup></span></p>
  <p class=MsoNormal style='page-break-after:avoid'><sup><span lang=EN-GB>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></sup><span lang=EN-GB>&lt;&nbsp;1.5&#8209;1.0 x 10<sup>9</sup>/L)</span></p>
  </td>
  <td width="62%" valign=top style='width:62.88%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Continue
  with the same dose and schedule.</span></p>
  </td>
 </tr>
 <tr>
  <td width="37%" valign=top style='width:37.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:41.3pt;text-indent:-41.3pt;page-break-after:
  avoid'><span lang=EN-GB>Grade 3 (&lt;&nbsp;1,000&#8209;500/mm<sup>3</sup></span></p>
  <p class=MsoNormal style='margin-left:41.3pt;text-indent:-41.3pt;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  &lt;&nbsp;1.0&#8209;0.5 x 10<sup>9</sup>/L) or</span></p>
  <p class=MsoNormal style='margin-left:41.3pt;text-indent:-41.3pt;page-break-after:
  avoid'><span lang=EN-GB>Grade 4 (&lt;&nbsp;500/mm<sup>3</sup></span></p>
  <p class=MsoNormal style='margin-left:41.3pt;text-indent:-41.3pt;page-break-after:
  avoid'><sup><span lang=EN-GB>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></sup><span lang=EN-GB>&lt;&nbsp;0.5 x 10<sup>9</sup>/L)</span></p>
  </td>
  <td width="62%" valign=top style='width:62.88%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Withhold
  dose until toxicity returns to &#8804;&nbsp;Grade&nbsp;2 or baseline then
  resume treatment at the same dose and schedule<sup>b</sup>. Consider G&#8209;CSF
  or GM&#8209;CSF in subsequent cycles for patients who develop Grade&nbsp;3 or
  Grade&nbsp;4 neutropenia.</span></p>
  </td>
 </tr>
</table>

<p class=Paragraph style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.25in;text-indent:-.25in;page-break-after:avoid'><sup><span
lang=EN-GB style='font-size:11.0pt'>a.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></sup><span lang=EN-GB style='font-size:9.0pt'>Grading based on
National Cancer Institute (NCI)&nbsp;Common Terminology Criteria for Adverse
Events (CTCAE) v3.0; see Neutrophils/granulocytes; LLN&nbsp;=&nbsp;lower limit
of normal.</span></p>

<p class=Paragraph style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:17.85pt;text-indent:-17.85pt'><sup><span lang=EN-GB
style='font-size:11.0pt'>b.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></sup><span lang=EN-GB style='font-size:9.0pt'>Patients who
develop Grade&nbsp;3 or Grade&nbsp;4 lymphopenia may continue treatment without
interruption.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Table 2: Dosing recommendations for
neutropenia during combination therapy </span></b></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="98%"
 style='width:98.84%;margin-left:5.4pt;border-collapse:collapse;border:none'>
 <tr>
  <td width="36%" valign=top style='width:36.54%;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Severity grade of neutropenia</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>(signs and symptoms </span></b><span lang=EN-GB>[abbreviated
  description of CTCAE<sup>a</sup>])</span></p>
  </td>
  <td width="63%" valign=top style='width:63.46%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Modification of dosing schedule</span></b></p>
  </td>
 </tr>
 <tr style='height:101.7pt'>
  <td width="36%" valign=top style='width:36.54%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:101.7pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=SV>Grade 1
  (&lt;&nbsp;LLN&#8209;1500/mm<sup>3</sup></span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=SV>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  &lt;&nbsp;LLN&#8209;1.5 x 10<sup>9</sup>/L) or</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=SV>Grade 2
  (&lt;&nbsp;1500&#8209;1000/mm<sup>3</sup></span></p>
  <p class=MsoNormal style='page-break-after:avoid'><sup><span lang=SV>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></sup><span lang=SV>&lt;&nbsp;1.5&#8209;1.0 x 10<sup>9</sup>/L)</span></p>
  <p class=MsoNormal style='margin-left:41.3pt;text-indent:-41.3pt;page-break-after:
  avoid'><span lang=SV>Grade 3 (&lt;&nbsp;1,000&#8209;500/mm<sup>3</sup></span></p>
  <p class=MsoNormal style='margin-left:41.3pt;text-indent:-41.3pt;page-break-after:
  avoid'><span lang=SV>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=EN-GB>&lt;&nbsp;1.0&#8209;0.5 x 10<sup>9</sup>/L) or</span></p>
  <p class=MsoNormal style='margin-left:41.3pt;text-indent:-41.3pt;page-break-after:
  avoid'><span lang=EN-GB>Grade 4 (&lt;&nbsp;500/mm<sup>3</sup></span></p>
  <p class=MsoNormal style='margin-left:41.3pt;text-indent:-41.3pt;page-break-after:
  avoid'><sup><span lang=EN-GB>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></sup><span lang=EN-GB>&lt;&nbsp;0.5 x 10<sup>9</sup>/L)</span></p>
  </td>
  <td width="63%" valign=top style='width:63.46%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:101.7pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Primary
  prophylaxis with G-CSF, beginning with the first dose, is recommended for all
  patients receiving combination therapy. </span><span lang=EN-GB>Continue with
  the same dose and schedule.</span></p>
  </td>
 </tr>
</table>

<p class=Paragraph style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.25in;text-indent:-.25in;page-break-after:avoid'><sup><span
lang=EN-GB style='font-size:11.0pt'>a.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></sup><span lang=EN-GB style='font-size:9.0pt'>Grading based on
National Cancer Institute (NCI)&nbsp;Common Terminology Criteria for Adverse
Events (CTCAE) v4.03; see Neutrophils/granulocytes; LLN&nbsp;=&nbsp;lower limit
of normal.</span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Peripheral
neuropathy</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>If
peripheral sensory or motor neuropathy emerges or worsens during treatment see
Table&nbsp;3 and&nbsp;4 for appropriate dosing recommendations for monotherapy
and combination therapy, respectively (see section&nbsp;4.4).</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
page-break-after:avoid;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB>Table 3: Dosing recommendations for new or worsening peripheral
sensory or motor neuropathy with monotherapy</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="99%"
 style='width:99.22%;margin-left:5.4pt;border-collapse:collapse;border:none'>
 <tr>
  <td width="43%" valign=top style='width:43.98%;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Severity of peripheral sensory or motor neuropathy
  </span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>(signs and symptoms </span></b><span lang=EN-GB>[abbreviated
  description of CTCAE<sup>a</sup>])</span></p>
  </td>
  <td width="56%" valign=top style='width:56.02%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Modification of dose and schedule</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="43%" valign=top style='width:43.98%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:39.7pt;text-indent:-39.7pt;page-break-after:
  avoid'><span lang=EN-GB>Grade&nbsp;1 (paraesthesia and/or loss of reflexes,
  with no loss of function)</span></p>
  </td>
  <td width="56%" valign=top style='width:56.02%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Continue
  with the same dose and schedule. </span></p>
  </td>
 </tr>
 <tr>
  <td width="43%" valign=top style='width:43.98%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:39.7pt;text-indent:-39.7pt;page-break-after:
  avoid'><span lang=EN-GB>Grade&nbsp;2 (interfering with function but not with
  activities of daily living) </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="56%" valign=top style='width:56.02%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Withhold
  dose until toxicity returns to&nbsp;&#8804;&nbsp;Grade&nbsp;1 or baseline,
  then restart treatment at a reduced dose of 1.2&nbsp;mg/kg </span><span
  lang=EN-GB>up to a maximum of 120&nbsp;mg</span><span lang=EN-GB> every
  3&nbsp;weeks.</span></p>
  </td>
 </tr>
 <tr>
  <td width="43%" valign=top style='width:43.98%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:39.7pt;text-indent:-39.7pt;page-break-after:
  avoid'><span lang=EN-GB>Grade&nbsp;3 (interfering with activities of daily
  living)</span></p>
  </td>
  <td width="56%" valign=top style='width:56.02%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Withhold
  dose until toxicity returns to &#8804;&nbsp;Grade&nbsp;1 or baseline, then
  restart treatment at a reduced dose of 1.2&nbsp;mg/kg </span><span
  lang=EN-GB>up to a maximum of 120&nbsp;mg</span><span lang=EN-GB> every
  3&nbsp;weeks.</span></p>
  </td>
 </tr>
 <tr>
  <td width="43%" valign=top style='width:43.98%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:39.7pt;text-indent:-39.7pt;page-break-after:
  avoid'><span lang=EN-GB>Grade&nbsp;4 (sensory neuropathy that is disabling or
  motor neuropathy that is life threatening or leads to paralysis)</span></p>
  </td>
  <td width="56%" valign=top style='width:56.02%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Discontinue
  treatment.</span></p>
  </td>
 </tr>
</table>

<p class=Paragraph style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.25in;text-indent:-.25in'><sup><span lang=EN-GB style='font-size:
11.0pt'>a.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></sup><span lang=EN-GB style='font-size:9.0pt'>Grading based on
National Cancer Institute (NCI)&nbsp;Common Terminology Criteria for Adverse
Events (CTCAE) v3.0; see neuropathy: motor; neuropathy: sensory; and
neuropathic pain. </span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB>Table 4: Dosing recommendations for new or worsening peripheral
sensory or motor neuropathy during combination therapy</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="102%"
 style='width:102.58%;margin-left:5.4pt;border-collapse:collapse;border:none'>
 <tr>
  <td width="42%" valign=top style='width:42.54%;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width="28%" valign=top style='width:28.74%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Combination therapy with AVD</span></b></p>
  </td>
  <td width="28%" valign=top style='width:28.74%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Combination therapy with CHP</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="42%" valign=top style='width:42.54%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Severity of peripheral sensory or motor neuropathy
  </span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>(signs and symptoms </span></b><span lang=EN-GB>[abbreviated
  description of CTCAE<sup>a</sup>])</span></p>
  </td>
  <td width="28%" valign=top style='width:28.74%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Modification of dose and schedule </span></b></p>
  </td>
  <td width="28%" valign=top style='width:28.74%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Modification of dose and schedule </span></b></p>
  </td>
 </tr>
 <tr>
  <td width="42%" valign=top style='width:42.54%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:39.7pt;text-indent:-39.7pt;page-break-after:
  avoid'><span lang=EN-GB>Grade&nbsp;1 (paraesthesia and/or loss of reflexes,
  with no loss of function)</span></p>
  </td>
  <td width="28%" valign=top style='width:28.74%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Continue
  with the same dose and schedule.</span></p>
  </td>
  <td width="28%" valign=top style='width:28.74%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Continue
  with the same dose and schedule.</span></p>
  </td>
 </tr>
 <tr>
  <td width="42%" valign=top style='width:42.54%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:41.1pt;text-indent:-39.7pt;page-break-after:
  avoid'><span lang=EN-GB>Grade&nbsp;2 (interfering with function but not with
  activities of daily living)</span></p>
  </td>
  <td width="28%" valign=top style='width:28.74%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Reduce
  dose to 0.9&nbsp;mg/kg up </span><span lang=EN-GB>to a maximum of 90&nbsp;mg</span><span
  lang=EN-GB> every 2&nbsp;weeks.</span></p>
  </td>
  <td width="28%" valign=top style='width:28.74%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:3.0pt'><u><span lang=EN-GB>Sensory
  neuropathy</span></u><span lang=EN-GB>: Continue treatment at same dose level.</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Motor
  neuropathy</span></u><span lang=EN-GB>: Reduce dose to 1.2&nbsp;mg/kg, up to
  a maximum of 120&nbsp;mg every 3&nbsp;weeks.</span></p>
  </td>
 </tr>
 <tr>
  <td width="42%" valign=top style='width:42.54%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:39.7pt;text-indent:-39.7pt;page-break-after:
  avoid'><span lang=EN-GB>Grade&nbsp;3 (interfering with activities of daily
  living)</span></p>
  </td>
  <td width="28%" valign=top style='width:28.74%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Withhold
  treatment with ADCETRIS until toxicity is &#8804;&nbsp;Grade&nbsp;2, then
  restart treatment at a reduced dose to 0.9&nbsp;mg/kg up </span><span
  lang=EN-GB>to a maximum of 90&nbsp;mg</span><span lang=EN-GB> </span><span
  lang=EN-GB>every 2&nbsp;weeks.</span></p>
  </td>
  <td width="28%" valign=top style='width:28.74%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:3.0pt'><u><span lang=EN-GB>Sensory
  neuropathy</span></u><span lang=EN-GB>: Reduce dose to 1.2&nbsp;mg/kg up to a
  maximum of 120&nbsp;mg every 3&nbsp;weeks.</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Motor
  neuropathy</span></u><span lang=EN-GB>: Discontinue treatment.</span></p>
  </td>
 </tr>
 <tr>
  <td width="42%" valign=top style='width:42.54%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:39.7pt;text-indent:-39.7pt;page-break-after:
  avoid'><span lang=EN-GB>Grade&nbsp;4 (sensory neuropathy which is disabling or
  motor neuropathy that is life threatening or leads to paralysis)</span></p>
  </td>
  <td width="28%" valign=top style='width:28.74%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Discontinue
  treatment.</span></p>
  </td>
  <td width="28%" valign=top style='width:28.74%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Discontinue
  treatment.</span></p>
  </td>
 </tr>
</table>

<p class=Paragraph style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:4.5pt'><sup><span lang=EN-GB style='font-size:9.0pt'>a.</span></sup><span
lang=EN-GB style='font-size:9.0pt'> Grading based on National Cancer Institute
(NCI)&nbsp;Common Terminology Criteria for Adverse Events (CTCAE) v4.03; see
neuropathy: motor; neuropathy: sensory; and neuropathic pain. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Special
patient populations</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Renal and
hepatic impairment</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Combination
therapy</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Patients with
renal impairment should be closely monitored for adverse events. </span><span
lang=EN-GB>There is no clinical trial experience using ADCETRIS in combination
with chemotherapy in patients with renal impairment, where serum creatinine is
&#8805;&nbsp;2.0&nbsp;mg/dL and/or creatinine clearance or calculated
creatinine clearance is &#8804;&nbsp;40&nbsp;mL/minute. Use of ADCETRIS in
combination with chemotherapy should be avoided in patients with severe renal
impairment. </span></p>

<h5 align=left style='text-align:left;page-break-after:auto'><span lang=EN-GB
style='font-style:normal'>&nbsp;</span></h5>

<p class=MsoNormal><span lang=EN-GB>Patients with hepatic impairment should be
closely monitored for adverse events. The recommended starting dose in patients
with mild hepatic impairment receiving ADCETRIS in combination with AVD is
0.9&nbsp;mg/kg administered as an intravenous infusion over 30&nbsp;minutes
every 2&nbsp;weeks. The recommended starting dose in patients with mild hepatic
impairment receiving ADCETRIS in combination with CHP is 1.2&nbsp;mg/kg
administered as an intravenous infusion over 30&nbsp;minutes every
3&nbsp;weeks. There is no clinical trial experience using ADCETRIS in
combination with chemotherapy in patients with hepatic impairment, where total
bilirubin is &gt;&nbsp;1.5 times the upper limit of normal (ULN) (unless due to
Gilbert syndrome), or aspartate aminotransferase (AST) or alanine
aminotransferase (ALT) are &gt;&nbsp;3 times the ULN, or &gt;&nbsp;5 times the
ULN if their elevation may be reasonably ascribed to the presence of HL in the
liver. Use of ADCETRIS in combination with chemotherapy should be avoided in patients
with moderate and severe hepatic impairment.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Monotherapy</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>The recommended starting dose in patients with severe renal
impairment is 1.2&nbsp;mg/kg administered as an intravenous infusion over
30&nbsp;minutes every 3&nbsp;weeks. Patients with renal impairment should be
closely monitored for adverse events (see section&nbsp;5.2).</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>The recommended
starting dose in patients with hepatic impairment is 1.2&nbsp;mg/kg
administered as an intravenous infusion over 30&nbsp;minutes every
3&nbsp;weeks. Patients with hepatic impairment should be closely monitored for
adverse events (see section&nbsp;5.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Elderly</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:windowtext'>The dosing
recommendations for patients aged 65 and older are the same as for adults.</span><span
style='color:windowtext'> Currently available data are described in sections&nbsp;4.8,
5.1 and 5.2.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Paediatric
population </span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The safety and efficacy of</span><span
lang=EN-GB> ADCETRIS in</span><span lang=EN-GB> children less than
18&nbsp;years have not yet been established. </span>Currently available data
are described in sections&nbsp;4.8, 5.1 and 5.2 but no recommendation on a
posology can be made.</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In nonclinical studies, thymus depletion
has been observed (see section&nbsp;5.3).</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
text-autospace:none'><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Method of
administration </span></u></p>

<p class=default0 style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=default0><span lang=EN-GB style='font-size:11.0pt'>The recommended
dose of ADCETRIS is infused over 30&nbsp;minutes. </span></p>

<p class=default0><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=default0><span lang=EN-GB style='font-size:11.0pt'>For instructions on
reconstitution and dilution of the medicinal product before administration, see
section&nbsp;6.6.</span></p>

<p class=MsoNormal><b><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal><span lang=EN-GB>ADCETRIS must not be administered as an
intravenous push or bolus. ADCETRIS should be administered through a dedicated
intravenous line and it must not be mixed with other medicinal products (see
section&nbsp;6.2).</span></p>

<p class=default0><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<h3><span lang=EN-GB>4.3&nbsp;&nbsp;&nbsp;&nbsp; Contraindications</span></h3>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Hypersensitivity to the active substance or
to any of the excipients listed in section&nbsp;6.1. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Combined use of bleomycin and ADCETRIS
causes pulmonary toxicity (see section&nbsp;4.5). </span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<h3><span lang=EN-GB>4.4&nbsp;&nbsp;&nbsp;&nbsp; Special warnings and
precautions for use</span></h3>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Progressive
multifocal leukoencephalopathy</span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>John Cunningham virus (JCV) reactivation
resulting in progressive multifocal leukoencephalopathy (PML) and death can
occur in ADCETRIS&#8209;treated patients. PML has been reported in patients who
received this treatment after receiving multiple prior chemotherapy regimens.
PML is a rare demyelinating disease of the central nervous system that results
from reactivation of latent JCV and is often fatal. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Patients should be closely monitored for
new or worsening neurological, cognitive, or behavioural signs or symptoms,
which may be suggestive of PML. ADCETRIS should be held for any suspected case
of PML. Suggested evaluation of PML includes neurology consultation, gadolinium&#8209;enhanced
magnetic resonance imaging of the brain and cerebrospinal fluid analysis for
JCV DNA by polymerase chain reaction or a brain biopsy with evidence of JCV. A
negative JCV PCR does not exclude PML. Additional follow up and evaluation may
be warranted if no alternative diagnosis can be established. ADCETRIS dosing should
be permanently discontinued if a diagnosis of PML is confirmed.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The physician should be particularly alert
to symptoms suggestive of PML that the patient may not notice (e.g., cognitive,
neurological, or psychiatric symptoms).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:0in;page-break-after:
avoid;text-autospace:none'><u><span lang=EN-GB>Pancreatitis</span></u></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;page-break-after:
avoid;text-autospace:none'><u><span lang=EN-GB><span style='text-decoration:
 none'>&nbsp;</span></span></u></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;text-autospace:none'><span
lang=EN-GB>Acute pancreatitis has been observed in patients treated with ADCETRIS.
Fatal outcomes have been reported.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:0in;text-autospace:none'><span
lang=EN-GB>Patients should be closely monitored for new or worsening abdominal
pain, which may be suggestive of acute pancreatitis. Patient evaluation may
include physical examination, laboratory evaluation for serum amylase and serum
lipase, and abdominal imaging, such as ultrasound and other appropriate
diagnostic measures. ADCETRIS should be held for any suspected case of acute
pancreatitis. ADCETRIS should be discontinued if a diagnosis of acute
pancreatitis is confirmed. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Pulmonary
toxicity</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Cases of pulmonary toxicity</span><span
lang=EN-GB>, including pneumonitis, interstitial lung disease, and acute
respiratory distress syndrome (ARDS), some with fatal outcomes,</span><span
lang=EN-GB> have </span><span lang=EN-GB>been </span><span lang=EN-GB>reported </span><span
lang=EN-GB>in patients </span><span lang=EN-GB>receiving ADCETRIS. Although a
causal association </span><span lang=EN-GB>with ADCETRIS</span><span
lang=EN-GB> has not been established, the risk of pulmonary toxicity cannot be
ruled out. In the event of new or worsening pulmonary symptoms (e.g. cough,
dyspnoea), a prompt diagnostic evaluation should be performed and patients
should be treated appropriately.</span><span lang=EN-GB> </span><span
lang=EN-GB>Consider holding ADCETRIS dosing during evaluation and until
symptomatic improvement.</span></p>

<p class=MsoListParagraph style='margin-left:0in;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Serious
infections and opportunistic infections</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Serious infections such as pneumonia,
staphylococcal bacteraemia, sepsis/septic shock (including fatal outcomes) and
herpes zoster, cytomegalovirus (CMV) (reactivation) and opportunistic
infections such as Pneumocystis jiroveci pneumonia and oral candidiasis have
been reported in patients treated with ADCETRIS. Patients should be carefully
monitored during treatment for the emergence of possible serious and
opportunistic infections.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Infusion&#8209;related
reactions</span></u></p>

<p class=Paragraph style='margin-bottom:0in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Paragraph style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Immediate and delayed infusion&#8209;related reactions (IRR), as well
as anaphylactic reactions, have been reported. </span></p>

<p class=Paragraph style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt;color:black'>&nbsp;</span></p>

<p class=Paragraph style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt;color:black'>Patients should be carefully monitored during and after
infusion.</span><span lang=EN-GB style='font-size:11.0pt'> <span
style='color:black'>If an anaphylactic reaction occurs, administration of ADCETRIS
should be immediately and permanently discontinued and appropriate medical
therapy should be administered.</span></span></p>

<p class=Paragraph style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=Paragraph style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>If an IRR occurs, the infusion should be interrupted and appropriate
medical management instituted. The infusion may be restarted at a slower rate
after symptom resolution. Patients who have experienced a prior IRR should be
premedicated for subsequent infusions. Premedication may include paracetamol,
an antihistamine and a corticosteroid. </span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>IRRs are more
frequent and more severe in patients with antibodies to brentuximab vedotin
(see section&nbsp;4.8).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Tumour
lysis syndrome</span></u></p>

<p class=MsoListBullet style='margin-left:0in;text-indent:0in;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoListBullet style='margin-left:0in;text-indent:0in'><span
lang=EN-GB style='font-size:11.0pt'>Tumour lysis syndrome (TLS) has been
reported with ADCETRIS. Patients with rapidly proliferating tumour and high
tumour burden are at risk of tumour lysis syndrome. These patients should be
monitored closely and managed according to best medical practice. Management of
TLS may include aggressive hydration, monitoring of renal function, correction
of electrolyte abnormalities, anti&#8209;hyperuricaemic therapy, and supportive
care.</span></p>

<p class=MsoListBullet style='margin-left:0in;text-indent:0in'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Peripheral
neuropathy</span></u></p>

<p class=Default style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><a name="_Hlk519675029"><span lang=EN-GB style='font-size:
11.0pt'>ADCETRIS may cause peripheral neuropathy, both sensory and motor. ADCETRIS&#8209;induced
peripheral neuropathy is typically an effect of cumulative exposure to this
medicinal product and is reversible in most cases. In clinical trials, the
majority of patients had resolution or improvement of their symptoms (see
section&nbsp;4.8). Patients should be monitored for symptoms of neuropathy,
such as hypoesthesia, hyperesthesia, paraesthesia, discomfort, a burning
sensation, neuropathic pain or weakness. Patients experiencing new or worsening
peripheral neuropathy may require a delay and a dose </span></a><span
lang=EN-GB style='font-size:11.0pt'>reduction of ADCETRIS or discontinuation of
treatment (see section&nbsp;4.2). </span></p>

<p class=MsoListBullet style='margin-left:0in;text-indent:0in'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Haematological
toxicities</span></u></p>

<p class=Default style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Grade 3 or
Grade&nbsp;4 anaemia, thrombocytopenia, and prolonged (&#8805;&nbsp;1&nbsp;week)
Grade&nbsp;3 or Grade&nbsp;4 neutropenia can occur with ADCETRIS. Complete
blood counts should be monitored prior to administration of each dose. If
Grade&nbsp;3 or Grade&nbsp;4 neutropenia develops, refer to section&nbsp;4.2.</span></p>

<p class=MsoListBullet style='margin-left:0in;text-indent:0in'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Febrile
neutropenia</span></u></p>

<p class=Default style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Febrile neutropenia
(fever of unknown origin without clinically or microbiologically documented
infection with an absolute neutrophil count &lt;&nbsp;1.0&nbsp;x 10<sup>9</sup>/L,
fever &#8805;&nbsp;38.5&nbsp;<sup>0</sup>C; ref CTCAE v3) has been reported
with treatment with ADCETRIS. Complete blood counts should be monitored prior
to administration of each dose of treatment. Patients should be monitored
closely for fever and managed according to best medical practice if febrile
neutropenia develops.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt'>In combination therapy with AVD
or CHP, advanced age was a risk factor for febrile neutropenia. </span><span
lang=EN-GB style='font-size:11.0pt'>When ADCETRIS is administered in
combination with AVD or CHP, primary prophylaxis with G&#8209;CSF, beginning
with the first dose, is recommended for all patients regardless of age.</span></p>

<p class=ListEnd><span lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Stevens&#8209;Johnson
syndrome and toxic epidermal necrolysis</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoListBullet style='margin-left:0in;text-indent:0in'><span
lang=EN-GB style='font-size:11.0pt'>Stevens&#8209;Johnson syndrome (SJS) and
toxic epidermal necrolysis (TEN) have been reported with ADCETRIS. Fatal
outcomes have been reported. If SJS or TEN occur, ADCETRIS should be
discontinued and appropriate medical therapy should be administered.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=ListEnd style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt;color:black'>Gastrointestinal complications</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoListBullet style='margin-left:0in;text-indent:0in;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt'>Gastrointestinal (GI)
complications including intestinal obstruction, ileus, enterocolitis,
neutropenic colitis, erosion, ulcer, perforation and haemorrhage, some with
fatal outcomes, have been reported in patients treated with ADCETRIS. In the
event of new or worsening GI symptoms, perform a prompt diagnostic evaluation
and treat appropriately.</span></p>

<p class=MsoListBullet style='margin-left:0in;text-indent:0in;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Hepatotoxicity</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB style='color:windowtext'>Hepatotoxicity in the form of elevations in
alanine aminotransferase (ALT) and aspartate aminotransferase (AST) has been
reported with ADCETRIS. </span><span lang=EN-GB style='color:windowtext'>Serious
cases of hepatotoxicity, including fatal outcomes, have also occurred. Pre&#8209;existing
liver disease, comorbidities, and concomitant medications may also increase the
risk. </span><span lang=EN-GB style='color:windowtext'>Liver function </span><span
lang=EN-GB style='color:windowtext'>should be </span><span lang=EN-GB
style='color:windowtext'>tested before initiating the treatment and </span><span
lang=EN-GB style='color:windowtext'>routinely</span><span lang=EN-GB
style='color:windowtext'> monitored in patients receiving ADCETRIS. </span><span
lang=EN-GB style='color:windowtext'>Patients experiencing hepatotoxicity may
require a delay, change in dose or discontinuation of ADCETRIS.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Hyperglycaemia</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Hyperglycaemia has been reported during
clinical trials in patients with an elevated Body Mass Index (BMI) with or
without a history of diabetes mellitus. However, any patient who experiences an
event of hyperglycaemia should have their serum glucose closely monitored. Anti&#8209;diabetic
treatment should be administered as appropriate. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Renal and
hepatic impairment</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>There is limited experience in patients
with renal and hepatic impairment. Available data indicate that MMAE clearance
might be affected by severe renal impairment, hepatic impairment, and by low
serum albumin concentrations (see section&nbsp;5.2). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>CD30+
CTCL</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The size of the treatment effect in CD30 +
CTCL subtypes other than mycosis fungoides (MF) and primary cutaneous
anaplastic large cell lymphoma (pcALCL) is not clear due to lack of high level
evidence. In two single arm phase II studies of ADCETRIS, disease activity has
been shown in the subtypes S&eacute;zary syndrome (SS), lymphomatoid papulosis
(LyP) and mixed CTCL histology. These data suggest that efficacy and safety can
be extrapolated to other CTCL CD30+ subtypes. Nevertheless, ADCETRIS should be
used with caution in other CD30+ CTCL patients after careful consideration of
the potential benefit&#8209;risk on an individual basis (see section&nbsp;5.1).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Sodium
content in excipients</span></u></p>

<p class=MsoListBullet style='margin-left:0in;text-indent:0in;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoListBullet style='margin-left:0in;text-indent:0in'><span
lang=EN-GB style='font-size:11.0pt'>This medicinal product contains 13.2&nbsp;mg
sodium per vial, equivalent to 0.7% of the WHO recommended maximum daily intake
of 2&nbsp;g sodium for an adult. </span></p>

<p class=MsoListBullet style='margin-left:0in;text-indent:0in'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Traceability</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>In order to improve the traceability of
biological medicinal products, the name and the batch number of the
administered product should be clearly recorded.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<h3><span lang=EN-GB>4.5&nbsp;&nbsp;&nbsp;&nbsp; Interaction with other
medicinal products and other forms of interaction</span></h3>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Interaction
with medicinal products metabolised through CYP3A4 route (CYP3A4
inhibitors/inducers)</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Co&#8209;administration of brentuximab
vedotin with ketoconazole, a strong CYP3A4 and P&#8209;gp inhibitor, increased
the exposure to the antimicrotubule agent MMAE by approximately 73%, and did
not alter the plasma exposure to brentuximab vedotin. Therefore, co&#8209;administration
of brentuximab vedotin with strong CYP3A4 and P&#8209;gp inhibitors may
increase the incidence of neutropenia. If neutropenia develops, refer to </span><span
lang=EN-GB>Tables&nbsp;1 and&nbsp;2 for dosing recommendations for neutropenia
(see section&nbsp;4.2). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Co&#8209;administration of </span><span
lang=EN-GB>brentuximab vedotin</span><span lang=EN-GB> with rifampicin, a
strong CYP3A4 inducer, did not alter the plasma exposure to </span><span
lang=EN-GB>brentuximab vedotin</span><span lang=EN-GB>. Though PK data are
limited, co-administration of rifampicin appeared to reduce plasma
concentrations of MMAE metabolites that could be assayed. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Co</span><span lang=EN-GB>&#8209;</span><span
lang=EN-GB>administration of midazolam, a CYP3A4 substrate, with brentuximab
vedotin did not alter the metabolism of midazolam; therefore brentuximab
vedotin is not expected to alter the exposure to medicines that are metabolised
by CYP3A4 enzymes.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Doxorubicin,
vinblastine and dacarbazine (AVD) </span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The serum
and plasma pharmacokinetic characteristics of </span><span lang=EN-GB>antibody
drug conjugate (</span><span lang=EN-GB>ADC) and MMAE respectively following
administration of brentuximab vedotin in combination with AVD were similar to
that in monotherapy.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Co&#8209;administration of brentuximab
vedotin did not affect the plasma exposure of AVD.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='color:windowtext'>Cyclophosphamide, Doxorubicin and Prednisone (CHP)</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='color:windowtext'>The serum and plasma pharmacokinetic characteristics
of ADC and MMAE, respectively, following administration of brentuximab vedotin
in combination with CHP were similar to that in monotherapy.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Co&#8209;administration of brentuximab
vedotin is not expected to affect the exposure of CHP.</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='color:windowtext'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='color:windowtext'>Bleomycin</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='color:windowtext'>There were no formal drug&#8209;drug interaction
studies with brentuximab vedotin and bleomycin (B). In a phase 1&nbsp;dose
finding and safety study (SGN35&#8209;009), unacceptable pulmonary toxicity
(including 2&nbsp;fatal events) was noted in 11 of 25&nbsp;patients (44%)
treated with brentuximab vedotin plus ABVD. No pulmonary toxicity or fatal
events were reported with brentuximab vedotin + AVD. Therefore, co&#8209;administration
of ADCETRIS with bleomycin is contraindicated (see section&nbsp;4.3).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<h3><span lang=EN-GB>4.6&nbsp;&nbsp;&nbsp;&nbsp; </span><span lang=EN-GB>Fertility,
p</span><span lang=EN-GB>regnancy and lactation</span></h3>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Women of
childbearing potential </span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Women of childbearing potential should be
using two methods of effective contraception during treatment with ADCETRIS and
until 6&nbsp;months after treatment. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Pregnancy</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>There are no data from the use of ADCETRIS
in pregnant women. Studies in animals have shown reproductive toxicity (see
section&nbsp;5.3). </span></p>

<p class=Paragraph style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>ADCETRIS should not be used during
pregnancy unless the benefit to the mother outweighs the potential risks to the
foetus. If a pregnant woman needs to be treated she should be clearly advised
on the potential risk to the foetus.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>See the fertility section below pertaining
to advice for women whose male partners are being treated with ADCETRIS.</span></p>

<p class=Paragraph style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Breast&#8209;feeding</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>There are no data as to whether brentuximab
vedotin or its metabolites are excreted in human milk. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>A risk to the newborn/infant cannot be
excluded. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>A decision should be made whether to
discontinue breast&#8209;feeding or to discontinue/abstain from this therapy,
taking into account a potential risk of breast&#8209;feeding for the child and
the benefit of therapy for the woman.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Fertility</span></u></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In non&#8209;clinical studies, </span><span
lang=EN-GB>brentuximab vedotin</span><span lang=EN-GB> treatment has resulted
in testicular toxicity, and may alter male fertility. MMAE has been shown to
have aneugenic properties (see section&nbsp;5.3). Therefore, men being treated
with this medicine are advised to have sperm samples frozen and stored before
treatment. Men being treated with this medicine are advised not to father a
child during treatment and for up to 6&nbsp;months following the last dose. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<h3><span lang=EN-GB>4.7&nbsp;&nbsp;&nbsp;&nbsp; Effects on ability to drive
and use machines</span></h3>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:windowtext'>ADCETRIS may have
a moderate influence on the ability to drive and use machines (e.g. dizziness),
see section&nbsp;4.8. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<h3><span lang=EN-GB>4.8&nbsp;&nbsp;&nbsp;&nbsp; Undesirable effects</span></h3>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Summary
of the safety profile</span></u></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>The safety
profile of ADCETRIS is based on available clinical trial data, the Named
Patient Program (NPP), and post&#8209;marketing experience to date. Frequencies
of adverse reactions described below and in Table&nbsp;5 have been determined
based on data generated from clinical studies. </span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><i><span
lang=EN-GB>Monotherapy</span></i></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:windowtext'>In the pooled dataset of </span><span lang=EN-GB
style='color:windowtext'>ADCETRIS</span><span lang=EN-GB style='color:windowtext'>
as monotherapy across HL, sALCL and CTCL studies (SG035&#8209;0003, SG035&#8209;0004,
SGN35&#8209;005, SGN35&#8209;006, C25001 and C</span><span lang=EN-GB
style='color:windowtext'>25007, see section&nbsp;5.1)</span><span lang=EN-GB
style='color:windowtext'> the most frequent adverse reactions (&#8805;&nbsp;10%)
were infections,</span><span lang=EN-GB style='color:windowtext'> peripheral
sensory neuropathy, nausea</span><span lang=EN-GB style='color:windowtext'>,
fatigue, diarrhoea, pyrexia, upper respiratory tract infection, neutropenia, rash,
cough, vomiting, arthralgia, peripheral motor neuropathy</span><span
lang=EN-GB style='color:windowtext'>, infusion-related reactions, pruritus,
constipation, dyspnoea, weight decreased, myalgia and abdominal pain.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Serious adverse
drug reactions occurred in 12% of patients. The frequency of unique serious
adverse drug reactions was &#8804;&nbsp;1%.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Adverse events
led to treatment discontinuation in 24% of patients receiving ADCETRIS. </span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:windowtext'>The safety data in patients retreated with ADCETRIS
(SGN35&#8209;006, see section&nbsp;5.1) were consistent with those observed in
the combined pivotal phase&nbsp;2 studies, with the exception of peripheral
motor neuropathy, which had a higher incidence (28% vs. 9% in the pivotal phase
2 studies) and was primarily Grade&nbsp;2. Patients also had a higher incidence
of arthralgia, Grade&nbsp;3 anaemia, and back pain compared to patients
observed in the combined pivotal phase&nbsp;2 studies.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>T</span><span lang=EN-GB>he safety data in
patients with relapsed or refractory HL who had not received an autologous stem
cell transplant and were treated with the recommended dose of 1.8&nbsp;mg/kg
every three weeks in a single&#8209;arm phase 4&nbsp;study (n&nbsp;=&nbsp;60), the
phase 1 dose escalation and clinical pharmacology studies (n&nbsp;=&nbsp;15&nbsp;patients)
and in the NPP (n&nbsp;=&nbsp;26&nbsp;patients) (see section&nbsp;5.1) were
consistent with the safety profile of the pivotal clinical studies. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Combination
therapy </span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For safety information of chemotherapy
agents given in combination with ADCETRIS (doxorubicin, vinblastine and
dacarbazine (AVD) or cyclophosphamide, doxorubicin and prednisone (CHP)), refer
to their summary of product characteristics. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In the studies of ADCETRIS as combination
therapy in 662&nbsp;patients with previously untreated advanced HL (C25003) and
223 patients with previously untreated CD30+ </span>peripheral T-cell lymphoma
(<span lang=EN-GB>PTCL) (SGN35&#8209;014), the most common adverse reactions
(&#8805;&nbsp;10%) were: infections, neutropenia, peripheral sensory
neuropathy, nausea, constipation, vomiting, diarrhoea, fatigue, pyrexia,
alopecia, anaemia, weight decreased, stomatitis, febrile neutropenia, abdominal
pain, decreased appetite, insomnia, bone pain, rash, cough, dyspnoea, arthralgia,
myalgia, back pain, peripheral motor neuropathy, upper respiratory tract
infection, and dizziness. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In patients receiving ADCETRIS combination
therapy, serious adverse reactions occurred in 34% of patients. Serious adverse
reactions occurring in &#8805;&nbsp;3% of patients included febrile neutropenia
(15%), pyrexia (5%), and neutropenia (3%). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Adverse events led to treatment discontinuation
in 10% of patients. Adverse events that led to treatment discontinuation in
&#8805;&nbsp;2% of patients included peripheral sensory neuropathy, and peripheral
neuropathy.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Tabulated
list of adverse reactions</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Adverse
reactions for ADCETRIS are listed by MedDRA System Organ Class and Preferred
Term (see Table&nbsp;5). Within each System Organ Class, adverse reactions are
listed under frequency categories of: Very common (&#8805;&nbsp;1/10); Common
(&#8805;&nbsp;1/100 to &lt;&nbsp;1/10); Uncommon (&#8805;&nbsp;1/1,000 to &lt;&nbsp;1/100);
Rare (&#8805;&nbsp;1/10,000 to &lt;&nbsp;1/1,000); Very rare (&lt;&nbsp;1/10,000);
not known (cannot be estimated from the available data). </span><span
lang=EN-GB>Within each frequency grouping, adverse reactions are presented in
the order of decreasing seriousness.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Table 5:
Adverse reactions to ADCETRIS <br>
<br>
</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=658
 style='width:493.5pt;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid;height:15.1pt'>
   <td width=149 valign=top style='width:111.75pt;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:15.1pt'>
   <p class=MsoNormal style='text-autospace:none'><a name="_Hlk5943718"><b><span
   lang=EN-GB>System organ class</span></b></a></p>
   </td>
   <td width=283 valign=top style='width:212.6pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt'>
   <p class=MsoNormal><b><span lang=EN-GB>Adverse reactions (monotherapy)</span></b></p>
   </td>
   <td width=226 valign=top style='width:169.15pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt'>
   <p class=MsoNormal><b><span lang=EN-GB>Adverse reactions <br>
   (combination therapy)</span></b></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid;height:15.1pt'>
   <td width=658 colspan=3 valign=top style='width:493.5pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Infections
   and infestations</span></b></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid'>
   <td width=149 valign=top style='width:111.75pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Very
   common: </span></p>
   </td>
   <td width=283 valign=top style='width:212.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Infection</span><sup><span
   lang=EN-GB>a</span></sup><span lang=EN-GB>, upper respiratory tract
   infection</span></p>
   </td>
   <td width=226 valign=top style='width:169.15pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><span lang=EN-GB>Infection</span><sup><span lang=EN-GB>a</span></sup><span
   lang=EN-GB>, upper respiratory tract infection</span></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid'>
   <td width=149 valign=top style='width:111.75pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Common:</span></p>
   </td>
   <td width=283 valign=top style='width:212.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><span lang=PT>Herpes
   zoster, pneumonia, herpes simplex, oral candidiasis</span></p>
   </td>
   <td width=226 valign=top style='width:169.15pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><span lang=EN-GB>Pneumonia, oral candidiasis,
   sepsis/septic shock, herpes zoster</span></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid'>
   <td width=149 valign=top style='width:111.75pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Uncommon:</span></p>
   </td>
   <td width=283 valign=top style='width:212.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Pneumocystis
   jiroveci pneumonia, staphylococcal bacteraemia, cytomegalovirus infection or
   reactivation,</span><span lang=EN-GB> sepsis/septic shock</span></p>
   </td>
   <td width=226 valign=top style='width:169.15pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><span lang=EN-GB>Herpes simplex, Pneumocystis jiroveci
   pneumonia</span></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid'>
   <td width=149 valign=top style='width:111.75pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><span lang=EN-GB>Frequency not known:</span></p>
   </td>
   <td width=283 valign=top style='width:212.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><span lang=EN-GB>Progressive multifocal
   leukoencephalopathy</span></p>
   </td>
   <td width=226 valign=top style='width:169.15pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid;height:15.1pt'>
   <td width=658 colspan=3 valign=top style='width:493.5pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Blood
   and lymphatic system disorders</span></b></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid'>
   <td width=149 valign=top style='width:111.75pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Very
   common:</span></p>
   </td>
   <td width=283 valign=top style='width:212.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><span lang=EN-GB>Neutropenia</span></p>
   </td>
   <td width=226 valign=top style='width:169.15pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><span lang=EN-GB>Neutropenia<sup>a</sup>, anaemia,
   febrile neutropenia</span></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid'>
   <td width=149 valign=top style='width:111.75pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Common:</span></p>
   </td>
   <td width=283 valign=top style='width:212.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><span lang=EN-GB>Anaemia, thrombocytopenia</span></p>
   </td>
   <td width=226 valign=top style='width:169.15pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><span lang=EN-GB>Thrombocytopenia</span></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid'>
   <td width=149 valign=top style='width:111.75pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><span lang=EN-GB>Uncommon:</span></p>
   </td>
   <td width=283 valign=top style='width:212.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><span lang=EN-GB>Febrile neutropenia</span></p>
   </td>
   <td width=226 valign=top style='width:169.15pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid'>
   <td width=658 colspan=3 valign=top style='width:493.5pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Immune
   system disorders</span></b></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid'>
   <td width=149 valign=top style='width:111.75pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><span lang=EN-GB>Uncommon:</span></p>
   </td>
   <td width=283 valign=top style='width:212.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><span lang=EN-GB>Anaphylactic reaction</span></p>
   </td>
   <td width=226 valign=top style='width:169.15pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><span lang=EN-GB>Anaphylactic transfusion reaction</span></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid;height:15.1pt'>
   <td width=658 colspan=3 valign=top style='width:493.5pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Metabolism
   and nutrition disorders</span></b></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid'>
   <td width=149 valign=top style='width:111.75pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Very
   common:</span></p>
   </td>
   <td width=283 valign=top style='width:212.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
   </td>
   <td width=226 valign=top style='width:169.15pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><span lang=EN-GB>Decreased appetite</span></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid'>
   <td width=149 valign=top style='width:111.75pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Common:</span></p>
   </td>
   <td width=283 valign=top style='width:212.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><span lang=EN-GB>Hyperglycaemia</span></p>
   </td>
   <td width=226 valign=top style='width:169.15pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><span lang=EN-GB>Hyperglycaemia</span></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid'>
   <td width=149 valign=top style='width:111.75pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><span lang=EN-GB>Uncommon:</span></p>
   </td>
   <td width=283 valign=top style='width:212.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><span lang=EN-GB>Tumour lysis syndrome</span></p>
   </td>
   <td width=226 valign=top style='width:169.15pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><span lang=EN-GB>Tumour lysis syndrome</span></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid'>
   <td width=658 colspan=3 valign=top style='width:493.5pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><b><span lang=EN-GB>Psychiatric disorders</span></b></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid'>
   <td width=149 valign=top style='width:111.75pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><span lang=EN-GB>Very common:</span></p>
   </td>
   <td width=283 valign=top style='width:212.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
   </td>
   <td width=226 valign=top style='width:169.15pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><span lang=EN-GB>Insomnia</span></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid;height:15.1pt'>
   <td width=658 colspan=3 valign=top style='width:493.5pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Nervous
   system disorders</span></b></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid'>
   <td width=149 valign=top style='width:111.75pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Very
   common:</span></p>
   </td>
   <td width=283 valign=top style='width:212.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><span lang=EN-GB>Peripheral sensory neuropathy,
   peripheral motor neuropathy</span></p>
   </td>
   <td width=226 valign=top style='width:169.15pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><span lang=EN-GB>Peripheral sensory neuropathy<sup>a</sup>,
   peripheral motor neuropathy<sup>a</sup>, dizziness</span></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid'>
   <td width=149 valign=top style='width:111.75pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Common:</span></p>
   </td>
   <td width=283 valign=top style='width:212.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><span lang=EN-GB>Dizziness</span></p>
   </td>
   <td width=226 valign=top style='width:169.15pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid'>
   <td width=149 valign=top style='width:111.75pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><span lang=EN-GB>Uncommon:</span></p>
   </td>
   <td width=283 valign=top style='width:212.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><span lang=EN-GB>Demyelinating polyneuropathy</span></p>
   </td>
   <td width=226 valign=top style='width:169.15pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid;height:15.1pt'>
   <td width=658 colspan=3 valign=top style='width:493.5pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Respiratory,
   thoracic and mediastinal disorders</span></b></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid'>
   <td width=149 valign=top style='width:111.75pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><span lang=EN-GB>Very common:</span></p>
   </td>
   <td width=283 valign=top style='width:212.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><span lang=EN-GB>Cough, dyspnoea</span></p>
   </td>
   <td width=226 valign=top style='width:169.15pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><span lang=EN-GB>Cough, dyspnoea</span></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid'>
   <td width=658 colspan=3 valign=top style='width:493.5pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Gastrointestinal
   disorders</span></b></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid'>
   <td width=149 valign=top style='width:111.75pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Very
   common:</span></p>
   </td>
   <td width=283 valign=top style='width:212.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><span lang=EN-GB>Nausea, diarrhoea, vomiting, constipation,
   abdominal pain</span></p>
   </td>
   <td width=226 valign=top style='width:169.15pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><span lang=EN-GB>Nausea, constipation, vomiting,
   diarrhoea, abdominal pain, stomatitis</span></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid;height:15.1pt'>
   <td width=149 valign=top style='width:111.75pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt'>
   <p class=MsoNormal><span lang=EN-GB>Uncommon:</span></p>
   </td>
   <td width=283 valign=top style='width:212.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:15.1pt'>
   <p class=MsoNormal><span lang=EN-GB>Pancreatitis acute</span></p>
   </td>
   <td width=226 valign=top style='width:169.15pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:15.1pt'>
   <p class=MsoNormal><span lang=EN-GB>Pancreatitis acute</span></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid;height:15.1pt'>
   <td width=658 colspan=3 valign=top style='width:493.5pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Hepatobiliary
   disorders</span></b></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid;height:15.1pt'>
   <td width=149 valign=top style='width:111.75pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt'>
   <p class=MsoNormal><span lang=EN-GB>Common:</span></p>
   </td>
   <td width=283 valign=top style='width:212.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:15.1pt'>
   <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Alanine
   aminotransferase/aspartate aminotransferase (ALT/AST) increased</span></p>
   </td>
   <td width=226 valign=top style='width:169.15pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:15.1pt'>
   <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Alanine
   aminotransferase/aspartate aminotransferase (ALT/AST) increased</span></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid;height:15.1pt'>
   <td width=658 colspan=3 valign=top style='width:493.5pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Skin
   and subcutaneous tissue disorders</span></b></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid'>
   <td width=149 valign=top style='width:111.75pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Very
   common:</span></p>
   </td>
   <td width=283 valign=top style='width:212.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><span lang=EN-GB>Rash<sup>a</sup>, pruritus</span></p>
   </td>
   <td width=226 valign=top style='width:169.15pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><span lang=EN-GB>Alopecia, rash<sup>a</sup></span></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid'>
   <td width=149 valign=top style='width:111.75pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Common:</span></p>
   </td>
   <td width=283 valign=top style='width:212.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><span lang=EN-GB>Alopecia</span></p>
   </td>
   <td width=226 valign=top style='width:169.15pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><span lang=EN-GB>Pruritus</span></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid'>
   <td width=149 valign=top style='width:111.75pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><span lang=EN-GB>Uncommon:</span></p>
   </td>
   <td width=283 valign=top style='width:212.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><span lang=EN-GB>Stevens-Johnson syndrome/toxic epidermal
   necrolysis</span></p>
   </td>
   <td width=226 valign=top style='width:169.15pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><span lang=EN-GB>Stevens-Johnson syndrome<sup>b</sup></span></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid;height:15.1pt'>
   <td width=658 colspan=3 valign=top style='width:493.5pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Musculoskeletal
   and connective tissue disorders</span></b></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid'>
   <td width=149 valign=top style='width:111.75pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Very
   common:</span></p>
   </td>
   <td width=283 valign=top style='width:212.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><span lang=EN-GB>Arthralgia, myalgia</span></p>
   </td>
   <td width=226 valign=top style='width:169.15pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><span lang=EN-GB>Bone pain, arthralgia, myalgia, back
   pain</span></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid;height:14.35pt'>
   <td width=149 valign=top style='width:111.75pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
   <p class=MsoNormal><span lang=EN-GB>Common:</span></p>
   </td>
   <td width=283 valign=top style='width:212.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
   <p class=MsoNormal><span lang=EN-GB>Back pain</span></p>
   </td>
   <td width=226 valign=top style='width:169.15pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
   <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid;height:15.1pt'>
   <td width=658 colspan=3 valign=top style='width:493.5pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>General
   disorders and administration site conditions</span></b></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid'>
   <td width=149 valign=top style='width:111.75pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Very
   common:</span></p>
   </td>
   <td width=283 valign=top style='width:212.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Fatigue,
   pyrexia, infusion-related reactions<sup>a</sup></span></p>
   </td>
   <td width=226 valign=top style='width:169.15pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Fatigue,
   pyrexia</span></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid'>
   <td width=149 valign=top style='width:111.75pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><span lang=EN-GB>Common:</span></p>
   </td>
   <td width=283 valign=top style='width:212.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Chills</span></p>
   </td>
   <td width=226 valign=top style='width:169.15pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Infusion-related
   reactions<sup>a</sup>, chills</span></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid'>
   <td width=658 colspan=3 valign=top style='width:493.5pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Investigations</span></b></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid'>
   <td width=149 valign=top style='width:111.75pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><span lang=EN-GB>Very common:</span></p>
   </td>
   <td width=283 valign=top style='width:212.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Weight
   decreased</span></p>
   </td>
   <td width=226 valign=top style='width:169.15pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Weight
   decreased</span></p>
   </td>
  </tr>
 </thead>
</table>

<p class=Paragraph style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.25in;text-indent:-.25in'><sup><span lang=EN-GB style='font-size:
11.0pt'>a.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></sup><span lang=EN-GB style='font-size:9.0pt'>Represents pooling
of preferred terms.</span></p>

<p class=Paragraph style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.25in;text-indent:-.25in'><sup><span lang=EN-GB style='font-size:
11.0pt'>b.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></sup><span lang=EN-GB style='font-size:9.0pt'>Toxic epidermal
necrolysis was not reported in the combination therapy setting.</span></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Description
of selected adverse reactions</span></u></p>

<p class=Paragraph style='margin-bottom:0in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Paragraph style='margin-bottom:0in'><i><span lang=EN-GB
style='font-size:11.0pt'>Neutropenia and febrile neutropenia</span></i></p>

<p class=Paragraph style='margin-bottom:0in;text-indent:28.35pt;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Paragraph style='margin-bottom:0in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>Monotherapy</span></p>

<p class=Paragraph style='margin-bottom:0in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Paragraph style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>In clinical trials, neutropenia</span><span lang=EN-GB
style='font-size:11.0pt'> led to dose delays in 14% of patients. Grade&nbsp;3
neutropenia was reported in </span><span lang=EN-GB style='font-size:11.0pt'>13%
and Grade&nbsp;4 neutropenia was reported in 5% of patients. No patients
required dose reduction or discontinued treatment for neutropenia. </span></p>

<p class=Paragraph style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Severe and prolonged (&#8805;&nbsp;1&nbsp;week)
neutropenia can occur with this treatment which may increase the risk of
patients developing serious infections. Febrile neutropenia reported in &lt;&nbsp;1%
of the patients (see section&nbsp;4.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:windowtext'>In the pivotal phase
2 population </span><span lang=EN-GB style='color:windowtext'>(SG035&#8209;0003
and SG035&#8209;0004)</span><span lang=EN-GB style='color:windowtext'>, </span><span
lang=EN-GB style='color:windowtext'>the median duration of Grade&nbsp;3 or
Grade&nbsp;4 neutropenia was limited (1&nbsp;week); 2% of patients had
Grade&nbsp;4 neutropenia that lasted &#8805;&nbsp;7&nbsp;days. Less </span><span
lang=EN-GB style='color:windowtext'>than half of the patients in the pivotal
phase&nbsp;2 population with Grade&nbsp;3 or Grade&nbsp;4 neutropenia had
temporally associated infections, and the majority of temporally associated
infections were Grade&nbsp;1 or Grade&nbsp;2.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=Paragraph style='margin-bottom:0in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt;color:black'>Combination therapy</span></p>

<p class=Paragraph style='margin-bottom:0in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>In the clinical
trials of </span><span lang=EN-GB>ADCETRIS</span><span lang=EN-GB> as
combination therapy, neutropenia led to dose delays in 19% of patients. Grade&nbsp;3
neutropenia was reported in 17% and Grade&nbsp;4 neutropenia was reported in 41%
of patients. Two percent of patients required dose reduction and &lt;&nbsp;1%
discontinued one of more of the study drugs due to neutropenia. </span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Febrile
neutropenia was reported in 20% of the patients who did not receive primary
prophylaxis with G-CSF (see section&nbsp;4.2). The frequency of febrile
neutropenia was 13% in patients who received primary prophylaxis with G-CSF. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Serious
infections and opportunistic infections</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Monotherapy</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>In clinical
trials, serious infections </span><span lang=EN-GB>and opportunistic infections
occurred in 10% of patients, sepsis or septic shock occurred in &lt;&nbsp;1% of
the patients. The most commonly reported opportunistic infections were herpes
zoster and herpes simplex.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>Combination therapy</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>In the clinical trials of </span><span lang=EN-GB>ADCETRIS</span><span
lang=EN-GB> as combination therapy, </span><span lang=EN-GB>serious infections
including opportunistic infections occurred in 15% of patients; sepsis,
neutropenic sepsis, septic shock or bacteraemia occurred in 4% of the patients.
The most commonly reported opportunistic infections were herpes viral
infections.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=Paragraph style='margin-bottom:0in;page-break-after:avoid'><i><span
lang=EN-GB style='font-size:11.0pt'>Peripheral neuropathy</span></i></p>

<p class=Paragraph style='margin-bottom:0in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Paragraph style='margin-bottom:0in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>Monotherapy </span></p>

<p class=Paragraph style='margin-bottom:0in;page-break-after:avoid'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Paragraph style='margin-bottom:0in'><span style='font-size:11.0pt'>In
clinical trials treatment emergent neuropathy occurred </span><span lang=EN-GB
style='font-size:11.0pt'>in 59% of the population, peripheral motor neuropathy occurred
in 14% of patients. </span><span style='font-size:11.0pt'>Peripheral neuropathy
led to treatment discontinuation in 15%, dose reductions in 15%, and </span><span
lang=EN-GB style='font-size:11.0pt'>dose delays in 17% of patients. </span><span
style='font-size:11.0pt'>For patients who experienced peripheral neuropathy the
median time of onset of peripheral neuropathy was 12&nbsp;weeks. The median
duration of treatment for patients who discontinued due to peripheral
neuropathy was 12&nbsp;cycles.</span></p>

<p class=Paragraph style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:windowtext'>Among patients who
experienced peripheral neuropathy in the pivotal phase&nbsp;2 studies
(SG035-0003 and SG035&#8209;0004) and randomised phase&nbsp;3 monotherapy
studies (SGN35&#8209;005 and C25001), the median follow up time from end of
treatment until last evaluation ranged from 48.9&nbsp;to 98 weeks. At the time
of last evaluation, most of the patients (82-85%) who experienced peripheral
neuropathy had resolution or improvement of their peripheral neuropathy
symptoms. The median time from onset to resolution or improvement for all
events ranged from 16&nbsp;to 23.4&nbsp;weeks. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In patients with relapsed or refractory HL
or sALCL who were retreated with ADCETRIS (SGN35&#8209;006), the majority of
patients (80%) also had improvement or resolution of their peripheral
neuropathy symptoms at the time of last evaluation.</span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><a name="_Hlk519675104"><span
lang=EN-GB>Combination therapy</span></a></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:windowtext'>In the clinical
trial of ADCETRIS as combination therapy with AVD, </span><span lang=EN-GB
style='color:windowtext'>treatment emergent neuropathy occurred in 67% of the
population; peripheral motor neuropathy occurred in 11% of patients. Peripheral
neuropathy led to treatment discontinuation in 7%, dose reductions in 21%, and
dose delays in 1% of patients. For patients who experienced peripheral
neuropathy the median time of onset of peripheral neuropathy was 8&nbsp;weeks.
Patients who discontinued due to peripheral neuropathy received a median of 8
doses of ADCETRIS+AVD (A+AVD) before discontinuation of one or more agents. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:windowtext'>Among patients who
experienced peripheral neuropathy, the median follow up time from end of
treatment until last evaluation was approximately 91&nbsp;weeks. At the time of
last evaluation, most of the patients (76%) who experienced peripheral
neuropathy had resolution or improvement of their peripheral neuropathy
symptoms. The median time from onset to resolution or improvement of peripheral
neuropathy events was 10&nbsp;weeks (ranged from 0&nbsp;weeks to 139&nbsp;weeks).</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In the clinical trial of ADCETRIS as
combination therapy with CHP, </span><span lang=EN-GB style='color:windowtext'>treatment
emergent neuropathy occurred in 52% of the population; peripheral motor
neuropathy occurred in 9% of patients. Peripheral neuropathy led to treatment
discontinuation in 1%, dose reductions in 7% and dose delays in </span><span
lang=EN-GB>&lt;</span><span lang=EN-GB style='color:windowtext'>1% of patients.
For patients who experienced peripheral neuropathy the median time of onset was
9.1&nbsp;weeks. Patients who discontinued due to peripheral neuropathy received
a median of 5&nbsp;doses of ADCETRIS&nbsp;+&nbsp;CHP (A+CHP) before
discontinuation of one or more agents.</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:silver'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:windowtext'>Among patients who
experienced peripheral neuropathy, the median follow up time from end of
treatment until last evaluation was approximately 177&nbsp;weeks. At the time
of last evaluation, 64% who experienced peripheral neuropathy had resolution or
improvement of their peripheral neuropathy symptoms. The median time from onset
to resolution or improvement of peripheral neuropathy events was 19.0&nbsp;weeks
(ranged from 0&nbsp;weeks to 205&nbsp;weeks).</span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Infusion-related
reactions</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Monotherapy</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>IRRs, such as headache, rash, back pain,
vomiting, chills, nausea, dyspnoea, pruritus and cough were reported in 13% of
patients. </span><span lang=EN-GB>Anaphylactic reactions have been reported
(see section&nbsp;4.4). Symptoms of an anaphylactic reaction may include, but
are not limited to, urticaria, angioedema, hypotension and bronchospasm. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Combination
therapy</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>IRRs, such as headache, rash, back pain,
vomiting, chills, nausea, dyspnoea, pruritus, cough, infusion site pain and
pyrexia were reported in 8% of patients. Anaphylactic reactions have been
reported (see section&nbsp;4.4). Symptoms of an anaphylactic reaction may
include, but are not limited to, urticaria, angioedema, hypotension and
bronchospasm.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Immunogenicity</span></i></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In clinical trials, patients were
periodically tested for antibodies to brentuximab vedotin using a sensitive
electrochemiluminescent immunoassay. There was a higher incidence of </span><span
lang=EN-GB>infusion-related reactions observed in</span><span lang=EN-GB> patients
with antibodies </span><span lang=EN-GB>to brentuximab vedotin relative to</span><span
lang=EN-GB> patients </span><span lang=EN-GB>who tested transiently positive or
negative.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The presence of antibodies to brentux</span><span
lang=EN-GB>imab vedotin did not correlate with a clinically meaningful
reduction in serum brentuximab vedotin levels and did not result in a decrease
in the efficacy of brentuximab vedotin. While the presence of antibodies to
brentuximab vedotin does not necessarily predict the development of an IRR,
there was a higher incidence of IRRs observed in patients with persistently
positive anti-drug antibodies (ADA) relative to patients with transiently
positive ADA and never positive ADA. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>There was a trend of increased clearance of
brentuximab vedotin in paediatric patients confirmed positive for ADAs. No
patients aged &lt;&nbsp;12 years (0&nbsp;of&nbsp;11) and 2&nbsp;patients aged
&#8805;&nbsp;12 years (2&nbsp;of&nbsp;23) became persistently ADA positive.</span></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><u><span
lang=EN-GB>Paediatric population</span></u></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:windowtext'>Safety was evaluated in a phase 1/2&nbsp;study in
paediatric patients aged 7&#8209;17&nbsp;years of age (n&nbsp;=&nbsp;36) with
relapsed or refractory (r/r) HL and sALCL (see section&nbsp;5.1).<i> </i>In
this study in 36&nbsp;patients, no new safety concerns were reported.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><u><span
lang=EN-GB>Elderly </span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Monotherapy
</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>The safety profile in elderly patients is
generally in line with that of adult patients. However, elderly patients may be
more susceptible to events such as pneumonia, neutropenia and febrile
neutropenia.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Combination
therapy </span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>In older
patients (&#8805;&nbsp;60 years of age; n&nbsp;=&nbsp;186 [21%]), the incidence
of adverse events was similar across treatment arms. More serious adverse
events and dose modifications (including dose delays, reductions, and
discontinuations) were reported in the older patients compared with the overall
study population. Advanced age was a risk factor for febrile neutropenia in
patients in both arms. Older patients who received G-CSF primary prophylaxis
had lower incidence of neutropenia and febrile neutropenia than those who did
not receive G-CSF primary prophylaxis.</span></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><u><span
lang=EN-GB>Reporting of suspected adverse reactions</span></u></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Reporting
suspected adverse reactions after authorisation of the medicinal product is
important. It allows continued monitoring of the benefit/risk balance of the medicinal
product. Healthcare professionals are asked to report any suspected adverse
reactions via <span style='background:silver'>the national reporting system
listed in </span></span><span lang=EN-GB><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='background:silver'>Appendix V</span></a></span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<h3><span lang=EN-GB>4.9&nbsp;&nbsp;&nbsp;&nbsp; Overdose</span></h3>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>There is no known antidote for overdose of ADCETRIS.
In case of overdose, the patient should be closely monitored for adverse
reactions, particularly neutropenia, and supportive treatment should be
administered (see section 4.4). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<h2><span lang=EN-GB style='font-family:"Times New Roman",serif'>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACOLOGICAL
PROPERTIES</span></h2>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<h3><span lang=EN-GB>5.1&nbsp;&nbsp;&nbsp;&nbsp; Pharmacodynamic properties</span></h3>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Pharmacotherapeutic group: Antineoplastic
agents; other antineoplastic agents; monoclonal antibodies, ATC code: L01XC12.</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Mechanism
of action</span></u></p>

<p class=paragraph0 style='margin-bottom:0in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=paragraph0 style='margin-bottom:0in'><span lang=EN-GB
style='font-size:11.0pt'>Brentuximab vedotin</span><span lang=EN-GB
style='font-size:11.0pt'> is an ADC that delivers an antineoplastic agent that
results in apoptotic cell death selectively in CD30&#8209;expressing tumour
cells. Nonclinical data suggest that the biological activity of </span><span
lang=EN-GB style='font-size:11.0pt'>brentuximab vedotin</span><span lang=EN-GB
style='font-size:11.0pt'> results from a multi-step process. Binding of the ADC
to CD30 on the cell surface initiates internalisation of the ADC&#8209;CD30
complex, which then traffics to the lysosomal compartment. Within the cell, a
single defined active species, MMAE, is released via proteolytic cleavage.
Binding of MMAE to tubulin disrupts the microtubule network within the cell,
induces cell cycle arrest and results in apoptotic death of the CD30&#8209;expressing
tumour cell.</span></p>

<p class=paragraph0 style='margin-bottom:0in'><span lang=EN-GB
style='font-size:11.0pt;background:yellow'>&nbsp;</span></p>

<p class=paragraph0 style='margin-bottom:0in'><span lang=EN-GB
style='font-size:11.0pt'>Classical HL, sALCL and subtypes of CTCL (including MF
and pcALCL) express CD30 as an antigen on the surface of their malignant cells.
This expression is independent of disease stage, line of therapy or transplant
status.</span><span lang=EN-GB style='font-size:11.0pt'> These features make
CD30 a target for therapeutic intervention. Because of the CD30&#8209;targeted
mechanism of action brentuximab vedotin is able to overcome chemo-resistance as
CD30 is consistently expressed in patients who are refractory to multi-agent
chemotherapy, irrespective of prior transplant status. </span><span lang=EN-GB
style='font-size:11.0pt'>The CD30&#8209;targeted mechanism of action of
brentuximab vedotin, the consistent expression of CD30 throughout the classical
HL, sALCL and CD30+ CTCL disease and therapeutic spectrums and<i> </i>clinical
evidence in CD30&#8209;positive malignancies following multiple lines of
treatment provide a biologic rationale for its use in patients with relapsed
and refractory classical HL, sALCL with or without prior ASCT and CD30+ CTCL after
at least 1 prior systemic therapy.</span></p>

<p class=paragraph0 style='margin-bottom:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=paragraph0 style='margin-bottom:0in'><span lang=EN-GB
style='font-size:11.0pt'>Contributions to the mechanism of action by other
antibody associated functions have not been excluded. </span></p>

<p class=paragraph0 style='margin-bottom:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Pharmacodynamic
effects</span></u></p>

<p class=Paragraph style='margin-bottom:0in;page-break-after:avoid'><i><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Cardiac
electrophysiology</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Forty&#8209;six (46) patients with CD30&#8209;expressing
haematologic malignancies were evaluable of the 52&nbsp;patients who received
1.8&nbsp;mg/kg of brentuximab vedotin every 3&nbsp;weeks as part of a phase 1,
single&#8209;arm, open-label, multicenter cardiac safety study. The primary
objective was to evaluate the effect of</span><span lang=EN-GB> brentuximab
vedotin on cardiac ventricular re-polarization and the predefined primary
analysis was the change in QTc from baseline to multiple time points in Cycle&nbsp;1.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The upper 90% confidence interval (CI)
around the mean effect on QTc was &lt;&nbsp;10</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>msec at each of the Cycle&nbsp;1 and Cycle&nbsp;3 post-baseline time
points. These data indicate the absence of clinically relevant QT prolongation
due to brentuximab vedotin administered at a dose of 1.8&nbsp;mg/kg every
3&nbsp;weeks in patients with CD30&#8209;expressing malignancies.</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Clinical efficacy and safety</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Hodgkin lymphoma</span></i></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Study C25003</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>The efficacy and safety of ADCETRIS were
evaluated in a randomised, open-label, 2&#8209;arm, multicenter trial in 1334&nbsp;patients
with previously untreated advanced HL in combination with chemotherapy
(doxorubicin [A], vinblastine [V] and dacarbazine [D] [AVD]). All patients had
a histologically confirmed CD30&#8209;expressing disease. Sixty&#8209;two
percent of patients had extranodal site involvement. Of the 1334&nbsp;patients,
664&nbsp;patients were randomised to the ADCETRIS + AVD arm and 670&nbsp;patients
were randomised to the ABVD (doxorubicin [A], bleomycin [B], vinblastine [V]
and dacarbazine [D]) arm and stratified by number of International Prognostic
Factor Project (IPFP) risk factors and region. Patients were treated on days&nbsp;1
and 15 of each 28&#8209;day cycle with 1.2&nbsp;mg/kg of ADCETRIS administered
as an intravenous infusion over 30&nbsp;minutes + doxorubicin 25&nbsp;mg/m<sup>2</sup>,
vinblastine&nbsp;6&nbsp;mg/m<sup>2</sup>, and dacarbazine 375&nbsp;mg/m<sup>2</sup>.
The median number of cycles received was 6 (range, 1&nbsp;to 6&nbsp;cycles).
Table&nbsp;6 provides a summary of the baseline patient and disease
characteristics.</span> There were no relevant differences in the patient and
disease characteristics between the two arms.<i><span lang=EN-GB> </span></i></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Table 6:
Summary of baseline patient and disease characteristics in the phase 3 previously
untreated HL study<br>
<br>
</span></b></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=619
 style='width:6.45in;border-collapse:collapse'>
 <tr style='height:26.4pt'>
  <td width=337 valign=top style='width:252.9pt;border-top:windowtext;
  border-left:windowtext;border-bottom:black;border-right:white;border-style:
  solid;border-width:1.0pt;padding:.7pt 5.4pt 0in 5.4pt;height:26.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Patient
  Characteristics </span></b></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid black 1.0pt;border-right:solid white 1.0pt;
  padding:.7pt 5.4pt 0in 5.4pt;height:26.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>ADCETRIS + AVD</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>n&nbsp;=&nbsp;664</span></b></p>
  </td>
  <td width=126 valign=top style='width:94.5pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid black 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.7pt 5.4pt 0in 5.4pt;height:26.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>ABVD</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>n&nbsp;=&nbsp;670</span></b></p>
  </td>
 </tr>
 <tr style='height:13.5pt'>
  <td width=337 valign=top style='width:252.9pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:.7pt 5.4pt 0in 5.4pt;height:13.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Median age
  (range) </span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:.7pt 5.4pt 0in 5.4pt;height:13.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>35 years
  (18&#8209;82)</span></p>
  </td>
  <td width=126 valign=top style='width:94.5pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.7pt 5.4pt 0in 5.4pt;height:13.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>37 years
  (18&#8209;83)</span></p>
  </td>
 </tr>
 <tr style='height:13.5pt'>
  <td width=337 valign=top style='width:252.9pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:.7pt 5.4pt 0in 5.4pt;height:13.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Patients
  &#8805;&nbsp;65 years old n (%)</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:.7pt 5.4pt 0in 5.4pt;height:13.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>60 (9)</span></p>
  </td>
  <td width=126 valign=top style='width:94.5pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.7pt 5.4pt 0in 5.4pt;height:13.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>62 (9)</span></p>
  </td>
 </tr>
 <tr style='height:13.5pt'>
  <td width=337 valign=top style='width:252.9pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:.7pt 5.4pt 0in 5.4pt;height:13.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Gender, n
  (%)</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:.7pt 5.4pt 0in 5.4pt;height:13.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>378M (57)</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>286F (43)</span></p>
  </td>
  <td width=126 valign=top style='width:94.5pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.7pt 5.4pt 0in 5.4pt;height:13.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>398M (59)</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>272F (41)</span></p>
  </td>
 </tr>
 <tr style='height:13.2pt'>
  <td width=337 valign=top style='width:252.9pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:.7pt 5.4pt 0in 5.4pt;height:13.2pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>ECOG
  status, n (%)</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:.7pt 5.4pt 0in 5.4pt;height:13.2pt'></td>
  <td width=126 valign=top style='width:94.5pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.7pt 5.4pt 0in 5.4pt;height:13.2pt'></td>
 </tr>
 <tr style='height:13.2pt'>
  <td width=337 valign=top style='width:252.9pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:.7pt 5.4pt 0in 5.4pt;height:13.2pt'>
  <p class=MsoNormal style='margin-left:.1in;page-break-after:avoid'><span
  lang=EN-GB>0 </span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:.7pt 5.4pt 0in 5.4pt;height:13.2pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>376 (57)</span></p>
  </td>
  <td width=126 valign=top style='width:94.5pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.7pt 5.4pt 0in 5.4pt;height:13.2pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>378 (57)</span></p>
  </td>
 </tr>
 <tr style='height:13.2pt'>
  <td width=337 valign=top style='width:252.9pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:.7pt 5.4pt 0in 5.4pt;height:13.2pt'>
  <p class=MsoNormal style='margin-left:.1in;page-break-after:avoid'><span
  lang=EN-GB>1 </span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:.7pt 5.4pt 0in 5.4pt;height:13.2pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>260 (39)</span></p>
  </td>
  <td width=126 valign=top style='width:94.5pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.7pt 5.4pt 0in 5.4pt;height:13.2pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>263 (39)</span></p>
  </td>
 </tr>
 <tr style='height:13.2pt'>
  <td width=337 valign=top style='width:252.9pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  solid white 1.0pt;padding:.7pt 5.4pt 0in 5.4pt;height:13.2pt'>
  <p class=MsoNormal style='margin-left:.1in;page-break-after:avoid'><span
  lang=EN-GB>2</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;
  padding:.7pt 5.4pt 0in 5.4pt;height:13.2pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>28 (4)</span></p>
  </td>
  <td width=126 valign=top style='width:94.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.7pt 5.4pt 0in 5.4pt;height:13.2pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>27 (4)</span></p>
  </td>
 </tr>
 <tr style='height:13.2pt'>
  <td width=337 valign=top style='width:252.9pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  solid white 1.0pt;padding:.7pt 5.4pt 0in 5.4pt;height:13.2pt'>
  <p class=MsoNormal style='margin-left:.1in;page-break-after:avoid'><span
  lang=EN-GB>Missing</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;
  padding:.7pt 5.4pt 0in 5.4pt;height:13.2pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>0</span></p>
  </td>
  <td width=126 valign=top style='width:94.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.7pt 5.4pt 0in 5.4pt;height:13.2pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>2</span></p>
  </td>
 </tr>
 <tr style='height:15.4pt'>
  <td width=337 valign=top style='width:252.9pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  solid white 1.0pt;padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Disease
  Characteristics </span></b></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;
  padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt'></td>
  <td width=126 valign=top style='width:94.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt'></td>
 </tr>
 <tr style='height:15.4pt'>
  <td width=337 valign=top style='width:252.9pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Median
  time from HL diagnosis to first dose (range)</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>0.92 mo
  (0.1&#8209;21.4)</span></p>
  </td>
  <td width=126 valign=top style='width:94.5pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>0.89 mo
  (0.0&#8209;81.4)</span></p>
  </td>
 </tr>
 <tr style='height:15.4pt'>
  <td width=337 valign=top style='width:252.9pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Disease
  stage<sup>a</sup> at initial diagnosis of HL, n (%)</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt'></td>
  <td width=126 valign=top style='width:94.5pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt'></td>
 </tr>
 <tr style='height:15.4pt'>
  <td width=337 valign=top style='width:252.9pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt'>
  <p class=MsoNormal style='margin-left:.1in;page-break-after:avoid'><span
  lang=EN-GB>III</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>237 (36)</span></p>
  </td>
  <td width=126 valign=top style='width:94.5pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>246 (37)</span></p>
  </td>
 </tr>
 <tr style='height:15.4pt'>
  <td width=337 valign=top style='width:252.9pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt'>
  <p class=MsoNormal style='margin-left:.1in;page-break-after:avoid'><span
  lang=EN-GB>IV</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>425 (64)</span></p>
  </td>
  <td width=126 valign=top style='width:94.5pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>421 (63)</span></p>
  </td>
 </tr>
 <tr style='height:15.4pt'>
  <td width=337 valign=top style='width:252.9pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt'>
  <p class=MsoNormal style='margin-left:.1in;page-break-after:avoid'><span
  lang=EN-GB>Not applicable</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>1 (&lt;&nbsp;1)</span></p>
  </td>
  <td width=126 valign=top style='width:94.5pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>1 (&lt;&nbsp;1)</span></p>
  </td>
 </tr>
 <tr style='height:15.4pt'>
  <td width=337 valign=top style='width:252.9pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt'>
  <p class=MsoNormal style='margin-left:.1in;page-break-after:avoid'><span
  lang=EN-GB>Missing</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>0</span></p>
  </td>
  <td width=126 valign=top style='width:94.5pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>2 (&lt;&nbsp;1&nbsp;)</span></p>
  </td>
 </tr>
 <tr style='height:15.85pt'>
  <td width=337 valign=top style='width:252.9pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Extranodal
  involvement at time of diagnosis, n (%)</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>411 (62)</span></p>
  </td>
  <td width=126 valign=top style='width:94.5pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>416 (62)</span></p>
  </td>
 </tr>
 <tr style='height:15.85pt'>
  <td width=337 valign=top style='width:252.9pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>IPFP<sup>b</sup>
  risk factors, n (%)</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=126 valign=top style='width:94.5pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:15.85pt'>
  <td width=337 valign=top style='width:252.9pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt'>
  <p class=MsoNormal style='margin-left:9.0pt;page-break-after:avoid'><span
  lang=EN-GB>0&#8209;1</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>141 (21)</span></p>
  </td>
  <td width=126 valign=top style='width:94.5pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>141 (21)</span></p>
  </td>
 </tr>
 <tr style='height:15.85pt'>
  <td width=337 valign=top style='width:252.9pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt'>
  <p class=MsoNormal style='margin-left:9.0pt;page-break-after:avoid'><span
  lang=EN-GB>2&#8209;3</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>354 (53)</span></p>
  </td>
  <td width=126 valign=top style='width:94.5pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>351 (52)</span></p>
  </td>
 </tr>
 <tr style='height:15.85pt'>
  <td width=337 valign=top style='width:252.9pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt'>
  <p class=MsoNormal style='margin-left:9.0pt;page-break-after:avoid'><span
  lang=EN-GB>4&#8209;7</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>169 (25)</span></p>
  </td>
  <td width=126 valign=top style='width:94.5pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>178 (27)</span></p>
  </td>
 </tr>
 <tr style='height:15.85pt'>
  <td width=337 valign=top style='width:252.9pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Bone
  marrow involvement at time of diagnosis or study entry, n (%)</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>147(22)</span></p>
  </td>
  <td width=126 valign=top style='width:94.5pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>151 (23)</span></p>
  </td>
 </tr>
 <tr style='height:16.75pt'>
  <td width=337 valign=top style='width:252.9pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  solid white 1.0pt;padding:.7pt 5.4pt 0in 5.4pt;height:16.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>B symptoms<sup>a
  </sup>n (%)</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;
  padding:.7pt 5.4pt 0in 5.4pt;height:16.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>400 (60)</span></p>
  </td>
  <td width=126 valign=top style='width:94.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.7pt 5.4pt 0in 5.4pt;height:16.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>381 (57)</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='page-break-after:avoid'><sup><span lang=EN-GB
style='font-size:9.0pt'>a</span></sup><span lang=EN-GB style='font-size:9.0pt'>
Per Ann Arbor Staging.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><sup><span lang=EN-GB
style='font-size:9.0pt'>b</span></sup><span lang=EN-GB style='font-size:9.0pt'>IPFP&nbsp;=&nbsp;International
Prognostic Factor Project.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>The primary
endpoint in Study C25003 was modified PFS (mPFS) per independent review
facility (IRF), defined as time from randomisation to disease progression,
death, or evidence of non-complete response (non-CR) after completion of first-line
therapy per IRF followed by subsequent anticancer therapy. Timing of the
modified event was the date of the first PET scan post completion of first-line
therapy demonstrating the absence of complete response (CR), defined as
Deauville score of&nbsp;&#8805;3. The median modified PFS by IRF assessment was
not reached in either treatment arm. The results in the intent-to-treat (ITT)
population showed a statistically significant improvement in modified PFS for
ADCETRIS+ AVD, with a stratified hazard ratio of 0.770 (95% CI, 0.603; 0.983,
p&nbsp;=<sup>&nbsp;</sup>0.035), indicating a 23% reduction in the risk of modified
PFS events for ADCETRIS+ AVD versus ABVD. </span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'>A pre-specified subgroup
analysis of mPFS <span lang=EN-GB style='letter-spacing:-.1pt'>by disease stage
showed that patients with Stage&nbsp;IV disease had a larger effect compared
with the ITT population</span><span lang=EN-GB>,</span><span lang=EN-GB> </span><span
lang=EN-GB>with an unstratified hazard ratio of 0.71&nbsp;(95%&nbsp;CI, 0.53;
0.96), compatible with a 29% reduction in the risk of modified PFS events for
ADCETRIS+ AVD versus ABVD. Of the ITT population, 846&nbsp;patients (64%) had
Stage&nbsp;IV disease.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Table&nbsp;7 provides the efficacy results
for modified PFS and overall survival (OS) in the ITT population and patients
with Stage&nbsp;IV disease.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Table 7:
Efficacy results for previously untreated HL patients treated with
1.2&nbsp;mg/kg of ADCETRIS + AVD on days 1 and 15 of a 28-day cycle (ITT and
Stage IV)</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=606
 style='width:454.4pt;margin-left:-.15pt;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid;height:33.0pt'>
  <td width=110 rowspan=2 style='width:82.85pt;border:solid windowtext 1.0pt;
  padding:.7pt 4.9pt 0in 4.9pt;height:33.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=266 colspan=3 style='width:199.15pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 0in 0in 0in;height:33.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Intent to Treat (ITT) Population</span></b></p>
  </td>
  <td width=230 colspan=3 style='width:172.4pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 0in 0in 0in;height:33.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Patients with Stage IV Disease</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:33.0pt'>
  <td width=89 valign=top style='width:66.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.7pt 4.9pt 0in 4.9pt;height:33.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>ADCETRIS</span></b><b><span lang=EN-GB> + AVD</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>n&nbsp;=&nbsp;664</span></b></p>
  </td>
  <td width=78 valign=top style='width:58.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.7pt 4.9pt 0in 4.9pt;height:33.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>ABVD</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>n&nbsp;=&nbsp;670</span></b></p>
  </td>
  <td width=98 valign=top style='width:73.7pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:33.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Stratified Hazard Ratio and p-value</span></b></p>
  </td>
  <td width=77 valign=top style='width:57.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:33.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>ADCETRIS</span></b><b><span lang=EN-GB> + AVD</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>n&nbsp;=&nbsp;425</span></b></p>
  </td>
  <td width=63 valign=top style='width:47.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:33.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>ABVD</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>n&nbsp;=&nbsp;421</span></b></p>
  </td>
  <td width=90 valign=top style='width:67.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:33.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Unstratified Hazard Ratio and p-value<sup>c</sup></span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:50.05pt'>
  <td width=110 style='width:82.85pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 0in 0in 0in;height:50.05pt'>
  <p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;
  margin-left:4.9pt;page-break-after:avoid'><b><span lang=EN-GB>Number of
  events (%)</span></b></p>
  </td>
  <td width=89 style='width:66.8pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:.7pt 4.9pt 0in 4.9pt;
  height:50.05pt'>
  <p class=MsoNormal align=center style='margin-bottom:8.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB>117 (18)</span></p>
  </td>
  <td width=78 style='width:58.65pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.7pt 4.9pt 0in 4.9pt;height:50.05pt'>
  <p class=MsoNormal align=center style='margin-bottom:8.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB>146 (22)</span></p>
  </td>
  <td width=98 rowspan=2 style='width:73.7pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:50.05pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:windowtext'>0.77</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:windowtext'>(95% CI [0.60, 0.98])</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:windowtext'>p-value=</span><span
  lang=EN-GB style='color:windowtext'>0.035</span></p>
  </td>
  <td width=77 style='width:57.85pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:50.05pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='color:windowtext'>77 (18)</span></p>
  </td>
  <td width=63 style='width:47.05pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:50.05pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='color:windowtext'>102 (24)</span></p>
  </td>
  <td width=90 rowspan=2 style='width:67.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:50.05pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:windowtext'>0.71 </span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:windowtext'>(95% CI [0.53, 0.96])</span></p>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='color:windowtext'>p-value=0.023</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:33.5pt'>
  <td width=110 style='width:82.85pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 0in 0in 0in;height:33.5pt'>
  <p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;
  margin-left:4.9pt;page-break-after:avoid'><b><span lang=EN-GB>Estimated mPFS<sup>a</sup>
  per IRF at 2 Year (%)</span></b></p>
  </td>
  <td width=89 style='width:66.8pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:.7pt 4.9pt 0in 4.9pt;
  height:33.5pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB>82.1</span></p>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB>(95% CI [78.8, 85.0])</span></p>
  </td>
  <td width=78 style='width:58.65pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.7pt 4.9pt 0in 4.9pt;height:33.5pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB>77.2</span></p>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB>(95% CI [73.7, 80.4])</span></p>
  </td>
  <td width=77 style='width:57.85pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:33.5pt'>
  <p class=MsoNormal align=center style='margin-bottom:8.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='color:windowtext'>82.0 (95%
  CI [77.8, 85.5])</span></p>
  </td>
  <td width=63 style='width:47.05pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:33.5pt'>
  <p class=MsoNormal align=center style='margin-bottom:8.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='color:windowtext'>75.3 (95%
  CI [70.6, 79.3])</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:33.5pt'>
  <td width=110 style='width:82.85pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 0in 0in 0in;height:33.5pt'>
  <p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;
  margin-left:4.9pt;page-break-after:avoid'><b><span lang=EN-GB>Overall Survival<sup>b</sup>
  Number of deaths (%)</span></b></p>
  </td>
  <td width=89 style='width:66.8pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:.7pt 4.9pt 0in 4.9pt;
  height:33.5pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB>28 (4)</span></p>
  </td>
  <td width=78 style='width:58.65pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.7pt 4.9pt 0in 4.9pt;height:33.5pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB>39 (6)</span></p>
  </td>
  <td width=98 style='width:73.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;
  height:33.5pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB>0.73</span></p>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB>(95% CI [0.45, 1.18])</span></p>
  <p class=MsoNormal align=center style='margin-bottom:8.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB>p-value=0.199</span></p>
  </td>
  <td width=77 style='width:57.85pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:33.5pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='color:windowtext'>14 (3)</span></p>
  </td>
  <td width=63 style='width:47.05pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:33.5pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='color:windowtext'>26 (6)</span></p>
  </td>
  <td width=90 style='width:67.5pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;
  height:33.5pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:windowtext'>0.51 </span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:windowtext'>(95% CI [0.27, 0.97])</span></p>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='color:windowtext'>p-value=0.037</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='page-break-after:avoid'><sup><span lang=EN-GB
style='font-size:9.0pt'>a</span></sup><span lang=EN-GB style='font-size:9.0pt'>At
the time of analysis, the median modified PFS follow-up time for both arms was
24.6 months.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><sup><span lang=EN-GB
style='font-size:9.0pt'>b</span></sup><span lang=EN-GB style='font-size:9.0pt'>Data
from an interim OS analysis. </span></p>

<p class=MsoNormal style='page-break-after:avoid'><sup><span lang=EN-GB
style='font-size:9.0pt'>c</span></sup><span lang=EN-GB style='font-size:9.0pt'>p-value
for Stage IV disease is not adjusted for multiplicity.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB>Figure 1: Modified progression-free survival per IRF in the ITT
population (ADCETRIS + AVD vs. ABVD)</span></b></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB><img border=0 width=604 height=302
src="Adcetris-ema-combined-h-2455-en-IB-SOB-C2500_files/image002.gif"></span></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><a
name=IDX></a><b><span lang=EN-GB>Figure 2: Modified progression-free survival
per IRF in patients with Stage&nbsp;IV disease (ADCETRIS + AVD vs. ABVD)</span></b></p>

<p class=MsoNormal style='line-height:150%;page-break-after:avoid'><span
lang=EN-GB style='line-height:150%'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB><img
border=0 width=598 height=284
src="Adcetris-ema-combined-h-2455-en-IB-SOB-C2500_files/image003.gif"></span></p>

<p class=MsoNormal style='text-autospace:none'><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=MsoNormal><span lang=EN-GB>Other secondary efficacy endpoints
including CR rate and ORR at the end of randomisation regimen, CR rate at the
end of first-line therapy, and the rate of PET negativity at the end of Cycle
2, duration of response (DOR), duration of complete remission (DOCR),
disease-free survival (DFS) and event&#8209;free survival (EFS) all trended in
favour of ADCETRIS + AVD<a name="_Hlk519081083"> in both the ITT and Stage&nbsp;IV
population</a>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Pre&#8209;specified subgroup analyses of
modified PFS per IRF were performed for the ITT population including age,
region, cancer stage at baseline, baseline extranodal sites, number of IPFP
risk factors, baseline B symptoms, Cycle 2 PET assessment, Cycle 2 PET
Deauville score, and receipt of alternative first-line medication (AFM). The
analyses showed a consistent trend towards benefit for patients who received
ADCETRIS&nbsp;+ AVD compared with patients who received ABVD in most subgroups.
The efficacy in elderly patient population (patients &#8805;&nbsp;60 years of
age [n&nbsp;=&nbsp;186] [HR&nbsp;=&nbsp;1.00, 95% CI (0.58, 1.72)] and &#8805;&nbsp;65
years of age [n&nbsp;=&nbsp;122] [HR&nbsp;=&nbsp;1.01, 95% CI (0.53, 1.94)])
and patients with no extranodal sites (n&nbsp;=&nbsp;445) (HR&nbsp;=&nbsp;1.04,
95% CI [0.67, 1.62]) showed no clinically meaningful difference between the two
arms.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:windowtext'>Post&#8209;hoc
subgroup analyses of modified PFS per IRF for patients with Stage&nbsp;IV
disease were performed including age, region, baseline extranodal sites, number
of IPFP risk factors, baseline B symptoms, baseline ECOG status and gender. The
analyses showed a consistent trend towards benefit for patients who received
ADCETRIS&nbsp;+ AVD compared with patients who received ABVD in most subgroups.
P</span><span lang=EN-GB style='color:windowtext'>atients with Stage IV disease
for whom extranodal disease was reported ([n&nbsp;=&nbsp;722] [HR&nbsp;=&nbsp;0.69,
95% CI (0.50, 0.94)]) showed an mPFS (per IRF) benefit. In patients with Stage
IV disease for whom no extranodal disease was reported, n</span><span
lang=EN-GB style='color:windowtext'>o benefit has been shown at time of
analysis </span><span lang=EN-GB style='color:windowtext'>([n&nbsp;=&nbsp;85]
[HR&nbsp;=&nbsp;1.49, 95% CI (0.51, 4.31)]). </span><span lang=EN-GB
style='color:windowtext'>The significance of this finding in stage IV HL
patients with no extranodal disease is not established due to small patient
numbers and low event rates (14&nbsp;events).<i> </i></span><span lang=EN-GB
style='color:windowtext'>The efficacy in elderly patients with Stage IV disease
in the A + AVD arm (patients &#8805;&nbsp;60 years of age [n&nbsp;=&nbsp;118]
[HR&nbsp;=&nbsp;0.80, 95% CI (0.42, 1.53)] and &#8805;&nbsp;65 years of age [n&nbsp;=&nbsp;78]
[HR&nbsp;=&nbsp;0.78, 95% CI (0.36, 1.67)]) showed better benefit compared with
elderly patients in ITT population.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><a name="_Hlk519587500"><span lang=EN-GB>In the ITT
population, 33% fewer patients treated with ADCETRIS + AVD in the ITT
population received subsequent salvage chemotherapy (n&nbsp;=&nbsp;66) and
high-dose chemotherapy and transplant (n&nbsp;=&nbsp;36) compared with those
treated with ABVD (n&nbsp;=&nbsp;99 and n&nbsp;=&nbsp;54, respectively). In the
Stage IV population, 35% fewer patients treated with ADCETRIS + AVD received
subsequent salvage chemotherapy (n&nbsp;=&nbsp;45) compared with those treated
with ABVD (n&nbsp;=&nbsp;69) and 22% fewer patients treated with ADCETRIS + AVD
received high-dose chemotherapy and transplant (n&nbsp;=&nbsp;29) compared with
those treated with ABVD (n&nbsp;=&nbsp;37).</span></a></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>The European
Organization for Research and Treatment of Cancer Quality of Life 30&#8209;Item
Questionnaire (EORTC&#8209;QLQ&#8209;C30) showed no clinically meaningful
difference between the two arms in both the ITT and Stage IV population.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Study SGN35&#8209;005</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The efficacy and safety of ADCETRIS were
evaluated in a randomised, double&#8209;blind, placebo&#8209;controlled, 2&#8209;arm
multicenter trial in 329&nbsp;patients with HL at risk of relapse or
progression following ASCT. Patients with known cerebral/meningeal disease,
including history of PML were excluded from the study. See Table&nbsp;8 for
patient characteristics. Of the 329&nbsp;patients, 165&nbsp;patients were
randomised to the treatment arm and 164&nbsp;patients were randomised to the
placebo arm. In the study, patients were to receive their first dose after
recovery from ASCT (between days 30&#8209;45 following ASCT). Patients were
treated with 1.8&nbsp;mg/kg of ADCETRIS or matching placebo intravenously over
30&nbsp;minutes every 3&nbsp;weeks for up to 16&nbsp;cycles.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=Paragraph style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Eligible patients were required to have at least one of the following
risk factors: </span></p>

<p class=Paragraph style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>HL that was refractory
to frontline treatment</span></p>

<p class=Paragraph style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Relapsed or progressive
HL that occurred &lt;12&nbsp;months from the end of frontline treatment</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Extranodal involvement at time of pre&#8209;ASCT
relapse, including extranodal extension of nodal masses into adjacent vital
organs.</span></p>

<p class=Paragraph style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.5in'><span lang=EN-GB style='font-size:11.0pt;background:silver'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-before:always;page-break-after:avoid'><b><span
lang=EN-GB>Table 8: Summary of baseline patient and disease characteristics in
the phase 3 HL post&#8209;ASCT Study<br>
<br>
</span></b></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=593
 style='width:444.45pt;border-collapse:collapse;border:none'>
 <tr style='height:15.1pt'>
  <td width=288 valign=top style='width:215.95pt;border:solid windowtext 1.0pt;
  border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.1pt'>
  <p class=MsoNormal style='margin-bottom:3.0pt;page-break-after:avoid'><b><span
  lang=EN-GB>Patient characteristics</span></b></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>ADCETRIS</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>n&nbsp;=&nbsp;165</span></b></p>
  </td>
  <td width=155 valign=top style='width:116.0pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Placebo</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>n&nbsp;=&nbsp;164</span></b></p>
  </td>
 </tr>
 <tr style='height:13.5pt'>
  <td width=288 valign=top style='width:215.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.5pt'>
  <p class=MsoNormal style='margin-left:3.1pt;text-indent:5.5pt;page-break-after:
  avoid'><span lang=EN-GB>Median age, years (range)</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.5pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>33&nbsp;years (18&#8209;71)</span></p>
  </td>
  <td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.5pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>32&nbsp;years (18&#8209;76)</span></p>
  </td>
 </tr>
 <tr style='height:13.5pt'>
  <td width=288 valign=top style='width:215.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.5pt'>
  <p class=MsoNormal style='text-indent:8.6pt'><span lang=EN-GB>Gender</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.5pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>76M
  (46%)/89F (54%)</span></p>
  </td>
  <td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.5pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>97M
  (59%)/67F (41%)</span></p>
  </td>
 </tr>
 <tr style='height:12.75pt'>
  <td width=288 valign=top style='width:215.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal style='text-indent:8.6pt'><span lang=EN-GB>ECOG status</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:12.75pt'>
  <td width=288 valign=top style='width:215.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal style='margin-left:19.6pt'><span lang=EN-GB>0</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>87
  (53%)</span></p>
  </td>
  <td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>97
  (59%)</span></p>
  </td>
 </tr>
 <tr style='height:5.65pt'>
  <td width=288 valign=top style='width:215.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:5.65pt'>
  <p class=MsoNormal style='margin-left:19.6pt'><span lang=EN-GB>1</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>77
  (47%)</span></p>
  </td>
  <td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>67
  (41%)</span></p>
  </td>
 </tr>
 <tr style='height:5.65pt'>
  <td width=288 valign=top style='width:215.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:5.65pt'>
  <p class=MsoNormal style='margin-left:19.6pt'><span lang=EN-GB>2</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>1
  (1%)</span></p>
  </td>
  <td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>0</span></p>
  </td>
 </tr>
 <tr style='height:15.1pt'>
  <td width=288 valign=top style='width:215.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.1pt'>
  <p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:3.0pt;
  margin-left:19.45pt;text-align:justify;text-justify:inter-ideograph;
  text-indent:-19.45pt'><b><span lang=EN-GB>Disease characteristics</span></b></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.1pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.1pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='height:8.0pt'>
  <td width=288 valign=top style='width:215.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:8.0pt'>
  <p class=MsoNormal style='margin-left:8.6pt;page-break-after:avoid'><span
  lang=EN-GB>Median number of prior chemotherapy regimens (range)</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:8.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>2
  (2&#8209;8)</span></p>
  </td>
  <td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:8.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>2
  (2&#8209;7)</span></p>
  </td>
 </tr>
 <tr style='height:7.15pt'>
  <td width=288 valign=top style='width:215.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:7.15pt'>
  <p class=MsoNormal style='margin-left:8.6pt;page-break-after:avoid'><span
  lang=EN-GB>Median time from HL diagnosis to first dose (range)</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:7.15pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>18.7&nbsp;mo
  (6.1&#8209;204.0)</span></p>
  </td>
  <td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:7.15pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>18.8&nbsp;mo
  (7.4&#8209;180.8)</span></p>
  </td>
 </tr>
 <tr style='height:6.4pt'>
  <td width=288 valign=top style='width:215.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.4pt'>
  <p class=MsoNormal style='margin-left:8.6pt;page-break-after:avoid'><span
  lang=EN-GB>Disease stage at initial diagnosis of HL</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:6.4pt'>
  <td width=288 valign=top style='width:215.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.4pt'>
  <p class=MsoNormal style='margin-left:19.6pt'><span lang=EN-GB>Stage I</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>1
  (1%)</span></p>
  </td>
  <td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>5
  (3%)</span></p>
  </td>
 </tr>
 <tr style='height:6.4pt'>
  <td width=288 valign=top style='width:215.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.4pt'>
  <p class=MsoNormal style='margin-left:19.6pt'><span lang=EN-GB>Stage II</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>73
  (44%)</span></p>
  </td>
  <td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>61
  (37%)</span></p>
  </td>
 </tr>
 <tr style='height:6.4pt'>
  <td width=288 valign=top style='width:215.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.4pt'>
  <p class=MsoNormal style='margin-left:19.6pt'><span lang=EN-GB>Stage III</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>48
  (29%)</span></p>
  </td>
  <td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>45
  (27%)</span></p>
  </td>
 </tr>
 <tr style='height:6.4pt'>
  <td width=288 valign=top style='width:215.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.4pt'>
  <p class=MsoNormal style='margin-left:19.6pt'><span lang=EN-GB>Stage IV</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>43
  (26%)</span></p>
  </td>
  <td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>51
  (31%)</span></p>
  </td>
 </tr>
 <tr style='height:6.4pt'>
  <td width=288 valign=top style='width:215.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.4pt'>
  <p class=MsoNormal style='margin-left:19.6pt'><span lang=EN-GB>Unknown</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>0</span></p>
  </td>
  <td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>2
  (1%)</span></p>
  </td>
 </tr>
 <tr style='height:6.35pt'>
  <td width=288 valign=top style='width:215.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.35pt'>
  <p class=MsoNormal style='margin-left:8.6pt;page-break-after:avoid'><span
  lang=EN-GB>PET scan Status prior to ASCT</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:6.35pt'>
  <td width=288 valign=top style='width:215.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.35pt'>
  <p class=MsoNormal style='margin-left:19.6pt'><span lang=EN-GB>FDG&#8209;AVID</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>64
  (39%)</span></p>
  </td>
  <td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>51
  (31%)</span></p>
  </td>
 </tr>
 <tr style='height:6.35pt'>
  <td width=288 valign=top style='width:215.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.35pt'>
  <p class=MsoNormal style='margin-left:19.6pt'><span lang=EN-GB>FDG&#8209;NEGATIVE</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>56
  (34%)</span></p>
  </td>
  <td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>57
  (35%)</span></p>
  </td>
 </tr>
 <tr style='height:6.35pt'>
  <td width=288 valign=top style='width:215.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.35pt'>
  <p class=MsoNormal style='margin-left:19.6pt'><span lang=EN-GB>NOT DONE</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>45
  (27%)</span></p>
  </td>
  <td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>56
  (34%)</span></p>
  </td>
 </tr>
 <tr style='height:6.35pt'>
  <td width=288 valign=top style='width:215.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.35pt'>
  <p class=MsoNormal style='margin-left:8.6pt;page-break-after:avoid'><span
  lang=EN-GB>Extranodal involvement at time of pre&#8209;ASCT relapse</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>54
  (33%)</span></p>
  </td>
  <td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>53
  (32%)</span></p>
  </td>
 </tr>
 <tr style='height:6.35pt'>
  <td width=288 valign=top style='width:215.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.35pt'>
  <p class=MsoNormal style='margin-left:8.6pt;page-break-after:avoid'><span
  lang=EN-GB>B symptoms</span><sup><span lang=EN-GB>a</span></sup></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>47
  (28%)</span></p>
  </td>
  <td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>40
  (24%)</span></p>
  </td>
 </tr>
 <tr style='height:6.35pt'>
  <td width=288 valign=top style='width:215.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.35pt'>
  <p class=MsoNormal style='margin-left:8.6pt;page-break-after:avoid'><span
  lang=EN-GB>Best response to salvage therapy pre&#8209;ASCT<sup>b</sup></span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:6.35pt'>
  <td width=288 valign=top style='width:215.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.35pt'>
  <p class=MsoNormal style='margin-left:19.6pt'><span lang=EN-GB>Complete
  Response</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>61
  (37%)</span></p>
  </td>
  <td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>62
  (38%)</span></p>
  </td>
 </tr>
 <tr style='height:6.35pt'>
  <td width=288 valign=top style='width:215.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.35pt'>
  <p class=MsoNormal style='margin-left:19.6pt'><span lang=EN-GB>Partial
  Response</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>57
  (35%)</span></p>
  </td>
  <td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>56
  (34%)</span></p>
  </td>
 </tr>
 <tr style='height:6.35pt'>
  <td width=288 valign=top style='width:215.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.35pt'>
  <p class=MsoNormal style='margin-left:19.6pt'><span lang=EN-GB>Stable Disease</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>47
  (28%)</span></p>
  </td>
  <td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>46
  (28%)</span></p>
  </td>
 </tr>
 <tr style='height:6.35pt'>
  <td width=288 valign=top style='width:215.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.35pt'>
  <p class=MsoNormal style='margin-left:8.6pt;page-break-after:avoid'><span
  lang=EN-GB>HL Status after the end of frontline standard chemotherapy<sup>b</sup></span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:6.35pt'>
  <td width=288 valign=top style='width:215.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.35pt'>
  <p class=MsoNormal style='margin-left:19.6pt'><span lang=EN-GB>Refractory</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>99
  (60%)</span></p>
  </td>
  <td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>97
  (59%)</span></p>
  </td>
 </tr>
 <tr style='height:6.35pt'>
  <td width=288 valign=top style='width:215.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.35pt'>
  <p class=MsoNormal style='margin-left:19.6pt'><span lang=EN-GB>Relapse
  occurred&nbsp;&lt;12&nbsp;months</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>53
  (32%)</span></p>
  </td>
  <td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>54
  (33%)</span></p>
  </td>
 </tr>
 <tr style='height:6.35pt'>
  <td width=288 valign=top style='width:215.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.35pt'>
  <p class=MsoNormal style='margin-left:19.6pt'><span lang=EN-GB>Relapse
  occurred&nbsp;&#8805;&nbsp;12&nbsp;months</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>13
  (8%)</span></p>
  </td>
  <td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>13
  (8%)</span></p>
  </td>
 </tr>
</table>

</div>

<p class=Paragraph style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.25in;text-indent:-.25in'><sup><span lang=EN-GB style='font-size:
11.0pt'>a.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></sup><span lang=EN-GB style='font-size:9.0pt'>For&nbsp;refractory&nbsp;disease,&nbsp;or&nbsp;upon&nbsp;progression&nbsp;or&nbsp;relapse&nbsp;after&nbsp;frontline&nbsp;therapy.</span></p>

<p class=Paragraph style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.25in;text-indent:-.25in'><sup><span lang=EN-GB style='font-size:
11.0pt'>b.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></sup><span lang=EN-GB style='font-size:9.0pt'>Stratification
factors at randomisation.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The efficacy results are shown in Table&nbsp;9.
The primary endpoint of PFS was met and showed a difference in median PFS of
18.8&nbsp;months in favour of the treatment arm.</span></p>

<p class=MsoNormal style='margin-left:43.1pt;text-indent:-43.1pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Table 9:
Efficacy results in HL patients at increased risk of relapse or progression following
ASCT treated with 1.8&nbsp;mg/kg of ADCETRIS every 3&nbsp;weeks<br>
<br>
</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=613
 style='width:459.4pt;border-collapse:collapse;border:none'>
 <tr style='height:39.0pt'>
  <td width=115 style='width:85.9pt;border:solid windowtext 1.0pt;padding:.7pt 4.9pt 0in 4.9pt;
  height:39.0pt'></td>
  <td width=168 style='width:1.75in;border:solid windowtext 1.0pt;border-left:
  none;padding:.7pt 4.9pt 0in 4.9pt;height:39.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>ADCETRIS</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>n&nbsp;=&nbsp;165</span></b></p>
  </td>
  <td width=174 style='width:130.5pt;border:solid windowtext 1.0pt;border-left:
  none;padding:.7pt 4.9pt 0in 4.9pt;height:39.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Placebo</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>n&nbsp;=&nbsp;164</span></b></p>
  </td>
  <td width=156 style='width:117.0pt;border:solid windowtext 1.0pt;border-left:
  none;padding:.7pt 4.9pt 0in 4.9pt;height:39.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Stratified Hazard Ratio</span></b></p>
  </td>
 </tr>
 <tr style='height:19.3pt'>
  <td width=115 rowspan=4 style='width:85.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:.7pt 4.9pt 0in 4.9pt;height:19.3pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Progression
  Free Survival<sup>a</sup> </span></b></p>
  </td>
  <td width=342 colspan=2 style='width:256.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.7pt 4.9pt 0in 4.9pt;height:19.3pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Median per IRF</span></b></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.7pt 4.9pt 0in 4.9pt;height:19.3pt'></td>
 </tr>
 <tr style='height:19.3pt'>
  <td width=168 style='width:1.75in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.7pt 4.9pt 0in 4.9pt;height:19.3pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>42.9&nbsp;months</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(95% CI [30.4, 42.9])</span></p>
  </td>
  <td width=174 style='width:130.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.7pt 4.9pt 0in 4.9pt;height:19.3pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>24.1&nbsp;months</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(95% CI [11.5, -])</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.7pt 4.9pt 0in 4.9pt;height:19.3pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.57</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(95% CI [0.40, 0.81])</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Stratified log-rank test p=0.001</span></p>
  </td>
 </tr>
 <tr style='height:19.3pt'>
  <td width=342 colspan=2 style='width:256.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.7pt 4.9pt 0in 4.9pt;height:19.3pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Median per Investigator </span></b></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.7pt 4.9pt 0in 4.9pt;height:19.3pt'></td>
 </tr>
 <tr style='height:19.3pt'>
  <td width=168 style='width:1.75in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.7pt 4.9pt 0in 4.9pt;height:19.3pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Not reached</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(95% CI [26.4, -])</span></p>
  </td>
  <td width=174 style='width:130.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.7pt 4.9pt 0in 4.9pt;height:19.3pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>15.8&nbsp;months</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(95% CI [8.5, -])</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.7pt 4.9pt 0in 4.9pt;height:19.3pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.5</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(95% CI [0.36, 0.70])<sup>b</sup></span></p>
  </td>
 </tr>
 <tr style='height:19.3pt'>
  <td width=115 rowspan=2 style='width:85.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:.7pt 4.9pt 0in 4.9pt;height:19.3pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Overall
  Survival</span></b></p>
  </td>
  <td width=342 colspan=2 style='width:256.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.7pt 4.9pt 0in 4.9pt;height:19.3pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Number of deaths (%)</span></b></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.7pt 4.9pt 0in 4.9pt;height:19.3pt'></td>
 </tr>
 <tr style='height:25.75pt'>
  <td width=168 style='width:1.75in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.7pt 4.9pt 0in 4.9pt;height:25.75pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>28 (17)</span></p>
  </td>
  <td width=174 style='width:130.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.7pt 4.9pt 0in 4.9pt;height:25.75pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>25 (15)</span></p>
  </td>
  <td width=156 style='width:117.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.7pt 4.9pt 0in 4.9pt;height:25.75pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>1.15</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(95% CI [0.67, 1.97]</span></p>
  </td>
 </tr>
</table>

<p class=Paragraph style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.25in;text-indent:-.25in;page-break-after:avoid'><sup><span
lang=EN-GB style='font-size:11.0pt'>a.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></sup><span lang=EN-GB style='font-size:9.0pt'>At the time of the
primary analysis, the median follow-up time for both arms was 30&nbsp;months (range,
0 to 50). </span></p>

<p class=Paragraph style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.25in;text-indent:-.25in;page-break-after:avoid'><sup><span
lang=EN-GB style='font-size:11.0pt'>b.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></sup><span lang=EN-GB style='font-size:9.0pt'>Stratified log&#8209;rank
test was not performed for PFS per Investigator.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Pre&#8209;specified subgroup analyses of
PFS per IRF were performed by patients&#8217; best response to pre&#8209;ASCT
salvage therapy, HL status after frontline therapy, age, gender, baseline
weight, baseline ECOG performance status, number of treatments pre&#8209;ASCT,
geographic region, pre&#8209;ASCT PET status, B symptom status after failure of
frontline therapy, and pre&#8209;ASCT extranodal disease status. The analyses
showed a consistent trend towards benefit for patients who received ADCETRIS
compared with patients who received placebo with the exception of patients
&#8805;65&nbsp;years of age (n&nbsp;=&nbsp;8).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>No differences were observed in quality of
life between the treatment and placebo arms. Medical resource utilization (MRU)
analysis showed that hospitalizations and outpatient visits, as well as working
days/other activities missed by patients and caregivers were lower with ADCETRIS
compared with placebo in patients with HL at increased risk of relapse.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>An updated analysis conducted after
3&nbsp;years of follow&#8209;up showed a sustained PFS improvement per IRF
(HR&nbsp;=&nbsp;0.58 [95% CI (0.41, 0.81)]).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Post&#8209;hoc
Risk Factor Analyses</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Post&#8209;hoc analyses were performed </span><span
lang=EN-GB>to evaluate the impact of increased</span><span lang=EN-GB> risk
(number of risk factors) on clinical benefit (Table&nbsp;10). </span><span
lang=EN-GB>Representative risk factors for these analyses were:</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>HL that occurred &lt;12&nbsp;months or HL that
was refractory to frontline therapy</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Best response of PR or SD to most recent salvage
therapy as determined by CT and/or PET scanning </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Extranodal disease at pre&#8209;ASCT relapse</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>B symptoms at pre&#8209;ASCT relapse</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Two or more prior salvage therapies. </span></p>

<p class=MsoListParagraphCxSpLast><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The results of these post&#8209;hoc
analyses suggest increased clinical benefit for patients with two or more risk
factors but no difference based on any of the individual risk factors. No benefit
in terms of PFS or OS has been observed in patients with one risk factor for
relapse or progression.</span></p>

<p class=MsoNormal style='margin-left:41.05pt;text-indent:-41.05pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:-4.5pt;text-indent:-.55pt;page-break-after:
avoid'><b><span lang=EN-GB>Table 10: Summary of PFS per IRF and OS by number of
risk factors in the phase&nbsp;3 HL post&#8209;ASCT Study <br>
<br>
</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=613
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=613 colspan=7 valign=top style='width:459.9pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Progression
  Free Survival per IRF</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=91 rowspan=2 valign=top style='width:.95in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'></td>
  <td width=172 colspan=2 valign=top style='width:128.85pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Number of Risk Factors</span></b><span lang=EN-GB>&nbsp;<b>=&nbsp;1</b></span></p>
  </td>
  <td width=182 colspan=2 valign=top style='width:136.65pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Number of Risk Factors&nbsp;&#8805;&nbsp;2</span></b></p>
  </td>
  <td width=168 colspan=2 valign=top style='width:1.75in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Number of Risk Factors&nbsp;&#8805;&nbsp;3</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=102 valign=top style='width:76.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>ADCETRIS</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>n&nbsp;=&nbsp;21</span></b></p>
  </td>
  <td width=70 valign=top style='width:52.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Placebo</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>n&nbsp;=&nbsp;28</span></b></p>
  </td>
  <td width=112 valign=top style='width:83.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>ADCETRIS</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>n&nbsp;=&nbsp;144</span></b></p>
  </td>
  <td width=70 valign=top style='width:52.7pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Placebo</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>n&nbsp;=&nbsp;136</span></b></p>
  </td>
  <td width=102 valign=top style='width:76.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>ADCETRIS</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>n&nbsp;=&nbsp;82</span></b></p>
  </td>
  <td width=66 valign=top style='width:49.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Placebo</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>n&nbsp;=&nbsp;84</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=91 valign=top style='width:.95in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Number of
  patients with disease progression or death<sup>a </sup></span><span
  lang=EN-GB>(%)</span></p>
  </td>
  <td width=102 valign=top style='width:76.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>9 (43)</span></p>
  </td>
  <td width=70 valign=top style='width:52.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>7 (25)</span></p>
  </td>
  <td width=112 valign=top style='width:83.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>51 (35)</span></p>
  </td>
  <td width=70 valign=top style='width:52.7pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>68 (50)</span></p>
  </td>
  <td width=102 valign=top style='width:76.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>32 (39)</span></p>
  </td>
  <td width=66 valign=top style='width:49.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>49 (58)</span></p>
  </td>
 </tr>
 <tr>
  <td width=91 valign=top style='width:.95in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Stratified
  Hazard Ratio </span></p>
  </td>
  <td width=172 colspan=2 valign=top style='width:128.85pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>1.65</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(95% CI [0.60, 4.55])<sup>b</sup></span></p>
  </td>
  <td width=182 colspan=2 valign=top style='width:136.65pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.49</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(95% CI [0.34, 0.71])</span></p>
  </td>
  <td width=168 colspan=2 valign=top style='width:1.75in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.43 </span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(95% CI [0.27, 0.68])</span></p>
  </td>
 </tr>
 <tr>
  <td width=613 colspan=7 valign=top style='width:459.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Overall Survival </span></b></p>
  </td>
 </tr>
 <tr>
  <td width=91 rowspan=2 valign=top style='width:.95in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'></td>
  <td width=172 colspan=2 valign=top style='width:128.85pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Number of Risk Factors&nbsp;=&nbsp;1</span></b></p>
  </td>
  <td width=182 colspan=2 valign=top style='width:136.65pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Number of Risk Factors&nbsp;&#8805;&nbsp;2</span></b></p>
  </td>
  <td width=168 colspan=2 valign=top style='width:1.75in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Number of Risk Factors&nbsp;&#8805;&nbsp;3</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=102 valign=top style='width:76.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>ADCETRIS</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>n&nbsp;=&nbsp;21</span></b></p>
  </td>
  <td width=70 valign=top style='width:52.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Placebo</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>n&nbsp;=&nbsp;28</span></b></p>
  </td>
  <td width=112 valign=top style='width:83.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>ADCETRIS</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>n&nbsp;=&nbsp;144</span></b></p>
  </td>
  <td width=70 valign=top style='width:52.7pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Placebo</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>n&nbsp;=&nbsp;136</span></b></p>
  </td>
  <td width=102 valign=top style='width:76.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>ADCETRIS</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>n&nbsp;=&nbsp;82</span></b></p>
  </td>
  <td width=66 valign=top style='width:49.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Placebo</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>n&nbsp;=&nbsp;84</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=91 valign=top style='width:.95in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Number of
  deaths<sup>c </sup></span><span lang=EN-GB>(%)</span></p>
  </td>
  <td width=102 valign=top style='width:76.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>5 (24)</span></p>
  </td>
  <td width=70 valign=top style='width:52.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>1 (4)</span></p>
  </td>
  <td width=112 valign=top style='width:83.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>23 (16)</span></p>
  </td>
  <td width=70 valign=top style='width:52.7pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>24 (18)</span></p>
  </td>
  <td width=102 valign=top style='width:76.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>15 (18)</span></p>
  </td>
  <td width=66 valign=top style='width:49.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>16 (19)</span></p>
  </td>
 </tr>
 <tr>
  <td width=91 valign=top style='width:.95in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Stratified
  Hazard Ratio </span></p>
  </td>
  <td width=172 colspan=2 valign=top style='width:128.85pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>7.94</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(95% CI [0.93, 68.06])<sup>b</sup></span></p>
  </td>
  <td width=182 colspan=2 valign=top style='width:136.65pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.94</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(95% CI [0.53, 1.67])</span></p>
  </td>
  <td width=168 colspan=2 valign=top style='width:1.75in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.92</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(95% CI [0.45, 1.88])</span></p>
  </td>
 </tr>
</table>

<p class=Paragraph style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.25in;text-indent:-.25in;page-break-after:avoid'><sup><span
lang=EN-GB style='font-size:11.0pt'>a.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></sup><span lang=EN-GB style='font-size:9.0pt'>Death&nbsp;without&nbsp;either&nbsp;prior&nbsp;progression&nbsp;or&nbsp;more&nbsp;than&nbsp;one&nbsp;missed&nbsp;assessment&nbsp;visit.</span></p>

<p class=Paragraph style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.25in;text-indent:-.25in;page-break-after:avoid'><sup><span
lang=EN-GB style='font-size:11.0pt'>b.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></sup><span lang=EN-GB style='font-size:9.0pt'>Indicates results
from non-stratified analysis.</span></p>

<p class=Paragraph style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.25in;text-indent:-.25in;page-break-after:avoid'><sup><span
lang=EN-GB style='font-size:11.0pt'>c.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></sup><span lang=EN-GB style='font-size:9.0pt'>Events&nbsp;are&nbsp;death&nbsp;due&nbsp;to&nbsp;any&nbsp;cause.</span></p>

<p class=MsoNormal style='margin-left:41.05pt;text-indent:-41.05pt;page-break-after:
avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>At the time of the updated analysis
(3&nbsp;years of follow-up) for patients with 2 or more risk factors, the
hazard ratio for PFS per IRF was 0.49 (95% CI [0.34, 0.71]) and the hazard
ratio for PFS per investigator was 0.41 (95% CI [0.29, 0.58]) (see Figures 3
and 4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Figure 3:
Kaplan-Meier Plot of PFS per IRF in Patients with &#8805;&nbsp;2 Risk Factors</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB><img
border=0 width=605 height=299 id="Picture 38"
src="Adcetris-ema-combined-h-2455-en-IB-SOB-C2500_files/image004.gif"></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Figure 4:
Kaplan-Meier Plot of PFS per Investigator in Patients with &#8805;&nbsp;2 Risk
Factors</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB><img
border=0 width=605 height=299 id="Picture 79"
src="Adcetris-ema-combined-h-2455-en-IB-SOB-C2500_files/image005.gif"></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Study SG035&#8209;0003</span></p>

<p class=Paragraph style='margin-bottom:0in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Paragraph style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>The efficacy and safety of </span><span lang=EN-GB style='font-size:
11.0pt'>ADCETRIS</span><span lang=EN-GB style='font-size:11.0pt'> as a single
agent was evaluated in a pivotal open-label, single&#8209;arm, multicenter
study in 102&nbsp;patients with relapsed or refractory HL. See Table&nbsp;11
below for a summary of baseline patient and disease characteristics. </span></p>

<p class=Paragraph style='margin-bottom:0in'><i><u><span lang=EN-GB
style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=Paragraph style='margin-bottom:0in;page-break-after:avoid'><b><span
lang=EN-GB style='font-size:11.0pt'>Table 11: Summary of baseline patient and
disease characteristics in the phase&nbsp;2 relapsed or refractory HL study<br>
<br>
</span></b></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=593
 style='width:444.45pt;border-collapse:collapse;border:none'>
 <tr style='height:15.1pt'>
  <td width=413 valign=top style='width:309.65pt;border:solid windowtext 1.0pt;
  border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.1pt'>
  <p class=MsoNormal style='margin-bottom:3.0pt;page-break-after:avoid'><a
  name="OLE_LINK4"></a><a name="RANGE!A1"></a><b><span lang=EN-GB>Patient
  characteristics</span></b></p>
  </td>
  <td width=180 valign=top style='width:134.8pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><a name="OLE_LINK3"><b><span lang=EN-GB>n&nbsp;=&nbsp;102</span></b></a></p>
  </td>
 </tr>
 <tr style='height:13.5pt'>
  <td width=413 valign=top style='width:309.65pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.5pt'>
  <p class=MsoNormal style='margin-left:3.1pt;text-indent:5.5pt;page-break-after:
  avoid'><span lang=EN-GB>Median age, years (range)</span></p>
  </td>
  <td width=180 valign=top style='width:134.8pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.5pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>31&nbsp;years (15&#8209;77)</span></p>
  </td>
 </tr>
 <tr style='height:13.5pt'>
  <td width=413 valign=top style='width:309.65pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.5pt'>
  <p class=MsoNormal style='text-indent:8.6pt;page-break-after:avoid'><span
  lang=EN-GB>Gender</span></p>
  </td>
  <td width=180 valign=top style='width:134.8pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.5pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>48M (47%)/54F (53%)</span></p>
  </td>
 </tr>
 <tr style='height:12.75pt'>
  <td width=413 valign=top style='width:309.65pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal style='text-indent:8.6pt;page-break-after:avoid'><span
  lang=EN-GB>ECOG status</span></p>
  </td>
  <td width=180 valign=top style='width:134.8pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:12.75pt'>
  <td width=413 valign=top style='width:309.65pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal style='margin-left:19.6pt;page-break-after:avoid'><span
  lang=EN-GB>0</span></p>
  </td>
  <td width=180 valign=top style='width:134.8pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>42 (41%)</span></p>
  </td>
 </tr>
 <tr style='height:5.65pt'>
  <td width=413 valign=top style='width:309.65pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.65pt'>
  <p class=MsoNormal style='margin-left:19.6pt;page-break-after:avoid'><span
  lang=EN-GB>1</span></p>
  </td>
  <td width=180 valign=top style='width:134.8pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>60 (59%)</span></p>
  </td>
 </tr>
 <tr style='height:5.65pt'>
  <td width=413 valign=top style='width:309.65pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.65pt'>
  <p class=MsoNormal style='margin-left:19.6pt;text-indent:-.15in;page-break-after:
  avoid'><span lang=EN-GB>Prior ASCT</span></p>
  </td>
  <td width=180 valign=top style='width:134.8pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>102 (100%)</span></p>
  </td>
 </tr>
 <tr style='height:5.65pt'>
  <td width=413 valign=top style='width:309.65pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.65pt'>
  <p class=MsoNormal style='margin-left:19.6pt;text-indent:-.15in;page-break-after:
  avoid'><span lang=EN-GB>Prior chemotherapy Regimens</span></p>
  </td>
  <td width=180 valign=top style='width:134.8pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>3.5 (1&#8209;13)</span></p>
  </td>
 </tr>
 <tr style='height:6.4pt'>
  <td width=413 valign=top style='width:309.65pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.4pt'>
  <p class=MsoNormal style='margin-left:19.6pt;text-indent:-.15in;page-break-after:
  avoid'><span lang=EN-GB>Time from ASCT to first post-transplant relapse</span></p>
  </td>
  <td width=180 valign=top style='width:134.8pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>6.7&nbsp;mo (0&#8209;131)</span></p>
  </td>
 </tr>
 <tr style='height:6.35pt'>
  <td width=413 valign=top style='width:309.65pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.35pt'>
  <p class=MsoNormal style='margin-left:19.6pt;text-indent:-.15in;page-break-after:
  avoid'><span lang=EN-GB>Histologically confirmed CD30&#8209;expressing
  disease</span></p>
  </td>
  <td width=180 valign=top style='width:134.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.35pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>102 (100%)</span></p>
  </td>
 </tr>
 <tr style='height:15.1pt'>
  <td width=413 valign=top style='width:309.65pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.1pt'>
  <p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:3.0pt;
  margin-left:19.45pt;text-align:justify;text-justify:inter-ideograph;
  text-indent:-19.45pt;page-break-after:avoid'><b><span lang=EN-GB>Disease
  characteristics</span></b></p>
  </td>
  <td width=180 valign=top style='width:134.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.1pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='height:8.0pt'>
  <td width=413 valign=top style='width:309.65pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:8.0pt'>
  <p class=MsoNormal style='margin-left:8.6pt;page-break-after:avoid'><span
  lang=EN-GB>Primary Refractory to frontline therapy<sup>a</sup></span></p>
  </td>
  <td width=180 valign=top style='width:134.8pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:8.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>72 (71%)</span></p>
  </td>
 </tr>
 <tr style='height:7.15pt'>
  <td width=413 valign=top style='width:309.65pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:7.15pt'>
  <p class=MsoNormal style='margin-left:8.6pt;page-break-after:avoid'><span
  lang=EN-GB>Refractory to most recent therapy</span></p>
  </td>
  <td width=180 valign=top style='width:134.8pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:7.15pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>43 (42%)</span></p>
  </td>
 </tr>
 <tr style='height:6.4pt'>
  <td width=413 valign=top style='width:309.65pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.4pt'>
  <p class=MsoNormal style='margin-left:8.6pt;page-break-after:avoid'><span
  lang=EN-GB>Baseline B symptoms</span></p>
  </td>
  <td width=180 valign=top style='width:134.8pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>35 (33%)</span></p>
  </td>
 </tr>
 <tr style='height:6.35pt'>
  <td width=413 valign=top style='width:309.65pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.35pt'>
  <p class=MsoNormal style='margin-left:8.6pt;page-break-after:avoid'><span
  lang=EN-GB>Stage&nbsp;III at initial diagnosis</span></p>
  </td>
  <td width=180 valign=top style='width:134.8pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.35pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>27 (26%)</span></p>
  </td>
 </tr>
 <tr style='height:6.35pt'>
  <td width=413 valign=top style='width:309.65pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.35pt'>
  <p class=MsoNormal style='margin-left:8.6pt;page-break-after:avoid'><span
  lang=EN-GB>Stage&nbsp;IV at initial diagnosis</span></p>
  </td>
  <td width=180 valign=top style='width:134.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.35pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>20 (20%)</span></p>
  </td>
 </tr>
</table>

</div>

<p class=Paragraph style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:22.5pt;text-indent:-.25in'><sup><span lang=EN-GB style='font-size:
11.0pt'>a.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></sup><span lang=EN-GB style='font-size:9.0pt'>Primary refractory
HL is defined as a failure to achieve a complete remission to, or progressed
within 3&nbsp;months of completing frontline therapy.</span></p>

<p class=Paragraph style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=Paragraph style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Eighteen (18) patients (18%) received 16&nbsp;cycles of </span><span
lang=EN-GB style='font-size:11.0pt'>ADCETRIS</span><span lang=EN-GB
style='font-size:11.0pt'>; and the median number of cycles received was 9
(ranging from 1 to 1</span><span lang=EN-GB style='font-size:11.0pt'>6).<sup> </sup></span></p>

<p class=Paragraph style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=Paragraph style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Response to treatment with </span><span lang=EN-GB style='font-size:
11.0pt'>ADCETRIS</span><span lang=EN-GB style='font-size:11.0pt'> was assessed
by Independent Review Facility (IRF) using the Revised Response Criteria for
Malignant Lymphoma (Cheson, 2007). Treatment response was assessed by spiral CT
of chest, neck, abdomen and pelvis; PET scans and clinical data. Response
assessments were performed at cycles 2, 4, 7, 10, 13, and 16 with PET at cycles
4 and 7.</span></p>

<p class=Paragraph style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>The objective response rate (ORR) per IRF assessment was 75% (76 of
102&nbsp;patients in the intent&#8209;to&#8209;treat [ITT] set) and tumour
reduction was achieved in 94% of patients. Complete remission (CR) was 33% (34
of 102&nbsp;patients in the ITT set). The median overall survival (OS) is
40.5&nbsp;months (the median observation time (time to death or last contact)
from first dose was 35.1&nbsp;months (range 1.8&nbsp;to 72.9+&nbsp;months). The
estimated overall survival rate at 5&nbsp;years was 41% (95%&nbsp;CI [31%,
51%]).<a name="OLE_LINK8"></a><a name="OLE_LINK9"> The investigator assessments
were generally consistent with the independent review of the scans.</a> </span><span
lang=EN-GB style='font-size:11.0pt'>Of the patients treated, 8&nbsp;responding
patients went on to receive an allogeneic SCT. </span><span lang=EN-GB
style='font-size:11.0pt'>For further efficacy results see Table&nbsp;12. </span></p>

<p class=MsoNormal style='margin-left:131.75pt;text-indent:-131.75pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Table 12:
Efficacy results in relapsed or refractory Hodgkin lymphoma patients treated
with 1.8&nbsp;mg/kg of </span></b><b><span lang=EN-GB>ADCETRIS</span><span
lang=EN-GB> every 3&nbsp;weeks<br>
<br>
</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=600
 style='margin-left:5.4pt;border-collapse:collapse;border:none'>
 <tr style='height:15.1pt'>
  <td width=251 nowrap valign=top style='width:188.1pt;border:solid windowtext 1.0pt;
  border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.1pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Best
  clinical response</span></b><b><sup><span lang=EN-GB> </span></sup></b><b><span
  lang=EN-GB>(n&nbsp;=&nbsp;102</span></b><sup><span lang=EN-GB> </span></sup><b><span
  lang=EN-GB>)</span></b></p>
  </td>
  <td width=187 nowrap valign=top style='width:1.95in;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.1pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>IRF n (%)</span></b></p>
  </td>
  <td width=162 nowrap valign=top style='width:121.5pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>95% CI</span></b></p>
  </td>
 </tr>
 <tr style='height:12.75pt'>
  <td width=251 nowrap valign=top style='width:188.1pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;
  border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;&nbsp;&nbsp;
  Objective response rate (CR + PR)</span></p>
  </td>
  <td width=187 nowrap valign=top style='width:1.95in;border-top:none;
  border-left:none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>76 (75)</span></p>
  </td>
  <td width=162 nowrap valign=top style='width:121.5pt;border-top:none;
  border-left:none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>64.9, 82.6</span></p>
  </td>
 </tr>
 <tr style='height:12.75pt'>
  <td width=251 nowrap valign=top style='width:188.1pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;
  border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  Complete remission (CR)</span></p>
  </td>
  <td width=187 nowrap valign=top style='width:1.95in;border-top:none;
  border-left:none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>34 (33)</span></p>
  </td>
  <td width=162 nowrap valign=top style='width:121.5pt;border-top:none;
  border-left:none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>24.3, 43.4</span></p>
  </td>
 </tr>
 <tr style='height:12.75pt'>
  <td width=251 nowrap valign=top style='width:188.1pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;
  border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  Partial remission (PR)</span></p>
  </td>
  <td width=187 nowrap valign=top style='width:1.95in;border-top:none;
  border-left:none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>42 (41)</span></p>
  </td>
  <td width=162 nowrap valign=top style='width:121.5pt;border-top:none;
  border-left:none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>NA</span></p>
  </td>
 </tr>
 <tr style='height:12.75pt'>
  <td width=251 nowrap valign=top style='width:188.1pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;
  border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;&nbsp;&nbsp;
  Disease control rate (CR + PR + SD)</span></p>
  </td>
  <td width=187 nowrap valign=top style='width:1.95in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>98 (96)</span></p>
  </td>
  <td width=162 nowrap valign=top style='width:121.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>90.3, 98.9</span></p>
  </td>
 </tr>
 <tr style='height:14.8pt'>
  <td width=251 nowrap valign=top style='width:188.1pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;
  border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:14.8pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Duration
  of response </span></b></p>
  </td>
  <td width=187 valign=top style='width:1.95in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.8pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Median per IRF </span></b></p>
  </td>
  <td width=162 nowrap valign=top style='width:121.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.8pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>95% CI</span></b></p>
  </td>
 </tr>
 <tr style='height:12.75pt'>
  <td width=251 nowrap valign=top style='width:188.1pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;
  border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;&nbsp;&nbsp;
  Objective response rate (CR + PR)<sup>a</sup></span></p>
  </td>
  <td width=187 nowrap valign=top style='width:1.95in;border-top:none;
  border-left:none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>6.7&nbsp;months </span></p>
  </td>
  <td width=162 nowrap valign=top style='width:121.5pt;border-top:none;
  border-left:none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>3.6, 14.8</span></p>
  </td>
 </tr>
 <tr style='height:12.75pt'>
  <td width=251 nowrap valign=top style='width:188.1pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;
  border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;&nbsp;&nbsp;
  Complete remission (CR)</span></p>
  </td>
  <td width=187 nowrap valign=top style='width:1.95in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>27.9&nbsp;months</span></p>
  </td>
  <td width=162 nowrap valign=top style='width:121.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>10.8, NE<sup>b</sup> </span></p>
  </td>
 </tr>
 <tr style='height:15.1pt'>
  <td width=251 valign=top style='width:188.1pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.1pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Overall
  survival </span></b></p>
  </td>
  <td width=187 valign=top style='width:1.95in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.1pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=162 valign=top style='width:121.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.1pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>95% CI</span></b></p>
  </td>
 </tr>
 <tr style='height:7.5pt'>
  <td width=251 valign=top style='width:188.1pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:7.5pt'>
  <p class=MsoNormal style='margin-left:9.0pt;page-break-after:avoid'><span
  lang=EN-GB>Median</span></p>
  </td>
  <td width=187 valign=top style='width:1.95in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:7.5pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>40.5&nbsp;months</span><b><sup><span lang=EN-GB> </span></sup></b></p>
  </td>
  <td width=162 valign=top style='width:121.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:7.5pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>28.7, 61.9</span></p>
  </td>
 </tr>
 <tr style='height:7.5pt'>
  <td width=251 valign=top style='width:188.1pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:7.5pt'>
  <p class=MsoNormal style='margin-left:9.0pt;page-break-after:avoid'><span
  lang=EN-GB>Estimated 5&#8209;year OS Rate</span></p>
  </td>
  <td width=187 valign=top style='width:1.95in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:7.5pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>41%</span></p>
  </td>
  <td width=162 valign=top style='width:121.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:7.5pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>31%, 51%</span></p>
  </td>
 </tr>
</table>

<p class=Paragraph style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.25in;text-indent:-.25in;page-break-after:avoid'><sup><span
lang=EN-GB style='font-size:11.0pt'>a.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></sup><span lang=EN-GB style='font-size:9.0pt'>The range of DOR
was 1.2+&nbsp;months to 43+&nbsp;months and the median follow-up time from
first dose for patients who achieved objective response (OR) per IRF was
9.0&nbsp;months.</span></p>

<p class=Paragraph style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.25in;text-indent:-.25in'><sup><span lang=EN-GB style='font-size:
11.0pt'>b.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></sup><span lang=EN-GB style='font-size:9.0pt'>Not estimable.</span></p>

<p class=Paragraph style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=Paragraph style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>An exploratory intra&#8209;patient analysis showed that approximately
64% of the HL patients treated with ADCETRIS as part of the SG035&#8209;0003
clinical study experienced an improvement in clinical benefit as measured by
longer progression free survival (PFS) compared with their most recent prior
line of therapy. </span></p>

<p class=Paragraph style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=Paragraph style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Of the 35&nbsp;patients (33%) who had B symptoms at baseline,
27&nbsp;patients (77%) experienced resolution of all B symptoms at a median
time of 0.7&nbsp;months from initiation of </span><span lang=EN-GB
style='font-size:11.0pt'>ADCETRIS</span><span lang=EN-GB style='font-size:11.0pt'>.</span></p>

<p class=Paragraph style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Data in HL
Patients Who Are Not Stem Cell Transplant (SCT) Candidates</span></p>

<p class=TableText style='margin-bottom:0in'><i><span style='font-size:11.0pt'>&nbsp;</span></i></p>

<p class=TableText style='margin-bottom:0in;page-break-after:avoid'><span
style='font-size:11.0pt'>Study&#8209;C25007 </span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>A phase&nbsp;4 single-arm study was
conducted in patients with relapsed or refractory HL (n&nbsp;=&nbsp;60) who had
received at least one prior chemotherapeutic regimen and at the time of
treatment initiation with ADCETRIS were not considered candidates for SCT or
multiagent chemotherapy. The median number of cycles was 7 (range 1 to 16
cycles). Patients were treated with 1.8&nbsp;mg/kg of ADCETRIS every 3&nbsp;weeks.
Per IRF, the objective response rate (ORR) in the ITT population was 50% (95%
CI, 37; 63%). A best overall response of CR was reported for 7&nbsp;patients
(12%); PR was reported for 23&nbsp;patients (38%). Among these 30&nbsp;patients,
the median time to response, defined as the time from first dose to the soonest
of PR or CR, was 6 weeks (range, 5 to 39&nbsp;weeks). The median time to best
overall response, defined as the time from first dose to the clinical best
response of CR or PR, was 11&nbsp;weeks (range, 5 to 60&nbsp;weeks). Twenty&#8209;eight
patients (47%) went on to receive SCT after a median of 7 cycles (range, 4 to&nbsp;16
cycles) of ADCETRIS treatment. The 32&nbsp;patients (53%) who did not receive
subsequent SCT also received ADCETRIS for a median of 7&nbsp;cycles (range, 1&nbsp;to
16&nbsp;cycles). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Of the study&#8217;s 60&nbsp;patients, 49&nbsp;patients
(82%) received &gt;&nbsp;1 prior cancer-related treatment and 11&nbsp;patients
(18%) received 1 prior cancer-related treatment. Per IRF, the ORR was 51% (95%&nbsp;CI&nbsp;[36%,
66%]) for the patients who had received &gt;&nbsp;1 prior cancer-related
treatment and 45% (95%&nbsp;CI&nbsp;[17%, 77%]) for the patients who had
received 1&nbsp;prior cancer-related treatment. For the patients who received
&gt;&nbsp;1 prior cancer-related treatment, a best overall response of CR was
reported for 6&nbsp;patients (12%); PR was reported for 19&nbsp;patients (39%).
For the patients who received 1&nbsp;prior cancer-related treatment, CR was
reported for 1&nbsp;patient (9%) and PR was reported for 4&nbsp;patients (36%).
Out of the 49&nbsp;patients receiving &gt;&nbsp;1 line of prior treatment, 22&nbsp;patients
(45%) received subsequent SCT; of the 11&nbsp;patients who had received 1 prior
treatment, 6&nbsp;patients (55%) received subsequent SCT.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Data were also collected from patients (n&nbsp;=&nbsp;15)
in phase&nbsp;1 dose escalation and clinical pharmacology studies, and from
patients (n&nbsp;=&nbsp;26) in a NPP, with relapsed or refractory HL who had
not received an ASCT, and who were treated with 1.8&nbsp;mg/kg of ADCETRIS
every 3&nbsp;weeks.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Baseline patient characteristics showed
failure from multiple prior chemotherapy regimens (median of 3&nbsp;with a
range of 1 to 7) before first administration with ADCETRIS. Fifty nine percent
(59%) of patients had advanced stage disease (Stage&nbsp;III or IV) at initial
diagnosis. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Results from these phase 1 studies and from
the NPP experience showed, that in patients with relapsed or refractory HL
without prior ASCT, clinically meaningful responses can be achieved as
evidenced by an investigator-assessed, objective response rate of 54% and a
complete remission rate of 22% after a median of 5&nbsp;cycles of ADCETRIS. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Study SGN35&#8209;006
(Retreatment Study)</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=Paragraph style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>The efficacy of retreatment in patients who had previously responded
(CR or PR) to treatment with ADCETRIS was evaluated in a phase&nbsp;2,
open-label, multicenter trial. Twenty patients with relapsed or refractory HL
received a starting dose of 1.8&nbsp;mg/kg and one patient received a starting
dose of 1.2&nbsp;mg/kg of ADCETRIS administered intravenously over
30&nbsp;minutes every 3&nbsp;weeks. The median number of cycles was 7 (range, 2
to 37&nbsp;cycles).</span><span lang=EN-GB style='font-size:11.0pt'> </span><span
lang=EN-GB style='font-size:11.0pt'>Of the 20&nbsp;evaluable patients with HL,
6&nbsp;patients (30%) achieved a CR and 6&nbsp;patients (30%) achieved a PR
with ADCETRIS retreatment, for an ORR of 60%. </span><span lang=EN-GB
style='font-size:11.0pt'>The median duration of response was 9.2 and
9.4&nbsp;months in patients who achieved OR (CR+PR) and CR, respectively.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Systemic anaplastic large cell lymphoma</span></i></p>

<p class=Paragraph style='margin-bottom:0in;page-break-after:avoid'><i><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></i></p>

<p class=Paragraph style='margin-bottom:0in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>Study SGN35&#8209;014</span></p>

<p class=Paragraph style='margin-bottom:0in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Paragraph style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>The efficacy and safety of ADCETRIS were evaluated in a randomised,
double-blind, double-dummy, active-controlled, multicenter trial of 452&nbsp;patients
with previously untreated CD30+ PTCL in combination with cyclophosphamide [C],
doxorubicin [H] and prednisone [P] (CHP). </span><span style='font-size:11.0pt'>For
enrollment, the trial required CD30 expression &#8805;10% per
immunohistochemistry. </span><span lang=EN-GB style='font-size:11.0pt'>Only
patients with CD30+ PTCLs who were eligible for a </span><span lang=EN-GB
style='font-size:11.0pt'>cyclophosphamide [C], doxorubicin [H], vincristine [O]
and prednisone [P]</span><span lang=EN-GB style='font-size:11.0pt'> (CHOP)-based
regimen were included.</span><span style='font-size:11.0pt'> The combination of
ADCETRIS&nbsp;+&nbsp;CHP has not been studied in all PTCL subtypes. See Table
13 for enrolled PTCL subtypes. </span><span lang=EN-GB style='font-size:11.0pt'>Of
the 452&nbsp;patients, 226&nbsp;were randomised to treatment with ADCETRIS&nbsp;+&nbsp;CHP
and 226&nbsp;patients were randomised to treatment with CHOP. Randomisation was
stratified by ALK-positive sALCL versus all other subtypes and by the
International Prognostic Index (IPI) score. Patients were treated with ADCETRIS
administered as an intravenous infusion over 30&nbsp;minutes on day&nbsp;1 of
each 21&#8209;day cycle for 6&nbsp;to 8&nbsp;cycles + CHP. The median number of
cycles received was 6&nbsp;(range, 1&nbsp;to&nbsp;8 cycles); 70% of patients
received 6&nbsp;cycles of treatment, and 18% received 8&nbsp;cycles of
treatment. Table 13&nbsp;provides a summary of baseline patient and disease
characteristics.</span></p>

<p class=Paragraph style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><a name="_Ref525816436"><b><span
lang=EN-GB>Table </span></b></a><b><span lang=EN-GB>13: Summary of baseline
patient and disease characteristics in the phase 3 previously untreated PTCL
study (ITT and sALCL)</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=613
 style='width:459.4pt;border-collapse:collapse;border:none'>
 <thead>
  <tr>
   <td width=253 valign=top style='width:189.45pt;border:solid windowtext 1.0pt;
   border-right:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
   </td>
   <td width=179 colspan=2 valign=bottom style='width:133.95pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB>ITT Population </span></b></p>
   </td>
   <td width=181 colspan=2 valign=bottom style='width:136.0pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB>sALCL Population<sup>b</sup></span></b></p>
   </td>
  </tr>
  <tr>
   <td width=253 valign=top style='width:189.45pt;border-top:none;border-left:
   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
   none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Patient
   characteristics</span></b></p>
   </td>
   <td width=90 valign=bottom style='width:67.65pt;border:none;border-bottom:
   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB>ADCETRIS + CHP</span></b></p>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB>n=226</span></b></p>
   </td>
   <td width=88 valign=bottom style='width:66.3pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB>CHOP</span></b></p>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB>n=226</span></b></p>
   </td>
   <td width=93 valign=bottom style='width:69.55pt;border:none;border-bottom:
   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB>ADCETRIS + CHP</span></b></p>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB>n=162</span></b></p>
   </td>
   <td width=89 valign=bottom style='width:66.45pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB>CHOP</span></b></p>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB>n=154</span></b></p>
   </td>
  </tr>
  <tr>
   <td width=253 valign=top style='width:189.45pt;border:none;border-left:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Median
   age (range)</span></p>
   </td>
   <td width=90 valign=top style='width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>58.0 (18&#8209;85)</span></p>
   </td>
   <td width=88 valign=top style='width:66.3pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>58.0 (18&#8209;83)</span></p>
   </td>
   <td width=93 valign=top style='width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>55.0 (18-85)</span></p>
   </td>
   <td width=89 valign=top style='width:66.45pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>54.0 (18-83)</span></p>
   </td>
  </tr>
  <tr>
   <td width=253 valign=top style='width:189.45pt;border:none;border-left:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Patients
   &#8805; 65 years old (%)</span></p>
   </td>
   <td width=90 valign=top style='width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>69 (31)</span></p>
   </td>
   <td width=88 valign=top style='width:66.3pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>70 (31)</span></p>
   </td>
   <td width=93 valign=top style='width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>38 (23)</span></p>
   </td>
   <td width=89 valign=top style='width:66.45pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>36 (23)</span></p>
   </td>
  </tr>
  <tr>
   <td width=253 valign=top style='width:189.45pt;border:none;border-left:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Male sex,
   n (%)</span></p>
   </td>
   <td width=90 valign=top style='width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>133 (59)</span></p>
   </td>
   <td width=88 valign=top style='width:66.3pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>151 (67)</span></p>
   </td>
   <td width=93 valign=top style='width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>95 (59)</span></p>
   </td>
   <td width=89 valign=top style='width:66.45pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>110 (71)</span></p>
   </td>
  </tr>
  <tr>
   <td width=253 valign=top style='width:189.45pt;border:none;border-left:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>ECOG
   status, n (%)</span></p>
   </td>
   <td width=90 valign=top style='width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>&nbsp;</span></p>
   </td>
   <td width=88 valign=top style='width:66.3pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>&nbsp;</span></p>
   </td>
   <td width=93 valign=top style='width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>&nbsp;</span></p>
   </td>
   <td width=89 valign=top style='width:66.45pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>&nbsp;</span></p>
   </td>
  </tr>
  <tr>
   <td width=253 valign=top style='width:189.45pt;border:none;border-left:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-left:.1in;page-break-after:avoid'><span
   lang=EN-GB>0</span></p>
   </td>
   <td width=90 valign=top style='width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>84 (37)</span></p>
   </td>
   <td width=88 valign=top style='width:66.3pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>93 (41)</span></p>
   </td>
   <td width=93 valign=top style='width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>58 (36)</span></p>
   </td>
   <td width=89 valign=top style='width:66.45pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>53 (34)</span></p>
   </td>
  </tr>
  <tr>
   <td width=253 valign=top style='width:189.45pt;border:none;border-left:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-left:.1in;page-break-after:avoid'><span
   lang=EN-GB>1</span></p>
   </td>
   <td width=90 valign=top style='width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>90 (40)</span></p>
   </td>
   <td width=88 valign=top style='width:66.3pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>86 (38)</span></p>
   </td>
   <td width=93 valign=top style='width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>62 (38)</span></p>
   </td>
   <td width=89 valign=top style='width:66.45pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>61 (40)</span></p>
   </td>
  </tr>
  <tr>
   <td width=253 valign=top style='width:189.45pt;border-top:none;border-left:
   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
   none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-left:.1in;page-break-after:avoid'><span
   lang=EN-GB>2</span></p>
   </td>
   <td width=90 valign=top style='width:67.65pt;border:none;border-bottom:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>51 (23)</span></p>
   </td>
   <td width=88 valign=top style='width:66.3pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>47 (21)</span></p>
   </td>
   <td width=93 valign=top style='width:69.55pt;border:none;border-bottom:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>41 (25)</span></p>
   </td>
   <td width=89 valign=top style='width:66.45pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>40 (26)</span></p>
   </td>
  </tr>
  <tr>
   <td width=253 valign=top style='width:189.45pt;border-top:none;border-left:
   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
   none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Disease
   characteristics</span></b></p>
   </td>
   <td width=90 valign=top style='width:67.65pt;border:none;border-bottom:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>&nbsp;</span></p>
   </td>
   <td width=88 valign=top style='width:66.3pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>&nbsp;</span></p>
   </td>
   <td width=93 valign=top style='width:69.55pt;border:none;border-bottom:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>&nbsp;</span></p>
   </td>
   <td width=89 valign=top style='width:66.45pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>&nbsp;</span></p>
   </td>
  </tr>
  <tr>
   <td width=253 valign=top style='width:189.45pt;border:none;border-left:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-left:.1in;page-break-after:avoid'><span
   lang=EN-GB>Diagnosis, per local assessment, n (%)<sup>a</sup></span></p>
   </td>
   <td width=90 valign=top style='width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>&nbsp;</span></p>
   </td>
   <td width=88 valign=top style='width:66.3pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>&nbsp;</span></p>
   </td>
   <td width=93 valign=top style='width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>&nbsp;</span></p>
   </td>
   <td width=89 valign=top style='width:66.45pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>&nbsp;</span></p>
   </td>
  </tr>
  <tr>
   <td width=253 valign=top style='width:189.45pt;border:none;border-left:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-left:.2in;page-break-after:avoid'><span
   lang=EN-GB>sALCL</span></p>
   </td>
   <td width=90 valign=top style='width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>162 (72)</span></p>
   </td>
   <td width=88 valign=top style='width:66.3pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>154 (68)</span></p>
   </td>
   <td width=93 valign=top style='width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>162 (100)</span></p>
   </td>
   <td width=89 valign=top style='width:66.45pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>154 (100)</span></p>
   </td>
  </tr>
  <tr>
   <td width=253 valign=top style='width:189.45pt;border:none;border-left:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-left:.4in;page-break-after:avoid'><span
   lang=EN-GB>ALK-positive</span></p>
   </td>
   <td width=90 valign=top style='width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>49 (22)</span></p>
   </td>
   <td width=88 valign=top style='width:66.3pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>49 (22)</span></p>
   </td>
   <td width=93 valign=top style='width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>49 (30)</span></p>
   </td>
   <td width=89 valign=top style='width:66.45pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>49 (32)</span></p>
   </td>
  </tr>
  <tr>
   <td width=253 valign=top style='width:189.45pt;border:none;border-left:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-left:.4in;page-break-after:avoid'><span
   lang=EN-GB>ALK-negative</span></p>
   </td>
   <td width=90 valign=top style='width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>113 (50)</span></p>
   </td>
   <td width=88 valign=top style='width:66.3pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>105 (46)</span></p>
   </td>
   <td width=93 valign=top style='width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>113 (70)</span></p>
   </td>
   <td width=89 valign=top style='width:66.45pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>105 (68)</span></p>
   </td>
  </tr>
  <tr>
   <td width=253 valign=top style='width:189.45pt;border:none;border-left:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-left:.2in;page-break-after:avoid'><span
   lang=FR>Peripheral T-cell lymphoma (PTCL-NOS)</span></p>
   </td>
   <td width=90 valign=top style='width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>29 (13)</span></p>
   </td>
   <td width=88 valign=top style='width:66.3pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>43 (19)</span></p>
   </td>
   <td width=93 valign=top style='width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>NA</span></p>
   </td>
   <td width=89 valign=top style='width:66.45pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>NA</span></p>
   </td>
  </tr>
  <tr>
   <td width=253 valign=top style='width:189.45pt;border:none;border-left:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-left:.2in;page-break-after:avoid'><span
   lang=EN-GB>Angioimmunoblastic T-cell lymphoma (AITL)</span></p>
   </td>
   <td width=90 valign=top style='width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>30 (13)</span></p>
   </td>
   <td width=88 valign=top style='width:66.3pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>24 (11)</span></p>
   </td>
   <td width=93 valign=top style='width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>NA</span></p>
   </td>
   <td width=89 valign=top style='width:66.45pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>NA</span></p>
   </td>
  </tr>
  <tr>
   <td width=253 valign=top style='width:189.45pt;border:none;border-left:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-left:.2in;page-break-after:avoid'><span
   lang=EN-GB>Adult T-cell leukemia/lymphoma (ATLL)</span></p>
   </td>
   <td width=90 valign=top style='width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>4 (2)</span></p>
   </td>
   <td width=88 valign=top style='width:66.3pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>3 (1)</span></p>
   </td>
   <td width=93 valign=top style='width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>NA</span></p>
   </td>
   <td width=89 valign=top style='width:66.45pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>NA</span></p>
   </td>
  </tr>
  <tr>
   <td width=253 valign=top style='width:189.45pt;border:none;border-left:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-left:.2in;page-break-after:avoid'><span
   lang=EN-GB>Enteropathy-associated T-cell lymphoma (EATL)</span></p>
   </td>
   <td width=90 valign=top style='width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>1 (0)</span></p>
   </td>
   <td width=88 valign=top style='width:66.3pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>2 (1)</span></p>
   </td>
   <td width=93 valign=top style='width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>NA</span></p>
   </td>
   <td width=89 valign=top style='width:66.45pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>NA</span></p>
   </td>
  </tr>
  <tr>
   <td width=253 valign=top style='width:189.45pt;border:none;border-left:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-left:.1in;page-break-after:avoid'><span
   lang=EN-GB>Median time from diagnosis to first dose, months (range)</span></p>
   </td>
   <td width=90 valign=top style='width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>0.8 (0, 19)</span></p>
   </td>
   <td width=88 valign=top style='width:66.3pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>0.9 (0, 10)</span></p>
   </td>
   <td width=93 valign=top style='width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>0.8 (0, 19)</span></p>
   </td>
   <td width=89 valign=top style='width:66.45pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>0.9 (0, 10)</span></p>
   </td>
  </tr>
  <tr>
   <td width=253 valign=top style='width:189.45pt;border:none;border-left:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-left:.1in;page-break-after:avoid'><span
   lang=EN-GB>Disease stage at initial diagnosis of PTCL, n (%)</span></p>
   </td>
   <td width=90 valign=top style='width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>&nbsp;</span></p>
   </td>
   <td width=88 valign=top style='width:66.3pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>&nbsp;</span></p>
   </td>
   <td width=93 valign=top style='width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>&nbsp;</span></p>
   </td>
   <td width=89 valign=top style='width:66.45pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>&nbsp;</span></p>
   </td>
  </tr>
  <tr>
   <td width=253 valign=top style='width:189.45pt;border:none;border-left:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-left:.2in;page-break-after:avoid'><span
   lang=EN-GB>Stage I</span></p>
   </td>
   <td width=90 valign=top style='width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>12 (5)</span></p>
   </td>
   <td width=88 valign=top style='width:66.3pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>9 (4)</span></p>
   </td>
   <td width=93 valign=top style='width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>12 (7)</span></p>
   </td>
   <td width=89 valign=top style='width:66.45pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>7 (5)</span></p>
   </td>
  </tr>
  <tr>
   <td width=253 valign=top style='width:189.45pt;border:none;border-left:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-left:.2in;page-break-after:avoid'><span
   lang=EN-GB>Stage II</span></p>
   </td>
   <td width=90 valign=top style='width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>30 (13)</span></p>
   </td>
   <td width=88 valign=top style='width:66.3pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>37 (16)</span></p>
   </td>
   <td width=93 valign=top style='width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>22 (14)</span></p>
   </td>
   <td width=89 valign=top style='width:66.45pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>27 (18)</span></p>
   </td>
  </tr>
  <tr>
   <td width=253 valign=top style='width:189.45pt;border:none;border-left:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-left:.2in;page-break-after:avoid'><span
   lang=EN-GB>Stage III</span></p>
   </td>
   <td width=90 valign=top style='width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>57 (25)</span></p>
   </td>
   <td width=88 valign=top style='width:66.3pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>67 (30)</span></p>
   </td>
   <td width=93 valign=top style='width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>29 (18)</span></p>
   </td>
   <td width=89 valign=top style='width:66.45pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>46 (30)</span></p>
   </td>
  </tr>
  <tr>
   <td width=253 valign=top style='width:189.45pt;border:none;border-left:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-left:.2in;page-break-after:avoid'><span
   lang=EN-GB>Stage IV</span></p>
   </td>
   <td width=90 valign=top style='width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>127 (56)</span></p>
   </td>
   <td width=88 valign=top style='width:66.3pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>113 (50)</span></p>
   </td>
   <td width=93 valign=top style='width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>99 (61)</span></p>
   </td>
   <td width=89 valign=top style='width:66.45pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>74 (48)</span></p>
   </td>
  </tr>
  <tr>
   <td width=253 valign=top style='width:189.45pt;border:none;border-left:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-left:.1in;page-break-after:avoid'><span
   lang=EN-GB>IPI score </span></p>
   </td>
   <td width=90 valign=top style='width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>&nbsp;</span></p>
   </td>
   <td width=88 valign=top style='width:66.3pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>&nbsp;</span></p>
   </td>
   <td width=93 valign=top style='width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>&nbsp;</span></p>
   </td>
   <td width=89 valign=top style='width:66.45pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>&nbsp;</span></p>
   </td>
  </tr>
  <tr>
   <td width=253 valign=top style='width:189.45pt;border:none;border-left:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-left:.2in;page-break-after:avoid'><span
   lang=EN-GB>0</span></p>
   </td>
   <td width=90 valign=top style='width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>8 (4)</span></p>
   </td>
   <td width=88 valign=top style='width:66.3pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>16 (7)</span></p>
   </td>
   <td width=93 valign=top style='width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>7 (4)</span></p>
   </td>
   <td width=89 valign=top style='width:66.45pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>14 (9)</span></p>
   </td>
  </tr>
  <tr>
   <td width=253 valign=top style='width:189.45pt;border:none;border-left:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-left:.2in;page-break-after:avoid'><span
   lang=EN-GB>1</span></p>
   </td>
   <td width=90 valign=top style='width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>45 (20)</span></p>
   </td>
   <td width=88 valign=top style='width:66.3pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>32 (14)</span></p>
   </td>
   <td width=93 valign=top style='width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>34 (21)</span></p>
   </td>
   <td width=89 valign=top style='width:66.45pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>18 (12)</span></p>
   </td>
  </tr>
  <tr>
   <td width=253 valign=top style='width:189.45pt;border:none;border-left:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-left:.2in;page-break-after:avoid'><span
   lang=EN-GB>2</span></p>
   </td>
   <td width=90 valign=top style='width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>74 (33)</span></p>
   </td>
   <td width=88 valign=top style='width:66.3pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>78 (35)</span></p>
   </td>
   <td width=93 valign=top style='width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>58 (36)</span></p>
   </td>
   <td width=89 valign=top style='width:66.45pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>60 (39)</span></p>
   </td>
  </tr>
  <tr>
   <td width=253 valign=top style='width:189.45pt;border:none;border-left:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-left:.2in;page-break-after:avoid'><span
   lang=EN-GB>3</span></p>
   </td>
   <td width=90 valign=top style='width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>66 (29)</span></p>
   </td>
   <td width=88 valign=top style='width:66.3pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>66 (29)</span></p>
   </td>
   <td width=93 valign=top style='width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>37 (23)</span></p>
   </td>
   <td width=89 valign=top style='width:66.45pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>40 (26)</span></p>
   </td>
  </tr>
  <tr>
   <td width=253 valign=top style='width:189.45pt;border:none;border-left:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-left:.2in;page-break-after:avoid'><span
   lang=EN-GB>4</span></p>
   </td>
   <td width=90 valign=top style='width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>29 (13)</span></p>
   </td>
   <td width=88 valign=top style='width:66.3pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>25 (11)</span></p>
   </td>
   <td width=93 valign=top style='width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>22 (14)</span></p>
   </td>
   <td width=89 valign=top style='width:66.45pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>16 (10)</span></p>
   </td>
  </tr>
  <tr>
   <td width=253 valign=top style='width:189.45pt;border:none;border-left:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-left:.2in;page-break-after:avoid'><span
   lang=EN-GB>5</span></p>
   </td>
   <td width=90 valign=top style='width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>4 (2)</span></p>
   </td>
   <td width=88 valign=top style='width:66.3pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>9 (4)</span></p>
   </td>
   <td width=93 valign=top style='width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>4 (2)</span></p>
   </td>
   <td width=89 valign=top style='width:66.45pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>6 (4)</span></p>
   </td>
  </tr>
  <tr>
   <td width=253 valign=top style='width:189.45pt;border:none;border-left:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-left:.1in;page-break-after:avoid'><span
   lang=EN-GB>Extranodal involvement at time of diagnosis, n (%)</span></p>
   </td>
   <td width=90 valign=top style='width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>&nbsp;</span></p>
   </td>
   <td width=88 valign=top style='width:66.3pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>&nbsp;</span></p>
   </td>
   <td width=93 valign=top style='width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>&nbsp;</span></p>
   </td>
   <td width=89 valign=top style='width:66.45pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>&nbsp;</span></p>
   </td>
  </tr>
  <tr>
   <td width=253 valign=top style='width:189.45pt;border:none;border-left:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-top:0in;margin-right:.2in;margin-bottom:
   0in;margin-left:.2in;margin-bottom:.0001pt;page-break-after:avoid'><span
   lang=EN-GB>&#8804; 1 site</span></p>
   </td>
   <td width=90 valign=top style='width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>142 (63)</span></p>
   </td>
   <td width=88 valign=top style='width:66.3pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>146 (65)</span></p>
   </td>
   <td width=93 valign=top style='width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>94 (58)</span></p>
   </td>
   <td width=89 valign=top style='width:66.45pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>95 (62)</span></p>
   </td>
  </tr>
  <tr>
   <td width=253 valign=top style='width:189.45pt;border:none;border-left:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-left:.2in;page-break-after:avoid'><span
   lang=EN-GB>&gt;1 site</span></p>
   </td>
   <td width=90 valign=top style='width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>84 (37)</span></p>
   </td>
   <td width=88 valign=top style='width:66.3pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>80 (35)</span></p>
   </td>
   <td width=93 valign=top style='width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>68 (42)</span></p>
   </td>
   <td width=89 valign=top style='width:66.45pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>59 (38)</span></p>
   </td>
  </tr>
  <tr>
   <td width=253 valign=top style='width:189.45pt;border:none;border-left:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-left:.1in;page-break-after:avoid'><span
   lang=EN-GB>Baseline bone marrow biopsy-lymphoma involvement, n (%)</span></p>
   </td>
   <td width=90 valign=top style='width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>&nbsp;</span></p>
   </td>
   <td width=88 valign=top style='width:66.3pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>&nbsp;</span></p>
   </td>
   <td width=93 valign=top style='width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>&nbsp;</span></p>
   </td>
   <td width=89 valign=top style='width:66.45pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>&nbsp;</span></p>
   </td>
  </tr>
  <tr>
   <td width=253 valign=top style='width:189.45pt;border:none;border-left:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-left:.2in;page-break-after:avoid'><span
   lang=EN-GB>Yes</span></p>
   </td>
   <td width=90 valign=top style='width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>30 (13)</span></p>
   </td>
   <td width=88 valign=top style='width:66.3pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>34 (15)</span></p>
   </td>
   <td width=93 valign=top style='width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>15 (9)</span></p>
   </td>
   <td width=89 valign=top style='width:66.45pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>13 (8)</span></p>
   </td>
  </tr>
  <tr>
   <td width=253 valign=top style='width:189.45pt;border-top:none;border-left:
   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
   none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-left:.2in;page-break-after:avoid'><span
   lang=EN-GB>No</span></p>
   </td>
   <td width=90 valign=top style='width:67.65pt;border:none;border-bottom:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>196 (87)</span></p>
   </td>
   <td width=88 valign=top style='width:66.3pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>192 (85)</span></p>
   </td>
   <td width=93 valign=top style='width:69.55pt;border:none;border-bottom:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>147 (91)</span></p>
   </td>
   <td width=89 valign=top style='width:66.45pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB>141 (92)</span></p>
   </td>
  </tr>
 </thead>
</table>

<p class=Paragraph style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:17.85pt;text-indent:-17.85pt'><sup><span lang=EN-GB
style='font-size:9.0pt'>a.</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; As
per the 2008 WHO classification.</span></p>

<p class=Paragraph style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:17.85pt;text-indent:-17.85pt'><sup><span lang=EN-GB
style='font-size:9.0pt'>b.</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For
patients with locally-diagnosed sALCL.</span></p>

<p class=Paragraph style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=Paragraph style='margin-bottom:0in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>The primary endpoint in SGN35&#8209;014 was
PFS per IRF, defined as the time from the date of randomisation to the date of
first documentation of progressive disease, death due to any cause, or receipt
of subsequent anticancer chemotherapy to treat residual or progressive disease,
whichever occurs first. Receipt of post&#8209;treatment consolidative
radiotherapy, post-treatment chemotherapy for the purpose of mobilising
peripheral blood stem cells, or consolidative autologous or allogeneic stem
cell transplant were not considered as disease progression or as having started
new anticancer therapy.</span></p>

<p class=Paragraph style='margin-bottom:0in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Key secondary
endpoints included PFS per IRF for patients with centrally-confirmed sALCL, CR
rate per IRF </span><span style='font-size:11.0pt'>following the completion of
study treatment</span><span lang=EN-GB style='font-size:11.0pt'>, OS and ORR
per IRF </span><span style='font-size:11.0pt'>following the completion of study
treatment</span><span lang=EN-GB style='font-size:11.0pt'> which were tested by
a fixed sequence testing procedure following the statistical significance of
PFS per IRF. </span></p>

<p class=Default><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>The primary
endpoint and alpha-protected, key secondary endpoints, which were evaluated
hierarchically, were met. The median PFS per IRF for the ITT population was
48.2&nbsp;months on the ADCETRIS&nbsp;+&nbsp;CHP arm versus 20.8&nbsp;months on
the CHOP arm. The stratified hazard ratio was 0.71&nbsp;(95%&nbsp;CI: 0.54;
0.93, p=0.011), indicating a 29% reduction in the risk of PFS events for ADCETRIS&nbsp;+&nbsp;CHP
versus CHOP. </span><span lang=EN-GB>For overall survival, the stratified
hazard ratio was </span><span lang=EN-GB style='color:windowtext'>0.66</span><span
lang=EN-GB>&nbsp;(95%&nbsp;CI:&nbsp;</span><span lang=EN-GB style='color:windowtext'>0.46;
0.95, p=0.024),</span><span lang=EN-GB> a 34% reduction in the risk of OS
events for ADCETRIS&nbsp;+&nbsp;CHP versus CHOP. </span></p>

<p class=MsoCaption style='margin:0in;text-indent:0in;page-break-after:auto'><a
name="_Hlk7682306"><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
font-weight:normal'>&nbsp;</span></a></p>

<p class=MsoCaption style='margin:0in;text-indent:0in;page-break-after:auto'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
font-weight:normal'>PFS per IRF for patients with centrally-confirmed sALCL was
a pre-specified key secondary endpoint. The median PFS per IRF was
55.7&nbsp;months on the ADCETRIS&nbsp;+&nbsp;CHP arm versus 54.2&nbsp;months on
the CHOP arm</span><span style='font-size:11.0pt;font-family:"Times New Roman",serif;
font-weight:normal'>. The stratified hazard ratio was 0.59&nbsp;(95%&nbsp;CI:
0.42; 0.84), compatible with a statistically significant 41% reduction in the
risk of PFS events for ADCETRIS&nbsp;+&nbsp;CHP versus CHOP (p&#8209;value=0.003),
see Figure 5 and Table 14.</span></p>

<p class=MsoCaption style='margin:0in;text-indent:0in;page-break-after:auto'><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;font-weight:normal'>&nbsp;</span></p>

<p class=MsoCaption style='margin:0in;text-indent:0in;page-break-after:auto'><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;font-weight:normal'>Subgroup
analyses were performed for patients with locally-diagnosed sALCL. For overall
survival, the stratified hazard ratio was </span><span style='font-size:11.0pt;
font-family:"Times New Roman",serif;color:windowtext;font-weight:normal'>0.54</span><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;font-weight:normal'>
(95% CI: </span><span style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:windowtext;font-weight:normal'>0.34; 0.87),</span><span style='font-size:
11.0pt;font-family:"Times New Roman",serif;font-weight:normal'> a 46% reduction
in the risk of OS events for ADCETRIS&nbsp;+&nbsp;CHP versus CHOP, see Figure 6.
At the end of treatment, the CR rate by IRF assessment was 71.0% for patients on
the ADCETRIS&nbsp;+&nbsp;CHP arm compared with 53.2% for patients on the CHOP
arm with a difference of 17.7% (95% CI: 7.2%; 28.3%). At the end of treatment,
the ORR rate by IRF assessment was 87.7% for patients on the ADCETRIS&nbsp;+&nbsp;CHP
arm compared with 70.8% for patients on the CHOP arm with a difference of 16.9%
(95% CI: 8.1%; 25.7%). In the subgroup of patients with ALK+ sALCL and ALK-
sALCL the stratified hazard ratio for PFS per IRF was </span><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:windowtext;
font-weight:normal'>0.29</span><span style='font-size:11.0pt;font-family:"Times New Roman",serif;
font-weight:normal'> (95% CI: </span><span style='font-size:11.0pt;font-family:
"Times New Roman",serif;color:windowtext;font-weight:normal'>0.11; 0.79) and 0.65</span><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;font-weight:normal'>
(95% CI: </span><span style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:windowtext;font-weight:normal'>0.44; 0.95), respectively. </span></p>

<p class=MsoNormal><b>&nbsp;</b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Table 14:
Efficacy results in patients with previously untreated sALCL with
1.8&nbsp;mg/kg of ADCETRIS on day 1 of a 3&#8209;week cycle </span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=587
 style='margin-left:5.35pt;border-collapse:collapse;border:none'>
 <tr style='height:30.35pt'>
  <td width=293 valign=top style='width:219.9pt;border:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:30.35pt'>
  <p class=TableParagraph align=left style='margin-left:5.1pt;text-align:left;
  line-height:normal;page-break-after:avoid'><b><span style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>
  </td>
  <td width=150 colspan=2 valign=top style='width:112.5pt;border:solid black 1.0pt;
  border-left:none;padding:0in 0in 0in 0in;height:30.35pt'>
  <p class=TableParagraph style='margin-top:0in;margin-right:15.35pt;
  margin-bottom:0in;margin-left:9.0pt;margin-bottom:.0001pt;text-indent:-4.5pt;
  line-height:125%;page-break-after:avoid'><b><span style='font-family:"Times New Roman",serif'>ADCETRIS&nbsp;+&nbsp;CHP</span></b></p>
  <p class=TableParagraph style='margin-top:0in;margin-right:15.35pt;
  margin-bottom:0in;margin-left:9.0pt;margin-bottom:.0001pt;text-indent:-4.5pt;
  line-height:125%;page-break-after:avoid'><b><span style='font-family:"Times New Roman",serif'>n=162<sup>a</sup></span></b></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:solid black 1.0pt;
  border-left:none;padding:0in 0in 0in 0in;height:30.35pt'>
  <p class=TableParagraph style='margin-top:0in;margin-right:15.35pt;
  margin-bottom:0in;margin-left:9.0pt;margin-bottom:.0001pt;text-indent:-4.5pt;
  line-height:125%;page-break-after:avoid'><b><span style='font-family:"Times New Roman",serif'>CHOP</span></b></p>
  <p class=TableParagraph style='margin-top:0in;margin-right:15.35pt;
  margin-bottom:0in;margin-left:9.0pt;margin-bottom:.0001pt;text-indent:-4.5pt;
  line-height:125%;page-break-after:avoid'><b><span style='font-family:"Times New Roman",serif'>n=154<sup>a</sup></span></b></p>
  </td>
 </tr>
 <tr style='height:15.1pt'>
  <td width=587 colspan=4 valign=bottom style='width:440.4pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:15.1pt'>
  <p class=TableParagraph align=left style='margin-left:7.25pt;text-align:left;
  text-indent:5.75pt;line-height:normal;page-break-after:avoid'><b><span
  style='font-family:"Times New Roman",serif'>PFS per IRF</span></b></p>
  </td>
 </tr>
 <tr style='height:15.8pt'>
  <td width=293 valign=top style='width:219.9pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:15.8pt'>
  <p class=TableParagraph align=left style='margin-left:26.5pt;text-align:left;
  line-height:11.5pt;page-break-after:avoid'><span style='font-family:"Times New Roman",serif'>Number
  of patients with a PFS event, n&nbsp;(%)</span></p>
  </td>
  <td width=150 colspan=2 valign=top style='width:112.5pt;border-top:none;
  border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:15.8pt'>
  <p class=TableParagraph style='line-height:11.5pt;page-break-after:avoid'><span
  style='font-family:"Times New Roman",serif'>56 (34)</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;
  height:15.8pt'>
  <p class=TableParagraph style='line-height:11.5pt;page-break-after:avoid'><span
  style='font-family:"Times New Roman",serif'>73 (48)</span></p>
  </td>
 </tr>
 <tr style='height:17.6pt'>
  <td width=293 valign=top style='width:219.9pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:17.6pt'>
  <p class=TableParagraph align=left style='margin-left:26.5pt;text-align:left;
  line-height:11.5pt;page-break-after:avoid'><span style='font-family:"Times New Roman",serif'>Median
  PFS, months (95%&nbsp;CI)</span></p>
  </td>
  <td width=150 colspan=2 valign=top style='width:112.5pt;border-top:none;
  border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:17.6pt'>
  <p class=TableParagraph style='line-height:11.5pt;page-break-after:avoid'><span
  style='font-family:"Times New Roman",serif'>55.66 (48.20, NE)</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;
  height:17.6pt'>
  <p class=TableParagraph style='line-height:11.5pt;page-break-after:avoid'><span
  style='font-family:"Times New Roman",serif'>54.18 (13.44, NE)</span></p>
  </td>
 </tr>
 <tr style='height:15.8pt'>
  <td width=293 valign=top style='width:219.9pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:15.8pt'>
  <p class=TableParagraph align=left style='margin-left:26.5pt;text-align:left;
  line-height:11.5pt;page-break-after:avoid'><span style='font-family:"Times New Roman",serif'>Hazard
  ratio (95%&nbsp;CI)<sup>b</sup></span></p>
  </td>
  <td width=294 colspan=3 valign=top style='width:220.5pt;border-top:none;
  border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:15.8pt'>
  <p class=TableParagraph style='line-height:11.5pt;page-break-after:avoid'><span
  style='font-family:"Times New Roman",serif'>0.59 (0.42, 0.84)</span></p>
  </td>
 </tr>
 <tr style='height:15.0pt'>
  <td width=293 valign=top style='width:219.9pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:15.0pt'>
  <p class=TableParagraph align=left style='margin-left:26.5pt;text-align:left;
  line-height:11.5pt;page-break-after:avoid'><span style='font-family:"Times New Roman",serif'>p-value<sup>c</sup></span></p>
  </td>
  <td width=294 colspan=3 valign=top style='width:220.5pt;border-top:none;
  border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:15.0pt'>
  <p class=TableParagraph style='line-height:11.5pt;page-break-after:avoid'><span
  style='font-family:"Times New Roman",serif'>0.0031</span></p>
  </td>
 </tr>
 <tr style='height:15.0pt'>
  <td width=293 valign=top style='width:219.9pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:15.0pt'>
  <p class=TableParagraph align=left style='margin-left:13.0pt;text-align:left;
  line-height:11.5pt;page-break-after:avoid'><b><span style='font-family:"Times New Roman",serif'>Estimated
  PFS (95% CI)</span></b><sup><span style='font-family:"Times New Roman",serif'>d</span></sup><b><span
  style='font-family:"Times New Roman",serif'> at:</span></b></p>
  </td>
  <td width=147 valign=top style='width:110.25pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:15.0pt'>
  <p class=TableParagraph style='line-height:11.5pt;page-break-after:avoid'><span
  style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=147 colspan=2 valign=top style='width:110.25pt;border-top:none;
  border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:15.0pt'>
  <p class=TableParagraph style='line-height:11.5pt;page-break-after:avoid'><span
  style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:29.75pt'>
  <td width=293 valign=top style='width:219.9pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:29.75pt'>
  <p class=TableParagraph align=left style='margin-left:26.5pt;text-align:left;
  line-height:11.5pt;page-break-after:avoid'><span style='font-family:"Times New Roman",serif'>6
  months</span></p>
  </td>
  <td width=147 valign=top style='width:110.25pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:29.75pt'>
  <p class=TableParagraph style='line-height:11.5pt;page-break-after:avoid'><span
  style='font-family:"Times New Roman",serif'>88.0% </span></p>
  <p class=TableParagraph style='line-height:11.5pt;page-break-after:avoid'><span
  style='font-family:"Times New Roman",serif'>(81.8%, 92.2%)</span></p>
  </td>
  <td width=147 colspan=2 valign=top style='width:110.25pt;border-top:none;
  border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:29.75pt'>
  <p class=TableParagraph style='line-height:11.5pt;page-break-after:avoid'><span
  style='font-family:"Times New Roman",serif'>68.4% </span></p>
  <p class=TableParagraph style='line-height:11.5pt;page-break-after:avoid'><span
  style='font-family:"Times New Roman",serif'>(60.3%, 75.2%)</span></p>
  </td>
 </tr>
 <tr style='height:26.6pt'>
  <td width=293 valign=top style='width:219.9pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:26.6pt'>
  <p class=TableParagraph align=left style='margin-left:26.5pt;text-align:left;
  line-height:11.5pt;page-break-after:avoid'><span style='font-family:"Times New Roman",serif'>12
  months</span></p>
  </td>
  <td width=147 valign=top style='width:110.25pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:26.6pt'>
  <p class=TableParagraph style='line-height:11.5pt;page-break-after:avoid'><span
  style='font-family:"Times New Roman",serif'>78.7% </span></p>
  <p class=TableParagraph style='line-height:11.5pt;page-break-after:avoid'><span
  style='font-family:"Times New Roman",serif'>(71.4%, 84.4%)</span></p>
  </td>
  <td width=147 colspan=2 valign=top style='width:110.25pt;border-top:none;
  border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:26.6pt'>
  <p class=TableParagraph style='line-height:11.5pt;page-break-after:avoid'><span
  style='font-family:"Times New Roman",serif'>60.3% </span></p>
  <p class=TableParagraph style='line-height:11.5pt;page-break-after:avoid'><span
  style='font-family:"Times New Roman",serif'>(51.9%, 67.6%)</span></p>
  </td>
 </tr>
 <tr style='height:27.05pt'>
  <td width=293 valign=top style='width:219.9pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:27.05pt'>
  <p class=TableParagraph align=left style='margin-left:26.5pt;text-align:left;
  line-height:11.5pt;page-break-after:avoid'><span style='font-family:"Times New Roman",serif'>24
  months</span></p>
  </td>
  <td width=147 valign=top style='width:110.25pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:27.05pt'>
  <p class=TableParagraph style='line-height:11.5pt;page-break-after:avoid'><span
  style='font-family:"Times New Roman",serif'>68.4% </span></p>
  <p class=TableParagraph style='line-height:11.5pt;page-break-after:avoid'><span
  style='font-family:"Times New Roman",serif'>(60.4%, 75.2%)</span></p>
  </td>
  <td width=147 colspan=2 valign=top style='width:110.25pt;border-top:none;
  border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:27.05pt'>
  <p class=TableParagraph style='line-height:11.5pt;page-break-after:avoid'><span
  style='font-family:"Times New Roman",serif'>53.9% </span></p>
  <p class=TableParagraph style='line-height:11.5pt;page-break-after:avoid'><span
  style='font-family:"Times New Roman",serif'>(45.5%, 61.5%)</span></p>
  </td>
 </tr>
 <tr style='height:27.05pt'>
  <td width=293 valign=top style='width:219.9pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:27.05pt'>
  <p class=TableParagraph align=left style='margin-left:26.5pt;text-align:left;
  line-height:11.5pt;page-break-after:avoid'><span style='font-family:"Times New Roman",serif'>36
  months</span></p>
  </td>
  <td width=147 valign=top style='width:110.25pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:27.05pt'>
  <p class=TableParagraph style='line-height:11.5pt;page-break-after:avoid'><span
  style='font-family:"Times New Roman",serif'>65.5% </span></p>
  <p class=TableParagraph style='line-height:11.5pt;page-break-after:avoid'><span
  style='font-family:"Times New Roman",serif'>(57.1%, 72.7%)</span></p>
  </td>
  <td width=147 colspan=2 valign=top style='width:110.25pt;border-top:none;
  border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:27.05pt'>
  <p class=TableParagraph style='line-height:11.5pt;page-break-after:avoid'><span
  style='font-family:"Times New Roman",serif'>50.2% </span></p>
  <p class=TableParagraph style='line-height:11.5pt;page-break-after:avoid'><span
  style='font-family:"Times New Roman",serif'>(41.6%, 58.1%)</span></p>
  </td>
 </tr>
 <tr style='height:15.1pt'>
  <td width=587 colspan=4 valign=bottom style='width:440.4pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:15.1pt'>
  <p class=TableParagraph align=left style='margin-top:0in;margin-right:38.55pt;
  margin-bottom:0in;margin-left:13.0pt;margin-bottom:.0001pt;text-align:left;
  line-height:11.5pt;page-break-after:avoid'><b><span style='font-family:"Times New Roman",serif'>OS</span></b><sup><span
  style='font-family:"Times New Roman",serif'>e</span></sup></p>
  </td>
 </tr>
 <tr style='height:15.1pt'>
  <td width=293 valign=top style='width:219.9pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:15.1pt'>
  <p class=TableParagraph align=left style='margin-left:.2in;text-align:left;
  text-indent:12.1pt;line-height:normal;page-break-after:avoid'><span
  style='font-family:"Times New Roman",serif'>Number of deaths (%)</span></p>
  </td>
  <td width=150 colspan=2 valign=top style='width:112.5pt;border-top:none;
  border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:15.1pt'>
  <p class=TableParagraph style='line-height:11.5pt;page-break-after:avoid'><span
  style='font-family:"Times New Roman",serif'>29 (18)</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;
  height:15.1pt'>
  <p class=TableParagraph style='line-height:11.5pt;page-break-after:avoid'><span
  style='font-family:"Times New Roman",serif'>44 (29)</span></p>
  </td>
 </tr>
 <tr style='height:15.1pt'>
  <td width=293 valign=top style='width:219.9pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:15.1pt'>
  <p class=TableParagraph align=left style='margin-left:.2in;text-align:left;
  text-indent:12.1pt;line-height:normal;page-break-after:avoid'><span
  style='font-family:"Times New Roman",serif'>Median OS, months (95% CI)</span></p>
  </td>
  <td width=150 colspan=2 valign=top style='width:112.5pt;border-top:none;
  border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:15.1pt'>
  <p class=TableParagraph style='margin-left:.25in;line-height:11.5pt;
  page-break-after:avoid'><span style='font-family:"Times New Roman",serif'>NE
  (NE, NE)</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;
  height:15.1pt'>
  <p class=TableParagraph style='line-height:11.5pt;page-break-after:avoid'><span
  style='font-family:"Times New Roman",serif'>NE (NE, NE)</span></p>
  </td>
 </tr>
 <tr style='height:17.6pt'>
  <td width=293 valign=top style='width:219.9pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:17.6pt'>
  <p class=TableParagraph align=left style='margin-left:.2in;text-align:left;
  text-indent:12.1pt;line-height:normal;page-break-after:avoid'><span
  style='font-family:"Times New Roman",serif'>Hazard ratio (95%&nbsp;CI)<sup>b</sup></span></p>
  </td>
  <td width=294 colspan=3 valign=top style='width:220.5pt;border-top:none;
  border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:17.6pt'>
  <p class=TableParagraph style='line-height:11.5pt;page-break-after:avoid'><span
  style='font-family:"Times New Roman",serif'>0.54 (0.34, 0.87)</span></p>
  </td>
 </tr>
 <tr style='height:15.1pt'>
  <td width=293 valign=top style='width:219.9pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:15.1pt'>
  <p class=TableParagraph align=left style='margin-left:.2in;text-align:left;
  text-indent:12.1pt;line-height:normal;page-break-after:avoid'><span
  style='font-family:"Times New Roman",serif'>p-value<sup>c, f</sup></span></p>
  </td>
  <td width=294 colspan=3 valign=top style='width:220.5pt;border-top:none;
  border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:15.1pt'>
  <p class=TableParagraph style='line-height:11.5pt;page-break-after:avoid'><span
  style='font-family:"Times New Roman",serif'>0.0096</span></p>
  </td>
 </tr>
 <tr style='height:15.1pt'>
  <td width=587 colspan=4 valign=bottom style='width:440.4pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:15.1pt'>
  <p class=TableParagraph align=left style='margin-left:13.0pt;text-align:left;
  line-height:11.5pt;page-break-after:avoid'><b><span style='font-family:"Times New Roman",serif'>CR
  Rate</span></b><sup><span style='font-family:"Times New Roman",serif'>g</span></sup></p>
  </td>
 </tr>
 <tr style='height:15.1pt'>
  <td width=293 valign=top style='width:219.9pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:15.1pt'>
  <p class=TableParagraph align=left style='margin-left:.2in;text-align:left;
  text-indent:12.1pt;line-height:normal;page-break-after:avoid'><span
  style='font-family:"Times New Roman",serif'>% (95% CI)</span></p>
  </td>
  <td width=150 colspan=2 valign=top style='width:112.5pt;border-top:none;
  border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:15.1pt'>
  <p class=TableParagraph style='line-height:11.5pt;page-break-after:avoid'><span
  style='font-family:"Times New Roman",serif'>71% (63.3%, 77.8%)</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;
  height:15.1pt'>
  <p class=TableParagraph style='line-height:11.5pt;page-break-after:avoid'><span
  style='font-family:"Times New Roman",serif'>53% (45.0%, 61.3%)</span></p>
  </td>
 </tr>
 <tr style='height:15.1pt'>
  <td width=293 valign=top style='width:219.9pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:15.1pt'>
  <p class=TableParagraph align=left style='margin-left:.2in;text-align:left;
  text-indent:12.1pt;line-height:normal;page-break-after:avoid'><span
  style='font-family:"Times New Roman",serif'>p-value<sup>f, h</sup></span></p>
  </td>
  <td width=294 colspan=3 valign=top style='width:220.5pt;border-top:none;
  border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:15.1pt'>
  <p class=TableParagraph style='line-height:11.5pt;page-break-after:avoid'><span
  style='font-family:"Times New Roman",serif'>0.0004</span></p>
  </td>
 </tr>
 <tr style='height:15.1pt'>
  <td width=587 colspan=4 valign=top style='width:440.4pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:15.1pt'>
  <p class=TableParagraph align=left style='margin-left:13.0pt;text-align:left;
  line-height:11.5pt;page-break-after:avoid'><b><span style='font-family:"Times New Roman",serif'>ORR</span></b><sup><span
  style='font-family:"Times New Roman",serif'>g</span></sup></p>
  </td>
 </tr>
 <tr style='height:15.1pt'>
  <td width=293 valign=top style='width:219.9pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:15.1pt'>
  <p class=TableParagraph align=left style='margin-left:.2in;text-align:left;
  text-indent:12.1pt;line-height:normal;page-break-after:avoid'><span
  style='font-family:"Times New Roman",serif'>% (95% CI)</span></p>
  </td>
  <td width=150 colspan=2 valign=top style='width:112.5pt;border-top:none;
  border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:15.1pt'>
  <p class=TableParagraph style='line-height:11.5pt;page-break-after:avoid'><span
  style='font-family:"Times New Roman",serif'>88% (81.6%, 92.3%)</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;
  height:15.1pt'>
  <p class=TableParagraph style='line-height:11.5pt;page-break-after:avoid'><span
  style='font-family:"Times New Roman",serif'>71% (62.9%, 77.8%)</span></p>
  </td>
 </tr>
 <tr style='height:15.1pt'>
  <td width=293 valign=top style='width:219.9pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:15.1pt'>
  <p class=TableParagraph align=left style='margin-left:.2in;text-align:left;
  text-indent:12.1pt;line-height:normal;page-break-after:avoid'><span
  style='font-family:"Times New Roman",serif'>p-value<sup>f, h</sup></span></p>
  </td>
  <td width=294 colspan=3 valign=top style='width:220.5pt;border-top:none;
  border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:15.1pt'>
  <p class=TableParagraph style='line-height:11.5pt;page-break-after:avoid'><span
  style='font-family:"Times New Roman",serif'>&lt;0.0001</span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=293 style='border:none'></td>
  <td width=147 style='border:none'></td>
  <td width=3 style='border:none'></td>
  <td width=144 style='border:none'></td>
 </tr>
</table>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:9.0pt'>CR=complete remission; IRF=Independent Review Facility;
NE: Not estimable; ORR=objective response rate; PFS=progression-free survival.</span></p>

<p class=TableFootnoteLetter style='margin-left:17.85pt;text-indent:-17.85pt;
page-break-after:avoid'><span style='color:black'>a<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>PFS per IRF is calculated using patients with centrally-confirmed
sALCL, with n=163 patients in A+CHP arm and n=151 in CHOP arm. OS, CR, and ORR
are calculated using patients with locally-diagnosed sALCL</p>

<p class=TableFootnoteLetter style='margin-left:17.85pt;text-indent:-17.85pt;
page-break-after:avoid'><span style='color:black'>b<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>Hazard ratio (A+CHP/CHOP) and 95% confidence intervals are based
on a stratified Cox&#8217;s proportional hazard regression model with
stratification factors (ALK-positive sALCL versus all others and International
Prognostic Index [IPI] score at baseline). Hazard ratio &lt;1 favours A+CHP
arm.</p>

<p class=TableFootnoteLetter style='margin-left:17.85pt;text-indent:-17.85pt;
page-break-after:avoid'><span style='color:black'>c<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>p-value is calculated using a stratified log-rank test.</p>

<p class=TableFootnoteLetter><span style='color:black'>d<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>PFS rate is estimated using Kaplan-Meier methods and 95% CI is
calculated using the complementary log-log</p>

<p class=TableFootnoteLetter style='margin-left:0in;text-indent:17.85pt'>transformation
method.</p>

<p class=TableFootnoteLetter style='margin-left:17.85pt;text-indent:-17.85pt;
page-break-after:avoid'><span style='color:black'>e<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>Median OS follow-up in the A+CHP arm was 38.5 months; in the CHOP
arm was 41.0&nbsp;months.</p>

<p class=TableFootnoteLetter style='margin-left:17.85pt;text-indent:-17.85pt;
page-break-after:avoid'><span style='color:black'>f<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>p-value is not adjusted for multiplicity. </p>

<p class=TableFootnoteLetter style='margin-left:17.85pt;text-indent:-17.85pt;
page-break-after:avoid'><span style='color:black'>g<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>Response per 2007 International Working Group Criteria at end of
treatment.</p>

<p class=TableFootnoteLetter style='margin-left:17.85pt;text-indent:-17.85pt;
page-break-after:avoid'><span style='color:black'>h<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>p-value is calculated using a stratified Cochran-Mantel-Haenszel
test.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=Paragraph style='margin-bottom:0in;page-break-after:avoid'><b><span
style='font-size:11.0pt'>Figure 5: </span></b><b><span style='font-size:11.0pt'>Progression-free
survival per IRF in the sALCL population (ADCETRIS&nbsp;+&nbsp;CHP vs. CHOP)</span></b></p>

<p class=Paragraph style='margin-bottom:0in;page-break-after:avoid'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Paragraph style='margin-bottom:0in'><span style='font-size:11.0pt'><img
border=0 width=605 height=416
src="Adcetris-ema-combined-h-2455-en-IB-SOB-C2500_files/image006.jpg"></span><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Paragraph style='margin-bottom:0in'><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Paragraph style='margin-bottom:0in;page-break-after:avoid'><b><span
style='font-size:11.0pt'>Figure 6: </span></b><b><span style='font-size:11.0pt'>Overall
survival in the sALCL population (ADCETRIS&nbsp;+&nbsp;CHP vs. CHOP)</span></b></p>

<p class=Paragraph style='margin-bottom:0in;page-break-after:avoid'><b><span
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><img border=0 width=604 height=340
src="Adcetris-ema-combined-h-2455-en-IB-SOB-C2500_files/image007.jpg"></p>

<p class=MsoCaption style='margin:0in;text-indent:0in;page-break-after:auto'><span
style='font-size:9.0pt;font-family:"Times New Roman",serif;font-weight:normal'>*p-value
for overall survival is not adjusted for multiplicity.</span></p>

<p class=Paragraph style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=Paragraph style='margin-bottom:0in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>Study SG035&#8209;0004</span></p>

<p class=Paragraph style='margin-bottom:0in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Paragraph style='margin-bottom:0in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>The efficacy and safety of </span><span
lang=EN-GB style='font-size:11.0pt'>ADCETRIS</span><span lang=EN-GB
style='font-size:11.0pt'> as a single agent was evaluated in an open-label,
single&#8209;arm, multicenter study in 58&nbsp;patients with relapsed or
refractory sALCL. See Table&nbsp;15 below for a summary of baseline patient and
disease characteristics. </span></p>

<p class=Paragraph style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=Paragraph style='margin-bottom:0in;page-break-after:avoid'><b><span
lang=EN-GB style='font-size:11.0pt'>Table 15: Summary of baseline patient and
disease characteristics in the phase&nbsp;2 relapsed or refractory sALCL study<br>
<br>
</span></b></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=600
 style='width:6.25in;border-collapse:collapse;border:none'>
 <tr style='height:23.65pt'>
  <td width=384 valign=top style='width:288.05pt;border:solid windowtext 1.0pt;
  border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:23.65pt'>
  <p class=MsoNormal style='margin-bottom:3.0pt;page-break-after:avoid'><b><span
  lang=EN-GB>Patient characteristics</span></b></p>
  </td>
  <td width=216 valign=top style='width:161.95pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:23.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>n&nbsp;=&nbsp;58</span></b></p>
  </td>
 </tr>
 <tr style='height:13.5pt'>
  <td width=384 valign=top style='width:288.05pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.5pt'>
  <p class=MsoNormal style='margin-left:3.1pt;text-indent:5.5pt;page-break-after:
  avoid'><span lang=EN-GB>Median age, years (range)</span></p>
  </td>
  <td width=216 valign=top style='width:161.95pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.5pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>52&nbsp;years (14&#8209;76)</span></p>
  </td>
 </tr>
 <tr style='height:13.5pt'>
  <td width=384 valign=top style='width:288.05pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.5pt'>
  <p class=MsoNormal style='text-indent:8.6pt;page-break-after:avoid'><span
  lang=EN-GB>Gender</span></p>
  </td>
  <td width=216 valign=top style='width:161.95pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.5pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>33M (57%)/25F (43%)</span></p>
  </td>
 </tr>
 <tr style='height:12.75pt'>
  <td width=384 valign=top style='width:288.05pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal style='text-indent:8.6pt;page-break-after:avoid'><span
  lang=EN-GB>ECOG status<sup>a</sup></span></p>
  </td>
  <td width=216 valign=top style='width:161.95pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:12.75pt'>
  <td width=384 valign=top style='width:288.05pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal style='margin-left:19.6pt;page-break-after:avoid'><span
  lang=EN-GB>0</span></p>
  </td>
  <td width=216 valign=top style='width:161.95pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>19 (33%)</span></p>
  </td>
 </tr>
 <tr style='height:5.65pt'>
  <td width=384 valign=top style='width:288.05pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.65pt'>
  <p class=MsoNormal style='margin-left:19.6pt;page-break-after:avoid'><span
  lang=EN-GB>1</span></p>
  </td>
  <td width=216 valign=top style='width:161.95pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>38 (66%)</span></p>
  </td>
 </tr>
 <tr style='height:5.65pt'>
  <td width=384 valign=top style='width:288.05pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.65pt'>
  <p class=MsoNormal style='margin-left:19.6pt;text-indent:-.15in;page-break-after:
  avoid'><span lang=EN-GB>Prior ASCT</span></p>
  </td>
  <td width=216 valign=top style='width:161.95pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>15 (26%)</span></p>
  </td>
 </tr>
 <tr style='height:6.4pt'>
  <td width=384 valign=top style='width:288.05pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.4pt'>
  <p class=MsoNormal style='margin-left:19.6pt;text-indent:-.15in;page-break-after:
  avoid'><span lang=EN-GB>Prior chemotherapy Regimens (range)</span></p>
  </td>
  <td width=216 valign=top style='width:161.95pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>2 (1&#8209;6)</span></p>
  </td>
 </tr>
 <tr style='height:6.4pt'>
  <td width=384 valign=top style='width:288.05pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.4pt'>
  <p class=MsoNormal style='margin-left:19.6pt;text-indent:-.15in;page-break-after:
  avoid'><span lang=EN-GB>Histologically confirmed CD30&#8209;expressing
  disease</span></p>
  </td>
  <td width=216 valign=top style='width:161.95pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>57 (98%)</span></p>
  </td>
 </tr>
 <tr style='height:6.35pt'>
  <td width=384 valign=top style='width:288.05pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.35pt'>
  <p class=MsoNormal style='margin-left:19.6pt;text-indent:-.15in;page-break-after:
  avoid'><span lang=EN-GB>Anaplastic lymphoma kinase (ALK)-negative disease</span></p>
  </td>
  <td width=216 valign=top style='width:161.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.35pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>42 (72%)</span></p>
  </td>
 </tr>
 <tr style='height:15.1pt'>
  <td width=384 valign=top style='width:288.05pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.1pt'>
  <p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:3.0pt;
  margin-left:19.45pt;text-align:justify;text-justify:inter-ideograph;
  text-indent:-19.45pt;page-break-after:avoid'><b><span lang=EN-GB>Disease
  characteristics</span></b></p>
  </td>
  <td width=216 valign=top style='width:161.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.1pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='height:8.0pt'>
  <td width=384 valign=top style='width:288.05pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:8.0pt'>
  <p class=MsoNormal style='margin-left:8.6pt;page-break-after:avoid'><span
  lang=EN-GB>Primary Refractory to frontline therapy<sup>b</sup></span></p>
  </td>
  <td width=216 valign=top style='width:161.95pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:8.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>36 (62%)</span></p>
  </td>
 </tr>
 <tr style='height:7.15pt'>
  <td width=384 valign=top style='width:288.05pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:7.15pt'>
  <p class=MsoNormal style='margin-left:8.6pt;page-break-after:avoid'><span
  lang=EN-GB>Refractory to most recent therapy</span></p>
  </td>
  <td width=216 valign=top style='width:161.95pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:7.15pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>29 (50%)</span></p>
  </td>
 </tr>
 <tr style='height:6.4pt'>
  <td width=384 valign=top style='width:288.05pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.4pt'>
  <p class=MsoNormal style='margin-left:8.6pt;page-break-after:avoid'><span
  lang=EN-GB>Relapsed to most recent therapy</span></p>
  </td>
  <td width=216 valign=top style='width:161.95pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>29 (50%)</span></p>
  </td>
 </tr>
 <tr style='height:6.4pt'>
  <td width=384 valign=top style='width:288.05pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.4pt'>
  <p class=MsoNormal style='margin-left:8.6pt;page-break-after:avoid'><span
  lang=EN-GB>Baseline B symptoms</span></p>
  </td>
  <td width=216 valign=top style='width:161.95pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>17 (29%)</span></p>
  </td>
 </tr>
 <tr style='height:6.35pt'>
  <td width=384 valign=top style='width:288.05pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.35pt'>
  <p class=MsoNormal style='margin-left:8.6pt;page-break-after:avoid'><span
  lang=EN-GB>Stage III at initial diagnosis</span></p>
  </td>
  <td width=216 valign=top style='width:161.95pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.35pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>8 (14%)</span></p>
  </td>
 </tr>
 <tr style='height:6.35pt'>
  <td width=384 valign=top style='width:288.05pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.35pt'>
  <p class=MsoNormal style='margin-left:8.6pt;page-break-after:avoid'><span
  lang=EN-GB>Stage IV at initial diagnosis</span></p>
  </td>
  <td width=216 valign=top style='width:161.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.35pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>21 (36%)</span></p>
  </td>
 </tr>
</table>

</div>

<p class=Paragraph style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.25in;text-indent:-.25in;page-break-after:avoid'><span lang=EN-GB
style='font-size:8.0pt'>a.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:9.0pt'>One&nbsp;patient had a
baseline ECOG status of 2, which was prohibited by protocol and is captured as
Inclusion Criteria Not Met.</span></p>

<p class=Paragraph style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.25in;text-indent:-.25in;page-break-after:avoid'><span lang=EN-GB
style='font-size:8.0pt'>b.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:9.0pt'>Primary refractory sALCL
is defined as a failure to achieve a complete remission to, or progressed
within 3&nbsp;months of completing frontline therapy.</span></p>

<p class=Paragraph style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=Paragraph style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>The median time from initial sALCL diagnosis to first dose with ADCETRIS
was 16.8&nbsp;months. </span></p>

<p class=Paragraph style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=Paragraph style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Ten (10) patients (17%) received 16&nbsp;cycles of </span><span
lang=EN-GB style='font-size:11.0pt'>ADCETRIS</span><span lang=EN-GB
style='font-size:11.0pt'>; the median number of cycles received was 7&nbsp;(range,
1 to 16). </span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Response to
treatment with </span><span lang=EN-GB>ADCETRIS</span><span lang=EN-GB> was
assessed by Independent Review Facility (IRF) using the Revised Response
Criteria for Malignant Lymphoma (Cheson, 2007). Treatment response was assessed
by spiral CT of chest, neck, abdomen and pelvis; PET scans and clinical data.
Response assessments were performed at cycles&nbsp;2, 4, 7, 10, 13 and 16 with
PET at cycles 4 and 7. </span></p>

<p class=Paragraph style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The ORR per IRF assessment was 86% (50 of
58&nbsp;patients in the ITT set). CR was 59% (34 of 58&nbsp;patients in the ITT
set) and tumour reduction (of any degree) was achieved in 97% of patients. The
estimated overall survival at 5&nbsp;years was 60% (95% CI [47%,73%]). The
median observation time (time to death or last contact) from first dose was
71.4&nbsp;months. The investigator assessments were generally consistent with
the independent review of the scans. Of the patients treated, 9&nbsp;responding
patients went on to receive an allogeneic stem cell transplant (SCT) and 9&nbsp;responding
patients went on to autologous SCT. For further efficacy results, see Table&nbsp;16
and Figure&nbsp;7.</span></p>

<p class=Paragraph style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Table 16:
Efficacy results in relapsed or refractory sALCL patients treated with
1.8&nbsp;mg/kg of </span></b><b><span lang=EN-GB>ADCETRIS</span><span
lang=EN-GB> every 3&nbsp;weeks<br>
<br>
</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=600
 style='margin-left:5.4pt;border-collapse:collapse;border:none'>
 <tr style='height:15.1pt'>
  <td width=252 nowrap valign=top style='width:189.0pt;border:solid windowtext 1.0pt;
  border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.1pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Best
  clinical response</span></b><b><sup><span lang=EN-GB> </span></sup></b><b><span
  lang=EN-GB>(n&nbsp;=&nbsp;58</span></b><sup><span lang=EN-GB> </span></sup><b><span
  lang=EN-GB>)</span></b></p>
  </td>
  <td width=186 nowrap valign=top style='width:139.5pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.1pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>IRF n (%)</span></b></p>
  </td>
  <td width=162 nowrap valign=top style='width:121.5pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>95% CI</span></b></p>
  </td>
 </tr>
 <tr style='height:12.75pt'>
  <td width=252 nowrap valign=top style='width:189.0pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;
  border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;&nbsp;&nbsp;
  Objective response rate (CR + PR)</span></p>
  </td>
  <td width=186 nowrap valign=top style='width:139.5pt;border-top:none;
  border-left:none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>50 (86)</span></p>
  </td>
  <td width=162 nowrap valign=top style='width:121.5pt;border-top:none;
  border-left:none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>74.6, 93.9</span></p>
  </td>
 </tr>
 <tr style='height:12.75pt'>
  <td width=252 nowrap valign=top style='width:189.0pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;
  border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  Complete remission (CR)</span></p>
  </td>
  <td width=186 nowrap valign=top style='width:139.5pt;border-top:none;
  border-left:none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>34 (59)</span></p>
  </td>
  <td width=162 nowrap valign=top style='width:121.5pt;border-top:none;
  border-left:none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>44.9, 71.4</span></p>
  </td>
 </tr>
 <tr style='height:12.75pt'>
  <td width=252 nowrap valign=top style='width:189.0pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;
  border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  Partial remission (PR)</span></p>
  </td>
  <td width=186 nowrap valign=top style='width:139.5pt;border-top:none;
  border-left:none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>16 (28)</span></p>
  </td>
  <td width=162 nowrap valign=top style='width:121.5pt;border-top:none;
  border-left:none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>NA</span></p>
  </td>
 </tr>
 <tr style='height:12.75pt'>
  <td width=252 nowrap valign=top style='width:189.0pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;
  border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;&nbsp;&nbsp;
  Disease control rate (CR + PR + SD)</span></p>
  </td>
  <td width=186 nowrap valign=top style='width:139.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>52 (90)</span></p>
  </td>
  <td width=162 nowrap valign=top style='width:121.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>78.8, 96.1</span></p>
  </td>
 </tr>
 <tr style='height:15.1pt'>
  <td width=252 nowrap valign=top style='width:189.0pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;
  border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.1pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Duration
  of response</span></b><sup><span lang=EN-GB> </span></sup></p>
  </td>
  <td width=186 valign=top style='width:139.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.1pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Median per IRF </span></b></p>
  </td>
  <td width=162 nowrap valign=top style='width:121.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.1pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>95% CI</span></b></p>
  </td>
 </tr>
 <tr style='height:12.75pt'>
  <td width=252 nowrap valign=top style='width:189.0pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;
  border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=PT-BR>&nbsp;&nbsp;&nbsp;
  Objective response (CR + PR)<sup>a</sup></span></p>
  </td>
  <td width=186 nowrap valign=top style='width:139.5pt;border-top:none;
  border-left:none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>13.2 </span></p>
  </td>
  <td width=162 nowrap valign=top style='width:121.5pt;border-top:none;
  border-left:none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>5.7, 26.3 </span></p>
  </td>
 </tr>
 <tr style='height:12.75pt'>
  <td width=252 nowrap valign=top style='width:189.0pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;
  border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;&nbsp;&nbsp;
  Complete remission (CR)</span></p>
  </td>
  <td width=186 nowrap valign=top style='width:139.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>26.3</span></p>
  </td>
  <td width=162 nowrap valign=top style='width:121.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>13.2, NE<sup>b</sup></span></p>
  </td>
 </tr>
 <tr style='height:14.75pt'>
  <td width=252 valign=top style='width:189.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:14.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Progression
  Free Survival</span></b></p>
  </td>
  <td width=186 valign=top style='width:139.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.75pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Median per IRF</span></b></p>
  </td>
  <td width=162 valign=top style='width:121.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.75pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>95% CI</span></b></p>
  </td>
 </tr>
 <tr style='height:14.75pt'>
  <td width=252 valign=top style='width:189.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:14.75pt'>
  <p class=MsoNormal style='text-indent:9.05pt;page-break-after:avoid'><span
  lang=EN-GB>Median</span></p>
  </td>
  <td width=186 valign=top style='width:139.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.75pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>14.6</span></p>
  </td>
  <td width=162 valign=top style='width:121.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.75pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>6.9, 20.6</span></p>
  </td>
 </tr>
 <tr style='height:14.75pt'>
  <td width=252 valign=top style='width:189.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:14.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Overall
  survival</span></b><sup><span lang=EN-GB> </span></sup></p>
  </td>
  <td width=186 valign=top style='width:139.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.75pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Median</span></b></p>
  </td>
  <td width=162 valign=top style='width:121.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.75pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>95% CI</span></b></p>
  </td>
 </tr>
 <tr style='height:17.45pt'>
  <td width=252 valign=top style='width:189.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:17.45pt'>
  <p class=MsoNormal style='text-indent:9.0pt;page-break-after:avoid'><span
  lang=EN-GB>Median</span></p>
  </td>
  <td width=186 valign=top style='width:139.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.45pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Not reached<sup> </sup></span></p>
  </td>
  <td width=162 valign=top style='width:121.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.45pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>21.3, NE<sup>b</sup></span></p>
  </td>
 </tr>
</table>

<p class=Paragraph style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.25in;text-indent:-.25in;page-break-after:avoid'><sup><span
lang=EN-GB style='font-size:11.0pt'>a.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></sup><span lang=EN-GB style='font-size:9.0pt'>The range of DOR
was 0.1&nbsp;months to 39.1+&nbsp;months and the median follow&#8209;up time
from first dose for patients who achieved objective response (OR) per IRF was
15.5&nbsp;months. </span></p>

<p class=Paragraph style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.25in;text-indent:-.25in;page-break-after:avoid'><sup><span
lang=EN-GB style='font-size:11.0pt'>b.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></sup><span lang=EN-GB style='font-size:9.0pt'>Not estimable.</span></p>

<p class=Paragraph style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt;background:lime'>&nbsp;</span></p>

<p class=Paragraph style='margin-bottom:0in;page-break-after:avoid'><b><span
style='font-size:11.0pt'>Figure 7: Kaplan-Meier Plot of OS</span></b></p>

<p class=Paragraph style='margin-bottom:0in;page-break-after:avoid'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Paragraph style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'><img border=0 width=605 height=302
src="Adcetris-ema-combined-h-2455-en-IB-SOB-C2500_files/image008.gif"></span></p>

<p class=Paragraph style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=Paragraph style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>An exploratory intra-patient analysis showed that approximately 69% of
the sALCL patients treated with ADCETRIS as part of the SG035&#8209;0004
clinical study experienced an improvement in clinical benefit as measured by
longer progression free survival (PFS) compared with their most recent prior
line of therapy.</span></p>

<p class=Paragraph style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt;color:black'>&nbsp;</span></p>

<p class=Paragraph style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt;color:black'>Of the 17&nbsp;patients (29%) who had B symptoms at
baseline, 14&nbsp;patients (82%) experienced resolution of all B symptoms in a
median time from initiation of </span><span lang=EN-GB style='font-size:11.0pt;
color:black'>ADCETRIS</span><span lang=EN-GB style='font-size:11.0pt;
color:black'> of 0.7&nbsp;months.</span></p>

<p class=Paragraph style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Study SGN35&#8209;006
(Retreatment study)</span></p>

<p class=Paragraph style='margin-bottom:0in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:windowtext'>The efficacy of
retreatment in patients who had previously responded (CR or PR) to treatment
with ADCETRIS was evaluated in a phase 2, open&#8209;label, multicenter trial.
Seven patients with relapsed sALCL received a starting dose of 1.8&nbsp;mg/kg
and one patient received a starting dose of 1.2&nbsp;mg/kg of ADCETRIS
administered intravenously over 30&nbsp;minutes every 3&nbsp;weeks. The median
number of cycles was 8.5 (range, 2 to 30&nbsp;cycles).</span><span lang=EN-GB
style='color:windowtext'> </span><span lang=EN-GB style='color:windowtext'>Of
the 8 sALCL patients, 3&nbsp;were retreated twice for a total of
11&nbsp;retreatment experiences. Retreatment with ADCETRIS resulted in
6&nbsp;CRs (55%) and 4&nbsp;PRs (36%), for an ORR of 91%. </span><span
lang=EN-GB style='color:windowtext'>The median duration of response was 8.8 and
12.3&nbsp;months in patients who achieved OR (CR+PR) and CR, respectively.</span></p>

<p class=Paragraph style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Cutaneous
T&#8209;cell lymphoma</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='letter-spacing:-.1pt'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Study C25001
</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoBodyText><span lang=EN-GB style='font-size:11.0pt'>The efficacy and
safety of ADCETRIS as a single agent was evaluated in a pivotal phase&nbsp;3,
open-label, randomised, multicentre study in 128&nbsp;patients with
histologically confirmed CD30+ CTCL. </span><span style='font-size:11.0pt'>CD30
positivity was defined as&nbsp;&#8805;10% target lymphoid cells demonstrating
membrane, cytoplasmic, and/or Golgi staining pattern based on an
immunohistochemistry assay (Ventana anti&#8209;CD30 [Ber&#8209;H2]). </span><span
lang=EN-GB style='font-size:11.0pt'>Patients with a diagnosis of mycosis
fungoides [MF] or primary cutaneous anaplastic large cell lymphoma [pcALCL]
were considered eligible for the study. Patients were stratified by these
disease types and randomised 1:1 to receive either ADCETRIS or the
physician&#8217;s choice of either methotrexate or bexarotene. Patients with
pcALCL received either prior radiation therapy or at least 1 prior systemic
therapy and patients with MF received at least 1 prior systemic therapy.
Patients with a concurrent diagnosis of systemic ALCL, Sezary syndrome and
other non&#8209;Hodgkin lymphoma (except for lymphomatoid papulosis [LyP]) were
excluded from this study. Patients were treated with 1.8&nbsp;mg/kg of ADCETRIS
intravenously over 30&nbsp;minutes every 3&nbsp;weeks for up to 16&nbsp;cycles
or physician&#8217;s choice for up to 48&nbsp;weeks. The median number of
cycles was approximately 12&nbsp;cycles in the ADCETRIS arm. In the
physician&#8217;s choice arm, the median duration of treatment (number of
cycles) for patients receiving bexarotene was approximately 16&nbsp;weeks (5.5&nbsp;cycles)
and 11&nbsp;weeks (3&nbsp;cycles) for patients receiving methotrexate. Table&nbsp;17
provides a summary of the baseline patient and disease characteristics.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Table 17:
Summary of baseline patient and disease characteristics in the phase 3 CTCL
Study (ITT Population)<br>
<br>
</span></b></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=607
 style='width:455.6pt;border-collapse:collapse;border:none'>
 <tr style='height:15.1pt'>
  <td width=238 colspan=2 valign=top style='width:178.15pt;border:solid windowtext 1.0pt;
  border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.1pt'>
  <p class=MsoNormal style='margin-bottom:3.0pt;page-break-after:avoid'><b><span
  lang=EN-GB>Patient characteristics</span></b></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>ADCETRIS</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>n&nbsp;=&nbsp;64</span></b></p>
  </td>
  <td width=162 valign=top style='width:121.55pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Physician&#8217;s Choice (Methotrexate or Bexarotene)</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>n&nbsp;=&nbsp;64</span></b></p>
  </td>
 </tr>
 <tr style='height:13.5pt'>
  <td width=238 colspan=2 valign=top style='width:178.15pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;
  border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'>
  <p class=MsoNormal style='margin-left:3.1pt;text-indent:5.5pt;page-break-after:
  avoid'><span lang=EN-GB>Median age (range)</span></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.5pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>62&nbsp;years (22&#8209;83)</span></p>
  </td>
  <td width=162 valign=top style='width:121.55pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.5pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>58.5&nbsp;years (22&#8209;83)</span></p>
  </td>
 </tr>
 <tr style='height:13.5pt'>
  <td width=238 colspan=2 valign=top style='width:178.15pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;
  border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'>
  <p class=MsoNormal style='text-indent:8.6pt;page-break-after:avoid'><span
  lang=EN-GB>Patients &#8805;&nbsp;65 years old n (%)</span></p>
  <p class=MsoNormal style='text-indent:8.6pt;page-break-after:avoid'><span
  lang=EN-GB>Gender n (%)</span></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.5pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>28 (44%)</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>33M (52%)/31F (48%)</span></p>
  </td>
  <td width=162 valign=top style='width:121.55pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.5pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>24 (38%)</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>37M (58%)/27F (42%)</span></p>
  </td>
 </tr>
 <tr style='height:12.75pt'>
  <td width=238 colspan=2 valign=top style='width:178.15pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;
  border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal style='text-indent:8.6pt;page-break-after:avoid'><span
  lang=EN-GB>ECOG status n (%)</span></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=162 valign=top style='width:121.55pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:12.75pt'>
  <td width=238 colspan=2 valign=top style='width:178.15pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;
  border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal style='margin-left:19.6pt;page-break-after:avoid'><span
  lang=EN-GB>0</span></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>43 (67)</span></p>
  </td>
  <td width=162 valign=top style='width:121.55pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>46 (72)</span></p>
  </td>
 </tr>
 <tr style='height:5.65pt'>
  <td width=238 colspan=2 valign=top style='width:178.15pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;
  border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:5.65pt'>
  <p class=MsoNormal style='margin-left:19.6pt;page-break-after:avoid'><span
  lang=EN-GB>1</span></p>
  <p class=MsoNormal style='margin-left:19.6pt;page-break-after:avoid'><span
  lang=EN-GB>2</span></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>18 (28)</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>3 (5)</span></p>
  </td>
  <td width=162 valign=top style='width:121.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>16 (25)</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>2 (3)</span></p>
  </td>
 </tr>
 <tr style='height:15.1pt'>
  <td width=238 colspan=2 valign=top style='width:178.15pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;
  border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.1pt'>
  <p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:3.0pt;
  margin-left:19.45pt;text-align:justify;text-justify:inter-ideograph;
  text-indent:-19.45pt;page-break-after:avoid'><b><span lang=EN-GB>Disease
  characteristics</span></b></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.1pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=162 valign=top style='width:121.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.1pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='height:8.0pt'>
  <td width=238 colspan=2 valign=top style='width:178.15pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;
  border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:8.0pt'>
  <p class=MsoNormal style='margin-left:8.6pt;page-break-after:avoid'><span
  lang=EN-GB>Median number of prior therapies (range)</span></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:8.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>4 (0&#8209;13)</span></p>
  </td>
  <td width=162 valign=top style='width:121.55pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:8.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>3.5 (1&#8209;15)</span></p>
  </td>
 </tr>
 <tr style='height:7.15pt'>
  <td width=238 colspan=2 valign=top style='width:178.15pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;
  border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:7.15pt'>
  <p class=MsoNormal style='margin-left:8.6pt;page-break-after:avoid'><span
  lang=EN-GB>Median number of skin-directed therapies (range)</span></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:7.15pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>1 (0&#8209;6)</span></p>
  </td>
  <td width=162 valign=top style='width:121.55pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:7.15pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>1 (0&#8209;9)</span></p>
  </td>
 </tr>
 <tr style='height:6.4pt'>
  <td width=238 colspan=2 valign=top style='width:178.15pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;
  border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.4pt'>
  <p class=MsoNormal style='margin-left:8.6pt;page-break-after:avoid'><span
  lang=EN-GB>Median number of systemic therapies (range)</span></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>2 (0&#8209;11)</span></p>
  </td>
  <td width=162 valign=top style='width:121.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>2 (1&#8209;8)</span></p>
  </td>
 </tr>
 <tr style='height:6.4pt'>
  <td width=235 valign=top style='width:176.5pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  none;padding:0in 5.4pt 0in 5.4pt;height:6.4pt'>
  <p class=MsoNormal style='margin-left:8.6pt;page-break-after:avoid'><span
  lang=EN-GB>MF, n (%)</span></p>
  </td>
  <td width=210 colspan=2 valign=top style='width:157.55pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.4pt'>
  <p class=MsoNormal align=center style='margin-left:-.85pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB>48 (75)</span></p>
  </td>
  <td width=162 valign=top style='width:121.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.4pt'>
  <p class=MsoNormal align=center style='margin-left:-.85pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB>49 (77)</span></p>
  </td>
 </tr>
 <tr style='height:6.4pt'>
  <td width=238 colspan=2 valign=top style='width:178.15pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;
  border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.4pt'>
  <p class=MsoNormal style='margin-left:19.6pt;page-break-after:avoid'><span
  lang=EN-GB>Early (IA&#8209;IIA)</span></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>15 (31)</span></p>
  </td>
  <td width=162 valign=top style='width:121.55pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>18 (37)</span></p>
  </td>
 </tr>
 <tr style='height:6.4pt'>
  <td width=238 colspan=2 valign=top style='width:178.15pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;
  border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.4pt'>
  <p class=MsoNormal style='margin-left:19.6pt;page-break-after:avoid'><span
  lang=EN-GB>Advanced (IIB&#8209;IVB<sup>a</sup>)</span></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>32 (67)</span></p>
  </td>
  <td width=162 valign=top style='width:121.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>30 (61)</span></p>
  </td>
 </tr>
 <tr style='height:6.4pt'>
  <td width=235 valign=top style='width:176.5pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  none;padding:0in 5.4pt 0in 5.4pt;height:6.4pt'>
  <p class=MsoNormal style='margin-left:8.6pt;page-break-after:avoid'><span
  lang=EN-GB>pcALCL, n (%)</span></p>
  </td>
  <td width=210 colspan=2 valign=top style='width:157.55pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.4pt'>
  <p class=MsoNormal align=center style='margin-left:-.85pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB>16 (25)</span></p>
  </td>
  <td width=162 valign=top style='width:121.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.4pt'>
  <p class=MsoNormal align=center style='margin-left:-.85pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB>15 (23)</span></p>
  </td>
 </tr>
 <tr style='height:6.4pt'>
  <td width=238 colspan=2 valign=top style='width:178.15pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;
  border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.4pt'>
  <p class=MsoNormal style='margin-left:19.6pt;page-break-after:avoid'><span
  lang=EN-GB>Skin only </span></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>9 (56)</span></p>
  </td>
  <td width=162 valign=top style='width:121.55pt;border-top:none;border-left:
  none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>11 (73)</span></p>
  </td>
 </tr>
 <tr style='height:6.4pt'>
  <td width=238 colspan=2 valign=top style='width:178.15pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;
  border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.4pt'>
  <p class=MsoNormal style='margin-left:19.6pt;page-break-after:avoid'><span
  lang=EN-GB>Extracutaneous disease</span></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>7 (44)</span></p>
  </td>
  <td width=162 valign=top style='width:121.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>4 (27)</span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=235 style='border:none'></td>
  <td width=2 style='border:none'></td>
  <td width=208 style='border:none'></td>
  <td width=162 style='border:none'></td>
 </tr>
</table>

</div>

<p class=MsoNormal><sup><span lang=EN-GB>a</span></sup><span lang=EN-GB> </span><span
lang=EN-GB style='font-size:9.0pt'>One patient in each arm had incomplete
staging data and are not included in the table.</span></p>

<p class=MsoNormal><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=MsoNormal><span lang=EN-GB>The most common prior skin directed
therapies in the ITT population were radiotherapy (64%), phototherapy (48%) and
topical steroids (17%). The most common prior systemic therapies in the ITT
population were chemotherapy (71%), immunotherapy (43%) and bexarotene (38%).</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>The primary
endpoint was objective response rate that lasts at least 4 months (ORR4)
(duration from first response to last response &#8805;&nbsp;4 months), as
determined by an independent review of the Global Response Score (GRS)
consisting of skin evaluations (modified severity weighted assessment tool
[mSWAT] as assessed per investigator), nodal and visceral radiographic
assessment, and detection of circulating S&eacute;zary cells (Olsen 2011).
Table&nbsp;18 includes the results for ORR4 and other key secondary endpoints.</span></p>

<p class=MsoNormal><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Table 18:
Efficacy results in CTCL patients treated with 1.8&nbsp;mg/kg of ADCETRIS every
3&nbsp;weeks (ITT population)<br>
<br>
</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=225 valign=top style='width:168.45pt;border:solid windowtext 1.0pt;
  border-right:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>ADCETRIS&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (n&nbsp;=&nbsp;64)</span></b></p>
  </td>
  <td width=117 valign=top style='width:87.7pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=155 colspan=2 valign=top style='width:116.1pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Physician&#8217;s Choice (Methotrexate or
  Bexarotene) </span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>n&nbsp;=&nbsp;64</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=5 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Objective
  Response Rate lasting at least 4 months (ORR4) per IRF</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=225 valign=top style='width:168.45pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>n (%)</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Percent
  Difference (95% CI)</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>36 (56.3)</span></p>
  </td>
  <td width=132 colspan=2 valign=top style='width:99.25pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>43.8 (29.1, 58.4)</span></p>
  </td>
  <td width=139 valign=top style='width:104.55pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>8 (12.5)</span></p>
  </td>
 </tr>
 <tr>
  <td width=225 valign=top style='width:168.45pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>p-value</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=132 colspan=2 valign=top style='width:99.25pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&lt;0.001</span></p>
  </td>
  <td width=139 valign=top style='width:104.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=5 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=IT>Complete
  Response (CR) per IRF</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=225 valign=top style='width:168.45pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>n (%)</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Percent
  Difference (95% CI)</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>10 (15.6)</span></p>
  </td>
  <td width=117 valign=top style='width:87.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>14.1 (-4.0, 31.5)</span></p>
  </td>
  <td width=155 colspan=2 valign=top style='width:116.1pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>1 (1.6)</span></p>
  </td>
 </tr>
 <tr style='height:4.0pt'>
  <td width=225 valign=top style='width:168.45pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  none;padding:0in 5.4pt 0in 5.4pt;height:4.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Adjusted
  p-value<sup>a</sup></span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=117 valign=top style='width:87.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.0046</span></p>
  </td>
  <td width=155 colspan=2 valign=top style='width:116.1pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:4.0pt'>
  <td width=619 colspan=5 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:4.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Progression
  Free Survival (PFS) per IRF</span></b></p>
  </td>
 </tr>
 <tr style='height:4.0pt'>
  <td width=225 valign=top style='width:168.45pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:4.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Median
  (months)</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>16.7</span></p>
  </td>
  <td width=117 valign=top style='width:87.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=155 colspan=2 valign=top style='width:116.1pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>3.5</span></p>
  </td>
 </tr>
 <tr style='height:4.0pt'>
  <td width=225 valign=top style='width:168.45pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:4.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Hazard
  Ratio</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=117 valign=top style='width:87.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.270</span></p>
  </td>
  <td width=155 colspan=2 valign=top style='width:116.1pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:4.0pt'>
  <td width=225 valign=top style='width:168.45pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:4.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>95% CI</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=117 valign=top style='width:87.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(0.17, 0.43)</span></p>
  </td>
  <td width=155 colspan=2 valign=top style='width:116.1pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:4.0pt'>
  <td width=225 valign=top style='width:168.45pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  none;padding:0in 5.4pt 0in 5.4pt;height:4.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Adjusted
  p-value<sup>a</sup></span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=117 valign=top style='width:87.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&lt;0.001</span></p>
  </td>
  <td width=155 colspan=2 valign=top style='width:116.1pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=225 style='border:none'></td>
  <td width=123 style='border:none'></td>
  <td width=117 style='border:none'></td>
  <td width=15 style='border:none'></td>
  <td width=139 style='border:none'></td>
 </tr>
</table>

<p class=MsoNormal style='page-break-after:avoid'><sup><span lang=EN-GB>a</span></sup><span
lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp; Calculated from a weighted
Holm&#8217;s procedure.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Pre-specified
subgroup analyses of ORR4 per IRF were performed by patients&#8217; CTCL
subtype, physicians&#8217; choice of treatment, baseline ECOG status, age,
gender, and geographic region. The analyses showed a consistent trend towards
benefit for patients who received ADCETRIS compared with patients who received
physician&#8217;s choice. ORR4 was 50% and 75% in the ADCETRIS arm versus 10.2%
and 20% in the physician&#8217;s choice arm for MF and pcALCL, respectively.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>No meaningful differences in quality of
life (assessed by the EuroQol five dimensions questionnaire [EQ-5D] and
Functional Assessment of Cancer Therapy-General [FACT-G]) were observed between
the treatment arms.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The efficacy and safety of ADCETRIS were
evaluated in two additional open-label studies in 108&nbsp;patients with
relapsed CD30+ CTCL (including MF and pcALCL as well as SS, LyP and mixed CTCL
histology), <span style='background:white'>regardless of CD30 expression level.
Patients</span> were treated with ADCETRIS 1.8&nbsp;mg/kg intravenously over 30&nbsp;minutes
every 3&nbsp;weeks for up to 16&nbsp;cycles. The safety and efficacy results in
these studies were consistent with results in Study C25001. Overall response
rates for MF were 54&#8209;66%; pcALCL, 67%; SS, 50%; LyP, 92%; and mixed CTCL
histology, 82&#8209;85%.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=Paragraph style='margin-bottom:0in;page-break-after:avoid'><i><span
lang=EN-GB style='font-size:11.0pt'>Paediatric population</span></i></p>

<p class=Paragraph style='margin-bottom:0in;page-break-after:avoid'><i><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB
style='color:windowtext'>The safety, pharmacokinetics and anti-tumour activity
of ADCETRIS in 36&nbsp;paediatric patients (7&#8209;17&nbsp;years of age) with
r/r HL and sALCL (children aged 7&#8209;11 years, n&nbsp;=&nbsp;12 and
adolescents aged 12&nbsp;to 17&nbsp;years, n&nbsp;=&nbsp;24) were evaluated in
a phase 1/2 open-label, single-agent, multicentre dose-escalation study
(C25002). Phase&nbsp;1 of the study assessed the safety profile (see
section&nbsp;4.8), determined the paediatric maximum tolerated dose (MTD)
and/or recommended phase&nbsp;2 dose (RP2D), and assessed the pharmacokinetics
of ADCETRIS (see section&nbsp;5.2). Phase&nbsp;1 included&nbsp;3 r/r HL
patients treated at 1.4&nbsp;mg/kg and 9&nbsp;patients (7 r/r HL and
2&nbsp;sALCL) treated at 1.8&nbsp;mg/kg. The MTD was not reached. The RP2D was
determined to be 1.8&nbsp;mg/kg. Across the study, a total of 16&nbsp;patients
with r/r HL and 17&nbsp;patients with r/r sALCL, of whom 10&nbsp;were in first
relapse, were treated with 1.8&nbsp;mg/kg of ADCETRIS. The best overall
response rate (ORR) per independent review facility (IRF) was analysed across
both study phases at the RP2D. Of these 33&nbsp;patients who received the RP2D,
32&nbsp;were evaluable for response. The ORR was 47% in response-evaluable
patients with r/r HL, 53% in patients with r/r sALCL and 60% in sALCL patients
in first relapse. Eight HL patients and 9&nbsp;sALCL patients went on to
receive SCT following treatment with ADCETRIS. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>The European
Medicines Agency has deferred the obligation to submit the results of studies
with </span><span lang=EN-GB>ADCETRIS</span><span lang=EN-GB> in one or more
subsets of the paediatric population in the treatment of Hodgkin lymphoma and
treatment of anaplastic large cell lymphoma (see section&nbsp;4.2 for
information on paediatric use).</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>This medicinal
product has been authorised under a so-called &#8216;conditional
approval&#8217; scheme. This means that further evidence on this medicinal
product is awaited.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>The European
Medicines Agency will review new information on this medicinal product at least
every year and this SmPC will be updated as necessary.</span></p>

<p class=Paragraph style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<h3><span lang=EN-GB>5.2&nbsp;&nbsp;&nbsp;&nbsp; Pharmacokinetic properties</span></h3>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Monotherapy</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>The
pharmacokinetics of </span><span lang=EN-GB>brentuximab vedotin</span><span
lang=EN-GB> were evaluated in phase 1 studies and in a population
pharmacokinetic analysis of data from 314&nbsp;patients. In all clinical
trials, brentuximab vedotin was administered as an intravenous infusion. </span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Paragraph style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Maximum concentrations of brentuximab vedotin ADC were typically
observed at the end of infusion or the sampling timepoint closest to the end of
infusion. A multiexponential decline in ADC serum concentrations was observed
with a terminal half-life of approximately 4&nbsp;to&nbsp;6&nbsp;days.
Exposures were approximately dose proportional. Minimal to no accumulation of
ADC was observed with multiple doses at the every 3&#8209;week schedule,
consistent with the terminal half-life estimate. Typical C<sub>max</sub> and
AUC of ADC after a single 1.8&nbsp;mg/kg in a phase&nbsp;1 study was
approximately </span><span lang=EN-GB style='font-size:11.0pt'>31.98&nbsp;&#956;g/&nbsp;mL
and 79.41&nbsp;&#956;g/&nbsp;mL x day respectively.</span></p>

<p class=Paragraph style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=Paragraph style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>MMAE is the major metabolite of brentuximab vedotin. Median C<sub>max</sub>,
AUC and T<sub>max</sub> of MMAE after a single 1.8&nbsp;mg/kg of the ADC in a
phase 1 study was approximately 4.97&nbsp;ng/&nbsp;mL, 37.03&nbsp;ng/&nbsp;mL x
day and 2.09&nbsp;days respectively. MMAE exposures decreased after multiple
doses of brentuximab vedotin with approximately 50% to 80% of the exposure of
the first dose being observed at subsequent doses. MMAE is further metabolised
mainly to an equally potent metabolite; however, its exposure is an order of
magnitude lower than that of MMAE. Thus, it is not likely to have any
substantial contribution to the systemic effects of MMAE.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In the first cycle, higher MMAE exposure
was associated with an absolute decrease in neutrophil count.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Combination
therapy</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>The pharmacokinetics of ADCETRIS in
combination with AVD were evaluated in a single phase&nbsp;3 study in 661&nbsp;patients.
Population pharmacokinetic analysis indicated that the pharmacokinetics of
ADCETRIS in combination with AVD were consistent to that in monotherapy. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>After multiple&#8209;dose, IV infusion of
1.2&nbsp;mg/kg brentuximab vedotin every two weeks, maximal serum
concentrations of ADC were observed near the end of the infusion and
elimination exhibited a multi&#8209;exponential decline with a t<sub>1/2z</sub>
of approximately 4&nbsp;to 5&nbsp;days. Maximal plasma concentrations of MMAE
were observed approximately 2&nbsp;days after the end of infusion, and
exhibited a mono&#8209;exponential decline with a t<sub>1/2z </sub>of
approximately 3&nbsp;to 4&nbsp;days.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>After multiple&#8209;dose, IV infusion of
1.2&nbsp;mg/kg brentuximab vedotin every two weeks, steady&#8209;state trough
concentrations of ADC and MMAE were achieved by Cycle&nbsp;3. Once steady-state
was achieved, the PK of ADC did not appear to change with time. ADC
accumulation (as assessed by AUC<sub>14D</sub> between Cycle&nbsp;1 and
Cycle&nbsp;3) was 1.27&#8209;fold. The exposure of MMAE (as assessed by AUC<sub>14D</sub>
between Cycle&nbsp;1 and Cycle&nbsp;3) appeared to decrease with time by
approximately 50%.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The pharmacokinetics of ADCETRIS in
combination with CHP were evaluated in a single phase 3&nbsp;study in 223&nbsp;patients
(SGN35&#8209;014). After multiple-dose IV infusion of 1.8&nbsp;mg/kg ADCETRIS
every 3&nbsp;weeks, the pharmacokinetics of ADC and MMAE were similar to those
of monotherapy.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Distribution</span></u></p>

<p class=Paragraph style='margin-bottom:0in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Paragraph style='margin-bottom:0in'><i><span lang=EN-GB
style='font-size:11.0pt'>In vitro</span></i><span lang=EN-GB style='font-size:
11.0pt'>, </span><span lang=EN-GB style='font-size:11.0pt'>the binding of MMAE
to human serum plasma proteins ranged from 68&#8209;82%. MMAE is not likely to
displace or to be displaced by highly protein-bound medicines. <i>In vitro</i>,
MMAE was a substrate of P&#8209;gp and was not an inhibitor of P&#8209;gp at
clinical concentrations.</span></p>

<p class=Paragraph style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=Paragraph style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>In humans, the mean steady state volume of distribution was
approximately 6&#8209;10&nbsp;L for ADC. Based on population PK estimation the
typical apparent central volume of distribution of MMAE was 35.5&nbsp;L.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Metabolism</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>The ADC is
expected to be catabolised as a protein with component amino acids recycled or
eliminated.</span></p>

<p class=Paragraph style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><i><span lang=EN-GB>In</span></i><span
lang=EN-GB> <i>vivo</i> data in animals and humans suggest that only a small
fraction of MMAE released from </span><span lang=EN-GB>brentuximab vedotin is metabolised.
The levels of MMAE metabolites have not been measured in human plasma. At least
one metabolite of MMAE has been shown to be active <i>in vitro.</i> </span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>MMAE is a
substrate of CYP3A4 and possibly CYP2D6. <i>In vitro</i> data indicate that the
MMAE metabolism that occurs is primarily via oxidation by CYP3A4/5. <i>In vitro</i>
studies using human liver microsomes indicate that MMAE inhibits only CYP3A4/5
at concentrations much higher than was achieved during clinical application.
MMAE does not inhibit other isoforms. </span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>MMAE did not
induce any major CYP450 enzymes in primary cultures of human hepatocytes.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Elimination</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>The ADC is
eliminated by catabolism with a typical estimated CL and half life of 1.5&nbsp;L/day
and 4&#8209;6&nbsp;days respectively. </span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>The elimination
of MMAE was limited by its rate of release from ADC, typical apparent CL and
half life of MMAE was 19.99&nbsp;L/day and 3&#8209;4&nbsp;days respectively. </span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>An excretion
study was undertaken in patients who received a dose of 1.8&nbsp;mg/kg of
brentuximab vedotin. Approximately 24% of the total MMAE administered as part
of the ADC during a brentuximab vedotin infusion was recovered in both urine
and faeces over a 1&#8209;week period. Of the recovered MMAE, approximately 72%
was recovered in the faeces. A lesser amount of MMAE (28%) was excreted in the
urine.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Pharmacokinetics
in special populations</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Population PK analysis showed that baseline
serum albumin concentration was a significant covariate of MMAE clearance. The
analysis indicated that MMAE clearance was 2&#8209;fold lower in patients with
low serum albumin concentrations &lt;3.0&nbsp;g/dL compared with patients with
serum albumin concentrations within the normal range.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Hepatic
impairment</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>A study
evaluated the PK of brentuximab vedotin and MMAE after the administration of
1.2&nbsp;mg/kg of ADCETRIS to patients with mild (Child-Pugh A; n&nbsp;=&nbsp;1),
moderate (Child-Pugh B; n&nbsp;=&nbsp;5) and severe (Child-Pugh C; n&nbsp;=&nbsp;1)
hepatic impairment. Compared to patients with normal hepatic function, MMAE
exposure increased approximately 2.3&#8209;fold (90% CI 1.27&#8209;4.12&#8209;fold)
in patients with hepatic impairment.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Renal
impairment</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>A study
evaluated the PK of brentuximab vedotin and MMAE after the administration of
1.2&nbsp;mg/kg of ADCETRIS to patients with mild (n&nbsp;=&nbsp;4), moderate (n&nbsp;=&nbsp;3)
and severe (n&nbsp;=&nbsp;3) renal impairment. Compared to patients with normal
renal function, MMAE exposure increased approximately 1.9&#8209;fold (90% CI
0.85&#8209;4.21&#8209;fold) in patients with severe renal impairment
(creatinine clearance &lt;&nbsp;30&nbsp;mL/min). No effect was observed in
patients with mild or moderate renal impairment.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Elderly</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The population pharmacokinetics of
brentuximab vedotin were examined from several studies, including data from 380&nbsp;patients
up to 87&nbsp;years old (34&nbsp;patients&nbsp;</span><span lang=EN-GB>&#8805;65&#8209;&lt;&nbsp;75
and 17&nbsp;patients&nbsp;&#8805;75 years of age</span><span lang=EN-GB>). Additionally,
the population pharmacokinetics of brentuximab vedotin in combination with AVD
were examined, including data from 661&nbsp;patients up to 82&nbsp;years old (</span><span
lang=EN-GB>42&nbsp;patients &#8805;&nbsp;65&#8209;&lt;&nbsp;75 and 17&nbsp;patients&nbsp;&#8805;&nbsp;75&nbsp;years
of age). The influence of age on pharmacokinetics was investigated in each
analysis and it was not a significant covariate.</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph'><u><span
lang=EN-GB style='background:yellow'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Paediatric
population</span></i></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The pharmacokinetics of brentuximab vedotin
ADC and MMAE following a 30&#8209;minute intravenous infusion of BV administered
at 1.4&nbsp;mg/kg or 1.8&nbsp;mg/kg given every 3&nbsp;weeks were evaluated in
a phase 1/2&nbsp;clinical trial of 36&nbsp;paediatric patients (7&#8209;17&nbsp;years
of age) with r/r HL and sALCL (children aged 7&#8209;11&nbsp;years, n&nbsp;=&nbsp;12
and adolescents aged 12 to 17&nbsp;years, n&nbsp;=&nbsp;24) (see section&nbsp;5.1).
The C<sub>max</sub> of ADC was typically observed at the end of infusion or the
sampling closest to the end of infusion. A multi-exponential decline in ADC
serum concentrations was observed with a terminal half-life of approximately 4
to 5&nbsp;days. Exposures were approximately dose proportional with a trend
observed for lower ADC exposures at lower ages/ body weights in the study
population. </span></p>

<p class=MsoNormal><span lang=EN-GB style='color:windowtext'>Median ADC AUC in
children and adolescents from this study was approx. 14% and 3% lower than in
adult patients, respectively, while MMAE exposures were 53% lower and 13%
higher, respectively, than in adult patients.</span><span lang=EN-GB
style='color:windowtext'> Median C<sub>max</sub> and AUC of ADC after a single
1.8&nbsp;mg/kg dose were 29.8&nbsp;&micro;g/&nbsp;mL and
67.9&nbsp;&micro;g*day/&nbsp;mL, respectively, in patients &lt;&nbsp;12&nbsp;years
of age and 34.4&nbsp;&micro;g/mL and 77.8&nbsp;&micro;g*day/mL, respectively,
in patients &#8805;&nbsp;12&nbsp;years of age. Median C<sub>max</sub>, AUC, and
T<sub>max</sub> of MMAE after a single 1.8&nbsp;mg/kg dose were
3.73&nbsp;ng/mL, 17.3&nbsp;ng*day/mL, and 1.92 days, respectively, in patients
&lt;&nbsp;12&nbsp;years of age and 6.33&nbsp;ng/mL, 42.3&nbsp;ng*day/mL, and
1.82&nbsp;days, respectively, in patients &#8805;&nbsp;12&nbsp;years of age. </span><span
lang=EN-GB style='color:windowtext'>There was a trend of increased clearance of
brentuximab vedotin in paediatric patients confirmed positive for ADAs. No
patients aged &lt;&nbsp;12&nbsp;years (0 of 11) and 2&nbsp;patients aged
&#8805;&nbsp;12&nbsp;years (2 of 23) became persistently ADA positive.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<h3><span lang=EN-GB>5.3&nbsp;&nbsp;&nbsp;&nbsp; Preclinical safety data</span></h3>

<p class=Paragraph style='margin-bottom:0in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>MMAE has been shown
to have aneugenic properties in an <i>in vivo</i> rat bone marrow micronucleus
study. These results were consistent with the pharmacological effect of MMAE on
the mitotic apparatus (disruption of the microtubule network) in cells.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>The effects of </span><span
lang=EN-GB style='font-size:11.0pt'>brentuximab vedotin on human male and
female fertility have not been studied. However, results of repeat-dose
toxicity studies in rats indicate the potential for brentuximab vedotin to
impair male reproductive function and fertility. Testicular atrophy and
degeneration were partially reversible following a 16&#8209;week treatment-free
period.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoListBullet style='margin-left:0in;text-indent:0in'><span
lang=EN-GB style='font-size:11.0pt'>Brentuximab vedotin caused embryo-foetal
lethality in pregnant female rats. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In nonclinical studies, lymphoid depletion
and reduced thymic weight were observed, consistent with the pharmacologic
disruption of microtubules caused by MMAE derived from brentuximab vedotin.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<h2><span lang=EN-GB style='font-family:"Times New Roman",serif'>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
PARTICULARS</span></h2>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<h3><span lang=EN-GB>6.1&nbsp;&nbsp;&nbsp;&nbsp; List of excipients</span></h3>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB style='color:windowtext'>Citric acid monohydrate </span><span
style='color:windowtext'>(for pH-adjustment)</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB style='color:windowtext'>Sodium citrate dihydrate </span><span
style='color:windowtext'>(for pH-adjustment)</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>&#945;,&#945;&#8209;Trehalose dihydrate</span></p>

<p class=MsoNormal><span lang=EN-GB>Polysorbate 80</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<h3><span lang=EN-GB>6.2&nbsp;&nbsp;&nbsp;&nbsp; Incompatibilities</span></h3>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In the absence of compatibility studies,
this medicinal product must not be mixed with other medicinal products except
those mentioned in section&nbsp;6.6.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<h3><span lang=EN-GB>6.3&nbsp;&nbsp;&nbsp;&nbsp; Shelf life</span></h3>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>4&nbsp;years.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>After reconstitution/dilution, from a
microbiological point of view, the product should be used immediately. However,
chemical and physical in&#8209;use stability has been demonstrated for
24&nbsp;hours at 2&nbsp;</span><span lang=EN-GB>&deg;</span><span lang=EN-GB>C&#8209;8&nbsp;</span><span
lang=EN-GB>&deg;</span><span lang=EN-GB>C.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<h3><span lang=EN-GB>6.4&nbsp;&nbsp;&nbsp;&nbsp; Special precautions for
storage</span></h3>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Store in a
refrigerator (2&nbsp;&deg;C&#8209;8&nbsp;&deg;C). </span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Do not freeze. </span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Keep the vial
in the original carton in order to protect from light.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>For storage
conditions after reconstitution and dilution of the medicinal product, see
section&nbsp;6.3.</span></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<h3><span lang=EN-GB>6.5&nbsp;&nbsp;&nbsp;&nbsp; Nature and contents of
container </span></h3>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Type I glass vial with a butyl rubber
stopper and an aluminium/plastic flip-off seal, containing 50&nbsp;mg powder.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Pack of 1&nbsp;vial. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<h3><a name="OLE_LINK1"><span lang=EN-GB>6.6&nbsp;&nbsp;&nbsp;&nbsp; Special
precautions for disposal and other handling</span></a></h3>

<p class=Default style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>General
precautions</span></u></p>

<p class=Default style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Paragraph style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Procedures for proper handling and disposal of anticancer medicinal
products should be considered. </span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Proper aseptic
technique throughout the handling of this medicinal product should be followed.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Instructions
for reconstitution </span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each single use vial must be reconstituted
with 10.5&nbsp;mL of water for injections to a final concentration of
5&nbsp;mg/&nbsp;mL. Each vial contains a 10% overfill giving 55&nbsp;mg of
ADCETRIS per vial and a total reconstituted volume of 11&nbsp;mL.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Direct the stream toward the wall of the vial
and not directly at the cake or powder. </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Gently swirl the vial to aid dissolution. DO NOT
SHAKE.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The reconstituted solution in the vial is a
clear to slightly opalescent, colourless solution with a final pH of 6.6. </span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The reconstituted solution should be inspected
visually for any foreign particulate matter and/or discolouration. In the event
of either being observed, discard the medicinal product. </span></p>

<p class=Default><u><span lang=EN-GB style='font-size:11.0pt'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Preparation
of infusion solution</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The appropriate amount of reconstituted
ADCETRIS must be withdrawn from the vial(s) and added to an infusion bag
containing sodium chloride 9&nbsp;mg/&nbsp;mL (0.9%) solution for injection in
order to achieve a final concentration of 0.4&#8209;1.2&nbsp;mg/&nbsp;mL
ADCETRIS. The recommended diluent volume is 150&nbsp;mL. The already
reconstituted ADCETRIS can also be diluted into 5% dextrose for injection or
Lactated Ringer's for injection. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Gently invert the bag to mix the solution
containing ADCETRIS. DO NOT SHAKE. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Any portion left in the vial, after
withdrawal of the volume to be diluted, must be disposed of in accordance with local
requirements. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not add other medicinal products to the
prepared ADCETRIS infusion solution or intravenous infusion set. The infusion
line should be flushed following administration with sodium chloride 9&nbsp;mg/&nbsp;mL
(0.9%) solution for injection, 5% dextrose for injection, or Lactated Ringer's
for injection. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Following dilution, infuse the ADCETRIS
solution immediately at the recommended infusion rate. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Total storage time of the solution from
reconstitution to infusion should not exceed 24&nbsp;hours. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Determining
dosage amount:</span></u></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Calculation
to determine the total ADCETRIS dose (mL) to be further diluted (see section&nbsp;4.2):
</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=662
 style='width:496.15pt;margin-left:5.4pt;border-collapse:collapse'>
 <tr>
  <td width=340 style='width:255.15pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>ADCETRIS
  dose (mg/kg)&nbsp;x&nbsp;patient&#8217;s body weight&nbsp;(kg)</span></p>
  </td>
  <td width=321 rowspan=2 style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;=&nbsp;Total ADCETRIS
  dose&nbsp;(mL) to be further diluted</span></p>
  </td>
 </tr>
 <tr>
  <td width=340 style='width:255.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>Reconstituted
  vial concentration&nbsp;(5&nbsp;mg/mL)</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Note: If patient&#8217;s weight is more
than 100&nbsp;kg, the dose calculation should use 100&nbsp;kg. The maximal
recommended dose is 180&nbsp;mg. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Calculation
to determine the total number of ADCETRIS vials needed: </span></i></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=662
 style='width:496.15pt;margin-left:5.4pt;border-collapse:collapse'>
 <tr>
  <td width=340 style='width:255.15pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>Total
  ADCETRIS dose&nbsp;(mL) to be administered</span></p>
  </td>
  <td width=321 rowspan=2 style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;=&nbsp;Number of ADCETRIS vials
  needed</span></p>
  </td>
 </tr>
 <tr>
  <td width=340 style='width:255.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>Total
  volume per vial&nbsp;(10&nbsp;mL/vial)</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Table 19:
Sample calculations for patients receiving the recommended dose of
1.8&nbsp;mg/kg of ADCETRIS for weights ranging from 60&nbsp;kg to 120&nbsp;kg<br>
<br>
</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='margin-left:5.4pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=59 valign=top style='width:44.55pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Patient
  weight (kg)</span></b></p>
  </td>
  <td width=169 valign=top style='width:126.45pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Total
  dose&nbsp;= </span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>patient
  weight multiplied by recommended dose [1.8&nbsp;mg/kg<sup>a</sup>])</span></b></p>
  </td>
  <td width=198 valign=top style='width:148.8pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Total
  volume to be diluted<sup>b</sup>&nbsp;= total dose divided by reconstituted
  vial concentration [5&nbsp;mg/&nbsp;mL])</span></b></p>
  </td>
  <td width=183 valign=top style='width:136.95pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Number
  of vials needed&nbsp;= </span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>total
  volume to be diluted divided by total volume per vial [10&nbsp;mL/vial])</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=59 valign=top style='width:44.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>60&nbsp;kg</span></p>
  </td>
  <td width=169 valign=top style='width:126.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>108&nbsp;mg</span></p>
  </td>
  <td width=198 valign=top style='width:148.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>21.6&nbsp;mL</span></p>
  </td>
  <td width=183 valign=top style='width:136.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>2.16&nbsp;vials</span></p>
  </td>
 </tr>
 <tr>
  <td width=59 valign=top style='width:44.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>80&nbsp;kg</span></p>
  </td>
  <td width=169 valign=top style='width:126.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>144&nbsp;mg</span></p>
  </td>
  <td width=198 valign=top style='width:148.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>28.8&nbsp;mL</span></p>
  </td>
  <td width=183 valign=top style='width:136.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>2.88&nbsp;vials</span></p>
  </td>
 </tr>
 <tr>
  <td width=59 valign=top style='width:44.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>100&nbsp;kg</span></p>
  </td>
  <td width=169 valign=top style='width:126.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>180&nbsp;mg</span></p>
  </td>
  <td width=198 valign=top style='width:148.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>36&nbsp;mL</span></p>
  </td>
  <td width=183 valign=top style='width:136.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>3.6&nbsp;vials</span></p>
  </td>
 </tr>
 <tr>
  <td width=59 valign=top style='width:44.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>120&nbsp;kg<sup>c</sup></span></p>
  </td>
  <td width=169 valign=top style='width:126.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>180&nbsp;mg<sup>
  d</sup></span></p>
  </td>
  <td width=198 valign=top style='width:148.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>36&nbsp;mL</span></p>
  </td>
  <td width=183 valign=top style='width:136.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>3.6&nbsp;vials</span></p>
  </td>
 </tr>
</table>

<p class=Paragraph style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.25in;text-indent:-.25in;page-break-after:avoid'><span lang=EN-GB
style='font-size:8.0pt'>a.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:9.0pt'>For a reduced dose, use
1.2&nbsp;mg/kg for the calculation.</span></p>

<p class=Paragraph style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.25in;text-indent:-.25in;page-break-after:avoid'><span lang=EN-GB
style='font-size:8.0pt'>b.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:9.0pt'>To be diluted in 150&nbsp;mL
of diluent and administered by intravenous infusion over 30&nbsp;minutes every
3&nbsp;weeks.</span></p>

<p class=Paragraph style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.25in;text-indent:-.25in;page-break-after:avoid'><span lang=EN-GB
style='font-size:8.0pt'>c.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:9.0pt'>If patient&#8217;s
weight is more than 100&nbsp;kg, the dose calculation should use 100&nbsp;kg.</span></p>

<p class=Paragraph style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.25in;text-indent:-.25in'><span lang=EN-GB style='font-size:8.0pt'>d.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:9.0pt'>The maximal recommended
dose is 180&nbsp;mg.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:4.5pt;page-break-after:avoid'><b><span
lang=EN-GB>Table 20: Sample calculations for patients receiving the recommended
dose of 1.2&nbsp;mg/kg of ADCETRIS for weights ranging from 60&nbsp;kg to
120&nbsp;kg as combination therapy or when a reduced dose is required<br>
<br>
</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='margin-left:5.4pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=59 valign=top style='width:44.55pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Patient
  weight (kg)</span></b></p>
  </td>
  <td width=169 valign=top style='width:126.45pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Total
  dose&nbsp;= </span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>patient
  weight multiplied by recommended dose [1.2&nbsp;mg/kg<sup>a</sup>])</span></b></p>
  </td>
  <td width=198 valign=top style='width:148.8pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Total
  volume to be diluted<sup>b</sup>&nbsp;= total dose divided by reconstituted
  vial concentration [5&nbsp;mg/mL])</span></b></p>
  </td>
  <td width=183 valign=top style='width:136.95pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Number
  of vials needed&nbsp;= </span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>total
  volume to be diluted divided by total volume per vial [10&nbsp;mL/vial])</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=59 valign=top style='width:44.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>60&nbsp;kg</span></p>
  </td>
  <td width=169 valign=top style='width:126.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>72&nbsp;mg</span></p>
  </td>
  <td width=198 valign=top style='width:148.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>14.4&nbsp;mL</span></p>
  </td>
  <td width=183 valign=top style='width:136.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>1.44 vials</span></p>
  </td>
 </tr>
 <tr>
  <td width=59 valign=top style='width:44.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>80&nbsp;kg</span></p>
  </td>
  <td width=169 valign=top style='width:126.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>96&nbsp;mg</span></p>
  </td>
  <td width=198 valign=top style='width:148.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>19.2&nbsp;mL</span></p>
  </td>
  <td width=183 valign=top style='width:136.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>1.92 vials</span></p>
  </td>
 </tr>
 <tr style='height:20.4pt'>
  <td width=59 valign=top style='width:44.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:20.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>100&nbsp;kg</span></p>
  </td>
  <td width=169 valign=top style='width:126.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:20.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>120&nbsp;mg</span></p>
  </td>
  <td width=198 valign=top style='width:148.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:20.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>24&nbsp;mL</span></p>
  </td>
  <td width=183 valign=top style='width:136.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:20.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>2.4 vials</span></p>
  </td>
 </tr>
 <tr>
  <td width=59 valign=top style='width:44.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>120&nbsp;kg<sup>c</sup></span></p>
  </td>
  <td width=169 valign=top style='width:126.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>120&nbsp;mg<sup>
  d</sup></span></p>
  </td>
  <td width=198 valign=top style='width:148.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>24&nbsp;mL</span></p>
  </td>
  <td width=183 valign=top style='width:136.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>2.4 vials</span></p>
  </td>
 </tr>
</table>

<p class=Paragraph style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.25in;text-indent:-.25in;page-break-after:avoid'><span lang=EN-GB
style='font-size:8.0pt'>a.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:9.0pt'>For a reduced dose, use
0.9&nbsp;mg/kg for the calculation.</span></p>

<p class=Paragraph style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.25in;text-indent:-.25in;page-break-after:avoid'><span lang=EN-GB
style='font-size:8.0pt'>b.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:9.0pt'>To be diluted in
150&nbsp;mL of diluent and administered by intravenous infusion over
30&nbsp;minutes every 2 weeks as combination therapy or every 3 weeks when a
reduced dose of the monotherapy is required.</span></p>

<p class=Paragraph style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.25in;text-indent:-.25in;page-break-after:avoid'><span lang=EN-GB
style='font-size:8.0pt'>c.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:9.0pt'>If patient&#8217;s
weight is more than 100&nbsp;kg, the dose calculation should use 100&nbsp;kg.</span></p>

<p class=Paragraph style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.25in;text-indent:-.25in;page-break-after:avoid'><span lang=EN-GB
style='font-size:8.0pt'>d.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:9.0pt'>The maximal recommended
dose for combination therapy is 120&nbsp;mg.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Disposal</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>ADCETRIS is for single use only. </span></p>

<p class=MsoNormal><span lang=EN-GB>Any unused product or waste material should
be disposed of in accordance with local requirements.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<h1 align=left style='text-align:left;page-break-after:avoid'><span lang=EN-GB>7.&nbsp;&nbsp; MARKETING
AUTHORISATION HOLDER</span></h1>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Takeda
Pharma A/S</span></p>

<p class=MsoNormal><span lang=DA>Dybendal Alle 10</span></p>

<p class=MsoNormal><span lang=DA>2630 Taastrup</span></p>

<p class=MsoNormal><span lang=DA>Denmark </span></p>

<p class=MsoNormal><span lang=DA>&nbsp;</span></p>

<p class=MsoNormal><span lang=DA>&nbsp;</span></p>

<h1 align=left style='text-align:left;page-break-after:avoid'><span lang=DA>8.&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER </span></h1>

<p class=MsoNormal style='page-break-after:avoid'><span lang=DA>&nbsp;</span></p>

<p class=MsoNormal><span lang=DA>EU/1/12/794/001</span></p>

<p class=MsoNormal><span lang=DA>&nbsp;</span></p>

<p class=MsoNormal><span lang=DA>&nbsp;</span></p>

<h1 align=left style='margin-left:17.85pt;text-align:left;text-indent:-17.85pt;
page-break-after:avoid'><span lang=EN-GB>9.&nbsp;&nbsp; DATE OF FIRST
AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></h1>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Date of first authorisation: 25 October
2012</span></p>

<p class=MsoNormal><span lang=EN-GB>Date of latest renewal: 19 September 2019</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<h1 align=left style='text-align:left;page-break-after:avoid'><span lang=EN-GB>10. DATE
OF REVISION OF THE TEXT</span></h1>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Detailed information on this medicinal
product is available on the website of the European Medicines Agency <a
href="http://www.ema.europa.eu/">http://www.ema.europa.eu</a></span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
style='text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
style='text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
style='text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
style='text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
style='text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
style='text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
style='text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
style='text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
style='text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
style='text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
style='text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
style='text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
style='text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
style='text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
style='text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
style='text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
style='text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
style='text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
style='text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
style='text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
style='text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
style='text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
style='text-transform:uppercase'>&nbsp;</span></p>

<p class=No-numheading3Agency align=center style='margin:0in;text-align:center'><span
lang=EN-GB style='font-family:"Times New Roman",serif;text-transform:uppercase'>Annex
II</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MANUFACTURERS OF THE BIOLOGICAL
ACTIVE SUBSTANCE AND <span style='text-transform:uppercase'>manufacturerS
responsible for batch release </span></span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='text-transform:uppercase'>B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Conditions
or restrictions regarding supply and use</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='text-transform:uppercase'>C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other
conditions and requirements of the marketing authorisation</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='text-transform:uppercase'>D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS
OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL
PRODUCT</span></b><b><span lang=EN-GB> </span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='text-transform:uppercase'>E.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIFIC
OBLIGATION TO COMPLETE POST-AUTHORISATION MEASURES FOR THE CONDITIONAL
MARKETING AUTHORISATION</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=NormalAgency><b><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=TitleB style='page-break-before:always'><span lang=EN-GB>A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MANUFACTURERS
OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURERS RESPONSIBLE FOR BATCH
RELEASE</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><b><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal><u><span lang=EN-GB>Name and address of the manufacturers of
the biological active substance </span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Piramal Healthcare UK Ltd.</span></p>

<p class=MsoNormal><span lang=EN-GB>Earls Road, Grangemouth</span></p>

<p class=MsoNormal><span lang=EN-GB>Stirlingshire, Scotland FK3 8XG</span></p>

<p class=MsoNormal><span lang=EN-GB>United Kingdom</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lonza AG</span></p>

<p class=MsoNormal><span lang=EN-GB>Lonzastrasse</span></p>

<p class=MsoNormal><span lang=EN-GB>3930 Visp</span></p>

<p class=MsoNormal><span lang=EN-GB>Switzerland</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><u><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Name
and address of the manufacturers responsible for batch release</span></u></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Takeda Austria GmbH</span></p>

<p class=MsoNormal><span lang=EN-GB>St. Peter&#8209;Stra&#946;e&nbsp;25</span></p>

<p class=MsoNormal><span lang=PT>A&#8209;4020 Linz</span></p>

<p class=MsoNormal><span lang=PT>Austria</span></p>

<p class=MsoNormal><span lang=PT>&nbsp;</span></p>

<p class=MsoNormal><span lang=PT>Delpharm Novara S.r.l.</span></p>

<p class=MsoNormal>Via Crosa, 86</p>

<p class=MsoNormal><span lang=EN-GB>28065 Cerano (NO)</span></p>

<p class=MsoNormal><span lang=EN-GB>Italy</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The printed package leaflet of the
medicinal product must state the name and address of the manufacturer
responsible for the release of the concerned batch.</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=TitleB><span lang=EN-GB>B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS OR
RESTRICTIONS REGARDING SUPPLY AND USE</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Medicinal
product subject to restricted medical prescription (see Annex I: Summary of
Product Characteristics, section&nbsp;4.2).</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency><b><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif;text-transform:uppercase'>&nbsp;</span></b></p>

<p class=TitleB><span lang=EN-GB>C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:28.35pt;text-indent:-28.35pt;
text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Periodic safety update reports (PSURs) </span></b></p>

<p class=MsoListParagraphCxSpLast style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>The
requirements for submission of PSURs for this medicinal product are set out in
the list of Union reference dates (EURD list) provided for under Article
107c(7) of Directive 2001/83/EC and any subsequent updates published on the
European medicines web-portal.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=TitleB><span lang=EN-GB>D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS OR
RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></p>

<p class=DraftingNotesAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif;color:windowtext'>&nbsp;</span></p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-28.35pt;
text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Risk management plan (RMP)</span></b></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>The marketing
authorisation holder (MAH) shall perform the required pharmacovigilance
activities and interventions detailed in the agreed RMP presented in Module
1.8.2 of the marketing authorisation and any agreed subsequent updates of the
RMP.</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>An updated RMP
should be submitted:</span></p>

<p class=NormalAgency style='margin-left:27.5pt;text-indent:-27.5pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>At
the request of the European Medicines Agency; </span></p>

<p class=NormalAgency style='margin-left:27.5pt;text-indent:-27.5pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Whenever
the risk management system is modified, especially as the result of new
information being received that may lead to a significant change to the benefit/risk
profile or as the result of an important (pharmacovigilance or risk
minimisation) milestone being reached</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=TitleB style='page-break-after:avoid'><span lang=EN-GB>E.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <span
style='text-transform:uppercase'>Specific Obligation to complete
post-authorisation measures for the conditional marketing authorisation</span> </span></p>

<p class=NormalAgency style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;text-transform:
uppercase'>&nbsp;</span></b></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>This
being a conditional marketing authorisation and pursuant to Article 14a(4) of
Regulation (EC) No<span style='layout-grid-mode:line'> 726/2004, the MAH shall
complete, within the stated timeframe, the following measure:</span></span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="98%"
 style='border-collapse:collapse;border:none'>
 <thead>
  <tr>
   <td width="55%" valign=top style='width:55.38%;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-right:-.05pt'><b><span lang=EN-GB>Description</span></b></p>
   </td>
   <td width="44%" valign=top style='width:44.62%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-right:-.05pt'><b><span lang=EN-GB>Due date</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width="55%" valign=top style='width:55.38%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  color:black'>To perform a single&#8209;arm study in a similar patient
  population as the sALCL population investigating response rate, duration of
  response, rate of (second) ASCT and data in subpopulations (including but not
  necessarily restricted to ALK status and age) based on a CHMP agreed protocol
  (Study C25006).</span></p>
  </td>
  <td width="44%" valign=top style='width:44.62%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  color:black'>&nbsp;</span></p>
  <p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  color:black'>Final Study Report by: Q4 2021</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<h1><span lang=EN-GB>ANNEX III</span></h1>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<h1><span lang=EN-GB>LABELLING AND PACKAGE LEAFLET</span></h1>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=TitleA><span lang=EN-GB>A. LABELLING</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>PARTICULARS
TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>OUTER
CARTON</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>ADCETRIS 50&nbsp;mg powder for concentrate
for solution for infusion</span></p>

<p class=MsoNormal><span lang=EN-GB>brentuximab vedotin</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each vial contains 50&nbsp;mg of
brentuximab vedotin</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>After reconstitution each vial contains
5&nbsp;mg/ml of brentuximab vedotin</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Excipients: Ci</span><span lang=EN-GB>tric
acid monohydrate</span><span lang=EN-GB>, s</span><span lang=EN-GB>odium
citrate dihydrate</span><span lang=EN-GB>, </span><span lang=EN-GB>&#945;,&#945;&#8209;</span><span
lang=EN-GB>t</span><span lang=EN-GB>rehalose dihydrate,</span><span lang=EN-GB>
p</span><span lang=EN-GB>olysorbate 80</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:silver'>See package
leaflet for further information</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB style='background:silver'>Powder for
concentrate for solution for infusion</span></i></p>

<p class=MsoNormal><span lang=EN-GB>1&nbsp;vial</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For intravenous use after reconstitution
and dilution </span></p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;border:none;
padding:0in'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep out of the sight and reach of children</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-before:always;border:none;padding:0in'><b><span
lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Store in a refrigerator </span></p>

<p class=MsoNormal><span lang=EN-GB>Do not freeze</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep the vial in the outer carton in order
to protect from light.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;border:none;
padding:0in'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp; SPECIAL PRECAUTIONS FOR
DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH
MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For single use only</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;border:none;
padding:0in'><b><span lang=EN-GB>11.&nbsp;&nbsp;&nbsp; NAME AND ADDRESS OF THE
MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=PT>Takeda Pharma A/S</span></p>

<p class=MsoNormal><span lang=PT>Dybendal Alle 10</span></p>

<p class=MsoNormal><span lang=EN-GB>2630 Taastrup</span></p>

<p class=MsoNormal><span lang=EN-GB>Denmark </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;border:none;
padding:0in'><b><span lang=EN-GB>12.&nbsp;&nbsp;&nbsp; MARKETING AUTHORISATION
NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/12/794/001</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;border:none;
padding:0in'><b><span lang=EN-GB>13.&nbsp;&nbsp;&nbsp; BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;border:none;
padding:0in'><b><span lang=EN-GB>14.&nbsp;&nbsp;&nbsp; GENERAL CLASSIFICATION
FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Medicinal product subject to medical
prescription</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;border:none;
padding:0in'><b><span lang=EN-GB>15.&nbsp;&nbsp;&nbsp; INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;border:none;
padding:0in'><b><span lang=EN-GB>16.&nbsp;&nbsp;&nbsp; INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB style='background:silver'>Justification
for not including Braille accepted</span></i></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER &#8211; 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:silver'>2D barcode
carrying the unique identifier included.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PC: </span></p>

<p class=MsoNormal><span lang=EN-GB>SN: </span></p>

<p class=MsoNormal><span lang=EN-GB>NN:</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><i><span lang=EN-GB style='background:silver'>&nbsp;</span></i></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;border:none;
padding:0in'><b><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON SMALL
IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;border:none;
padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;border:none;
padding:0in'><b><span lang=EN-GB>VIAL LABEL</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;border:none;
padding:0in'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME OF THE
MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>ADCETRIS 50&nbsp;mg powder for concentrate
for solution for infusion</span></p>

<p class=MsoNormal><span lang=EN-GB>brentuximab vedotin</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:silver'>IV use</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;border:none;
padding:0in'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD OF
ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For intravenous use after reconstitution
and dilution </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;border:none;
padding:0in'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;border:none;
padding:0in'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;border:none;
padding:0in'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONTENTS BY
WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>50&nbsp;mg</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;border:none;
padding:0in'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=TitleA><span lang=EN-GB>B. PACKAGE LEAFLET</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>Package
leaflet: Information for the patient</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>Adcetris
50&nbsp;mg powder for concentrate for solution for infusion</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>brentuximab
vedotin</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB><img border=0 width=21 height=18
id="Picture 2"
src="Adcetris-ema-combined-h-2455-en-IB-SOB-C2500_files/image009.gif"
alt="Description: Description: Description: BT_1000x858px"></span><span
lang=EN-GB>This medicine is subject to additional monitoring. This will allow
quick identification of new safety information. You can help by reporting any
side effects you may get. See the end of section 4 for how to report side
effects.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Read all
of this leaflet carefully before you start using this medicine because it
contains important information for you.</span></b></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:avoid'><span lang=EN-GB style='font-family:"Times",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep this leaflet. You may need to read it
again.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt;page-break-after:avoid'><span lang=EN-GB style='font-family:"Times",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you have any further questions, ask your
doctor.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt;page-break-after:avoid'><span lang=EN-GB style='font-family:"Times",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you get any side effects, talk to your
doctor. This includes any possible side effects not listed</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:0in;page-break-after:avoid'><span
lang=EN-GB>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in this
leaflet. See section&nbsp;4.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>What is
in this leaflet</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What Adcetris is and what it
is used for</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What you need to know before
you are given Adcetris</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How Adcetris will be given</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible side effects</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to store Adcetris</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents of the pack and
other information</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoHeading7 style='page-break-after:avoid'><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
Adcetris is and what it is used for</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Adcetris contains the active substance <b>brentuximab
vedotin</b>, an anti-cancer agent, which is made up of a monoclonal antibody
linked to a substance intended to kill cancer cells. This substance is
delivered to cancer cells by the monoclonal antibody. A monoclonal antibody is
a protein which recognises certain cancer cells. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Hodgkin lymphoma, systemic anaplastic large
cell lymphoma and cutaneous T&#8209;cell lymphoma are types of cancer of the
white blood cells.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Classical Hodgkin lymphoma expresses
specific proteins on the cell surface that are different from non-classical
Hodgkin lymphoma. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Adcetris is used to treat patients with advanced
classical Hodgkin lymphoma who have not had treatment before.</span><span
lang=EN-GB> Adcetris will be given to you together with doxorubicin,
vinblastine and dacarbazine which are other chemotherapy medicines used to
treat Hodgkin lymphoma. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Adcetris is used alone to lower the
likelihood of classical Hodgkin lymphoma coming back after an autologous stem
cell transplant in patients with certain risk factors.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Adcetris is also used alone to treat
classical Hodgkin lymphoma that has:</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:"Times",serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>come back after or not responded to an infusion
of your own healthy stem cells into your body (autologous stem cell
transplant), or</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:"Times",serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>come back after or never responded to at least
two previous therapies, and where you cannot receive additional combination
anti-cancer treatments or have an autologous stem cell transplant.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Systemic anaplastic large cell lymphoma is
a type of non&#8209;Hodgkin lymphoma found in your lymph nodes and/or
throughout other parts of your body.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Adcetris is used to treat patients with systemic
anaplastic large cell lymphoma who have not had treatment before.</span><span
lang=EN-GB> Adcetris will be given to you together with </span><span
lang=EN-GB>cyclophosphamide, doxorubicin and prednisone</span><span lang=EN-GB>
which are other chemotherapy medicines used to treat these conditions.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Adcetris is also used to treat systemic
anaplastic large cell lymphoma that has:</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:"Times",serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>not responded to other types of anti-cancer
treatments, or </span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:"Times",serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>come back after previous anti-cancer treatment.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:windowtext;background:yellow'>&nbsp;</span></p>

<p class=MsoNormal><span style='color:windowtext'>Cutaneous T&#8209;cell
lymphoma is a cancer of a certain type of white blood cell called a &#8216;T&#8209;cell&#8217;
that mainly affects the skin. </span><span lang=EN-GB style='color:windowtext'>Adcetris
is used to treat cutaneous T&#8209;cell lymphoma where a specific type of
protein is present on the cells&#8217; surface.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:windowtext'>Adcetris is used
to treat cutaneous T&#8209;cell lymphoma in patients who have previously
received at least one anti-cancer medicine that travels through the
bloodstream.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:17.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoHeading7 style='page-break-after:avoid'><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
you need to know before you are given Adcetris</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Do NOT
use Adcetris if you</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:"Times",serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>are allergic to brentuximab vedotin or any of
the other ingredients of this medicine (listed in section&nbsp;6). </span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:"Times",serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>are currently using bleomycin, an anti-cancer
agent. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Warnings
and precautions</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>When you
first receive this medicine and during the course of treatment, tell your
doctor if you:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:"Times",serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>have confusion, trouble thinking, memory loss,
blurred or loss of vision, decreased strength, decreased control or sensation
in one arm or leg, a change in the way of walking, or loss of balance, as these
may be symptoms of a serious and potentially fatal brain condition known as
progressive multifocal leukoencephalopathy (PML). If you have these symptoms
prior to treatment with this medicine, tell your doctor immediately about any
changes in these symptoms. You should also inform your partner or caregivers
about your treatment, since they may notice symptoms that you are not aware of</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:"Times",serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>have severe and persistent stomach pain, with or
without nausea and vomiting, as these may be symptoms of a serious and
potentially fatal condition known as pancreatitis (inflammation of the
pancreas)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:"Times",serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>have new or worsening shortness of breath or
cough as these may be symptoms of a serious and potentially fatal lung
complication (pulmonary toxicity)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:"Times",serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>are taking, or have previously taken, medicines
which may affect your immune system, such as chemotherapy or immunosuppressive
agents </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:"Times",serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>have, or think you have, an infection. Some
infections may be serious and can be due to viruses, bacteria, or other causes
that may be life-threatening</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:"Times",serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>experience a whistling sound during breathing
(wheezing)/difficulty breathing, hives, itching, or swelling (signs of an
infusion reaction). For more detailed information, see &#8220;Infusion reactions&#8221;
in section 4</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:"Times",serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>have any problems with a change in the
sensitivity of the skin, especially in the hands or feet, such as numbness,
tingling, a burning sensation, pain, discomfort or weakness (neuropathy)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:"Times",serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>have headaches, feel tired, experience dizziness,
look pale (anaemia), or have unusual bleeding or bruising under the skin,
longer than usual bleeding after your blood has been drawn, or bleeding from
your gums (thrombocytopenia) </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:"Times",serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>develop chills or shivering, or feel warm; you
should take your temperature as you may have a fever. A fever with a low white
blood cell count may be a sign of serious infection </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:"Times",serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>experience dizziness, decreased urination,
confusion, vomiting, nausea, swelling, shortness of breath, or heart rhythm
disturbances (this may be a potentially life-threatening complication known as
tumour lysis syndrome)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:"Times",serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>experience flu-like symptoms followed by a
painful red or purplish rash that spreads and blisters including extensive
detachment of the skin that may be life-threatening (this may be a serious skin
reaction known as Stevens-Johnson syndrome and toxic epidermal necrolysis)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:"Times",serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>have new or worsening stomach pain, nausea,
vomiting, constipation as these may be symptoms of a serious and potentially
fatal stomach or intestinal complication (gastrointestinal complications)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:"Times",serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>have abnormal liver test results as this may be
related to a serious and potentially fatal liver injury (hepatotoxicity). Liver
disease and other medical conditions that may have been present before you
start taking Adcetris and some medications that you are currently taking might
increase the risk of liver injury</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:"Times",serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>feel tired, have frequent urination, increased
thirst, increased appetite with unintended weight loss, or irritability
(hyperglycaemia)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:"Times",serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>have kidney or liver problems</span></p>

<p class=MsoListParagraph style='margin-left:31.5pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Your doctor will perform regular blood
tests to make sure that it is safe for you to receive this medicine.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Other
medicines and Adcetris</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Tell your doctor if you are taking any
other medicines, if you have taken any recently, or if you start taking new ones.
This includes herbal medicines and other medicines you can obtain without a
prescription. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Pregnancy,
breast&#8209;feeding and fertility</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>You and your partner must use two methods
of effective contraception during your treatment with this medicine. Women must
continue using contraception for 6&nbsp;months following the last dose of
Adcetris.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>You should not use this medicine if you are
pregnant unless you and your doctor decide that the benefit to you outweighs
the potential risk to the unborn baby. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>It is important to tell your doctor before
and during treatment if you are pregnant, think you may be pregnant, or are
planning to get pregnant.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If you are breast&#8209;feeding, you should
discuss with your doctor whether you should receive this medicine.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Men being treated with this medicine are
advised to have sperm samples frozen and stored before treatment. Men are
advised not to father a child during treatment with this medicine and for up to
6&nbsp;months following the last dose of this medicine. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Driving
and using machines</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Your treatment may influence your ability
to drive or operate machines. If you feel unwell during treatment then do not
drive or operate machines.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Adcetris
contains sodium</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>This medicine
contains 13.2&nbsp;mg sodium (main component of cooking/table salt) in each
vial. This is equivalent to 0.7% of the recommended maximum daily dietary
intake of sodium for an adult</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoHeading7 style='page-break-after:avoid'><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
Adcetris will be given</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If you have any questions on the use of
this medicine, ask the doctor or nurse who is giving you the infusion. </span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Dose and
frequency</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>The dose of
this medicine depends on your body weight. </span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The usual dose of Adcetris given in combination
with </span><span lang=EN-GB>doxorubicin, vinblastine and dacarbazine</span><span
lang=EN-GB> is </span><span lang=EN-GB>1.2&nbsp;mg/kg given every 2&nbsp;weeks
for 6&nbsp;months. </span></p>

<p class=MsoNormal style='margin-left:.25in;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The usual dose of Adcetris given in combination
with cyclophosphamide, doxorubicin and prednisone is </span><span lang=EN-GB>1.8&nbsp;mg/kg
given every 3&nbsp;weeks for approximately 4&#8209;6&nbsp;months.</span><span
lang=EN-GB> </span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>See the package
leaflets for these medicines given in combination with Adcetris for additional
information on their use and effects. After the first dose of Adcetris in
combination with chemotherapy, your doctor may also give you a medicine that
will help prevent development or reduce the severity of neutropenia (decrease
of white blood cell count) which can increase the risk of infection. Tell your
doctor </span><span lang=EN-GB>if you have kidney or liver problems as your
doctor may lower your starting dose or may not recommend Adcetris.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The usual dose of Adcetris given alone is
1.8&nbsp;mg/kg, given once every 3&nbsp;weeks for no more than one year. Your
doctor may lower your starting dose to 1.2&nbsp;mg/kg if you have kidney or
liver problems.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Adcetris is to be given to adults only. It
is not for use in children. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>How
Adcetris is given</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>This medicine is given to you into a vein
(intravenously) as an infusion. It is given by your doctor or nurse over
30&nbsp;minutes. Your doctor or nurse will also monitor you during and after
the infusion. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If you have any other questions on the use
of this medicine, ask your doctor.</span></p>

<p class=MsoNormal style='margin-right:17.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:17.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoHeading7 style='page-break-after:avoid'><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible
side effects </span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Like all medicines, this medicine may cause
side effects, although not everybody gets them. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Infusion
reactions</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Medicines of
this type (monoclonal antibodies) can cause infusion reactions such as:</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:"Times",serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>a rash </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB style='font-family:"Times",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>shortness of breath</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB style='font-family:"Times",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>difficulty breathing</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB style='font-family:"Times",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>cough</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB style='font-family:"Times",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>a tight chest </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB style='font-family:"Times",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>fever</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB style='font-family:"Times",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>back pain</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt;page-break-after:avoid'><span lang=EN-GB style='font-family:"Times",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>chills</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt;page-break-after:avoid'><span lang=EN-GB style='font-family:"Times",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>headache</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:"Times",serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>feeling sick (nausea) or being sick (vomiting).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Infusion
reactions to this medicine may affect more than 1 in 10&nbsp;people. </span></p>

<p class=MsoDate style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In general, these types of reactions occur
within minutes to several hours following completion of the infusion. However,
they may develop more than several hours after completion of the infusion but
this is uncommon. These infusion reactions can be serious or even fatal (known
as an anaphylactic reaction). It is not known how frequently infusion-related
reactions to this medicine are serious or fatal. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>You may be given other medicines such as </span></p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:"Times",serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>anti-histamines, corticosteroids or paracetamol </span></p>

<p class=MsoNormal><span lang=EN-GB>to help reduce any of the reactions above
if you have already experienced these when receiving this type of medicine. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If you think you have previously had a
similar reaction, tell your doctor BEFORE you are given this medicine. </span></p>

<p class=MsoNormal><span lang=EN-GB>If you develop infusion reactions (as
stated previously), your doctor may stop giving this medicine and start support
treatment.</span></p>

<p class=MsoNormal><span lang=EN-GB>If your infusion is restarted, your doctor
may increase the time over which your infusion is given so that you may be able
to tolerate it better. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Tell your
doctor straight away if you notice any of the following symptoms because some
of them may be signs of a serious or possibly fatal condition:</span></b></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:"Times",serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>progressive multifocal leukoencephalopathy (PML)
symptoms such as confusion, trouble thinking, memory loss, blurred or loss of
vision, decreased strength, decreased control or sensation in one arm or leg, a
change in the way of walking, or loss of balance (for more detailed
information, see section&nbsp;2) (affects less than 1 in 100&nbsp;people)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB style='font-family:"Times",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>symptoms of inflammation of the pancreas
(pancreatitis) such as severe and persistent stomach pain, with or without
nausea and vomiting (may affect up to 1 in 100&nbsp;people).</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB style='font-family:"Times",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>shortness of breath or cough (may affect more
than 1 in 10&nbsp;people)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB style='font-family:"Times",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>flu-like symptoms followed by a painful red or
purplish rash that spreads and blisters including extensive detachment of the
skin (may affect up to 1 in 100&nbsp;people)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB style='font-family:"Times",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>a change in feeling or sensitivity, especially
in the skin, numbness, tingling, discomfort, a burning sensation, weakness, or
pain in the hands or feet (neuropathy; may affect more than 1 in
10&nbsp;people)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB style='font-family:"Times",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>a feeling of weakness (may affect more than 1 in
10&nbsp;people)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB style='font-family:"Times",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>constipation (may affect more than 1 in
10&nbsp;people)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB style='font-family:"Times",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>diarrhoea, vomiting (may affect more than 1 in
10&nbsp;people)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB style='font-family:"Times",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>chills or shivering (may affect up to 1 in
10&nbsp;people)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB style='font-family:"Times",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>feeling tired, frequent urination, increased
thirst, increased appetite with unintended weight loss, and irritability (these
may be signs of hyperglycaemia, which may affect up to 1 in 10&nbsp;people)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB style='font-family:"Times",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>unusual bleeding or bruising under the skin,
longer than usual bleeding after your blood has been drawn, or bleeding from
your gums (these may be signs of thrombocyopenia which may affect up to 1 in
10&nbsp;people)</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:"Times",serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>headaches, experience dizziness, look pale
(these may be signs of anaemia, which may affect more than 1 in 10&nbsp;people)</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>You may
experience the following side effects:</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The
following side effects have been reported with Adcetris alone:</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;page-break-after:avoid'><b><span
lang=EN-GB>Very common side effects</span></b><span lang=EN-GB> (may affect
more than 1 in 10&nbsp;people)</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:"Times",serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>decreased level of white blood cells</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB style='font-family:"Times",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>upper respiratory tract infection</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB style='font-family:"Times",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>decrease in weight</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB style='font-family:"Times",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>infection</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB style='font-family:"Times",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>nausea</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB style='font-family:"Times",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>abdominal pain</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB style='font-family:"Times",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>itching</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB style='font-family:"Times",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>muscle pain</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:"Times",serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>joint pain or painful, swollen joints</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:.25in;page-break-after:avoid'><b><span
lang=EN-GB>Common side effects</span></b><span lang=EN-GB> (may affect up to 1
in 10&nbsp;people)</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:"Times",serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>pneumonia</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB style='font-family:"Times",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>sore, creamy-yellow, raised patches in the mouth
(thrush)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB style='font-family:"Times",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>decreased level of blood platelets</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB style='font-family:"Times",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>dizziness</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB style='font-family:"Times",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>blisters which may crust or scab</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB style='font-family:"Times",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>increased level of blood sugar</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB style='font-family:"Times",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>increased liver enzyme levels </span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:"Times",serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>unusual hair loss or thinning</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:21.3pt;page-break-after:avoid'><b><span
lang=EN-GB>Uncommon side effects</span></b><span lang=EN-GB> (may affect up to
1 in 100&nbsp;people)</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:"Times",serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Tumour lysis syndrome &#8211; a potentially-life
threatening condition in which you may experience dizziness, decreased
urination, confusion, vomiting, nausea, swelling, shortness of breath, or heart
rhythm disturbances. </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB style='font-family:"Times",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>new or recurring cytomegalovirus (CMV) infection</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB style='font-family:"Times",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>an infection in the blood (sepsis) and/or septic
shock (a life-threatening form of sepsis)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB style='font-family:"Times",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Stevens-Johnson syndrome and toxic epidermal
necrolysis - a rare, serious disorder in which you may experience flu-like
symptoms followed by a painful red or purplish rash that spreads and blisters
including extensive detachment of the skin </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB style='font-family:"Times",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>decreased level of white blood cells with a fever</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:"Times",serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>damage to the nerves and nerve coverings
(demyelinating polyneuropathy)</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The
following side effects have been reported with Adcetris in combination with
chemotherapy medicines:</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;page-break-after:avoid'><b><span
lang=EN-GB>Very common side effects</span></b><span lang=EN-GB> (may affect
more than 1 in 10&nbsp;people)</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:"Times",serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>decreased level of white blood cells</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB style='font-family:"Times",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>decreased level of blood platelets</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB style='font-family:"Times",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>decreased level of white blood cells with a
fever</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB style='font-family:"Times",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>upper respiratory tract infection</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB style='font-family:"Times",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>decrease in weight</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB style='font-family:"Times",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>infection</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB style='font-family:"Times",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>nausea</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB style='font-family:"Times",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>abdominal pain</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB style='font-family:"Times",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>unusual hair loss or thinning</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB style='font-family:"Times",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>muscle pain</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB style='font-family:"Times",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>joint pain or painful, swollen joints</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB style='font-family:"Times",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>dizziness</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB style='font-family:"Times",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>decreased appetite</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB style='font-family:"Times",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>not being able to sleep</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB style='font-family:"Times",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>bone pain</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:"Times",serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>blisters which may crust or scab</span></p>

<p class=MsoNormal style='margin-left:28.35pt'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:.25in;page-break-after:avoid'><b><span
lang=EN-GB>Common side effects</span></b><span lang=EN-GB> (may affect up to 1
in 10&nbsp;people)</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:"Times",serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>an infection in the blood (sepsis) and/or septic
shock (a life-threatening form of sepsis); pneumonia</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB style='font-family:"Times",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>sore or inflammation in the mouth</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB style='font-family:"Times",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>sore, creamy-yellow, raised patches in the mouth
(thrush)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB style='font-family:"Times",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>itching</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB style='font-family:"Times",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>increased level of blood sugar</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:"Times",serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>increased liver enzyme levels</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:21.3pt;page-break-after:avoid'><b><span
lang=EN-GB>Uncommon side effects</span></b><span lang=EN-GB> (may affect up to
1 in 100&nbsp;people)</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:"Times",serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Tumour lysis syndrome &#8211; a potentially-life
threatening condition in which you may experience dizziness, decreased
urination, confusion, vomiting, nausea, swelling, shortness of breath, or heart
rhythm disturbances </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB style='font-family:"Times",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Stevens&#8209;Johnson syndrome - a rare, serious
disorder in which you may experience flu&#8209;like symptoms followed by a
painful red or purplish rash that spreads and blisters including extensive
detachment of the skin </span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:"Times",serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>new or recurring cytomegalovirus (CMV) infection</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:windowtext'>If you are an
older patient (&#8805;&nbsp;65&nbsp;years of age) you may experience serious
adverse events more frequently. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Reporting
of side effects</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If you get any side effects, talk to your
doctor. This includes any possible side effects not listed in this leaflet.</span><span
lang=EN-GB> You can also report side effects directly via <span
style='background:silver'>the national reporting system listed in </span></span><span
lang=EN-GB><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='background:silver'>Appendix V</span></a><a name="_Hlt351112648"></a><a
name="_Hlt351112647"></a></span><span lang=EN-GB>. By reporting side effects
you can help provide more information on the safety of this medicine.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoHeading7 style='page-break-after:avoid'><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to store Adcetris </span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Keep this
medicine out of the sight and reach of children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not use this medicine after the expiry
date which is stated on the vial label and the carton after EXP. The expiry
date refers to the last day of that month. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Unopened vial:</span></b><span
lang=EN-GB> Store in a refrigerator (2&nbsp;&deg;C&#8209;8&nbsp;&deg;C). Do not
freeze.</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep the vial in the original carton in
order to protect from light. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Reconstituted/diluted solution:</span></b><span
lang=EN-GB> </span><span lang=EN-GB>Use immediately or </span><span lang=EN-GB>store
in a refrigerator (2&nbsp;</span><span lang=EN-GB style='font-family:Symbol'>&deg;</span><span
lang=EN-GB>C&#8209;8&nbsp;&deg;C) and use within 24&nbsp;hours.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not use this medicine if you notice any
particulate matter or discolouration prior to administration. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not throw away any medicines via
wastewater or household waste. The doctor or nurse will dispose of this
medicine. These measures will help protect the environment. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoHeading7 style='page-break-after:avoid'><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents
of the pack and other information</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>What
Adcetris contains</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:"Times",serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The active substance is brentuximab vedotin.
Each vial contains 50&nbsp;mg of brentuximab vedotin. After reconstitution each&nbsp;mL
of solution contains </span><span lang=EN-GB>5&nbsp;mg of Adcetris. </span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:"Times",serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The other ingredients are citric acid
monohydrate, sodium citrate dihydrate, &#945;,&#945;&#8209;trehalose dihydrate,
and polysorbate 80 See section&nbsp;2 for further information about sodium. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>What
Adcetris looks like and contents of the pack</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Adcetris is a white to off-white cake or
powder for concentrate for solution for infusion provided in a glass vial. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each pack of Adcetris consists of one vial.
</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><a name="_Hlk19873870"><b><span lang=EN-GB>Marketing
Authorisation Holder</span></b></a></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Takeda Pharma A/S</span></p>

<p class=MsoNormal><span lang=EN-GB>Dybendal Alle 10</span></p>

<p class=MsoNormal><span lang=EN-GB>2630 Taastrup</span></p>

<p class=MsoNormal><span lang=EN-GB>Denmark </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Manufacturer</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='background:silver'>Takeda Austria GmbH</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='background:silver'>St. Peter&#8209;Stra&#946;e&nbsp;25</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=PT
style='background:silver'>A&#8209;4020 Linz</span></p>

<p class=MsoNormal><span lang=PT style='background:silver'>Austria</span></p>

<p class=MsoNormal><span lang=PT>&nbsp;</span></p>

<p class=MsoNormal><span lang=PT>Delpharm Novara S.r.l.</span></p>

<p class=MsoNormal><span lang=IT>Via Crosa, 86</span></p>

<p class=MsoNormal><span lang=EN-GB>28065 Cerano (NO) </span></p>

<p class=MsoNormal><span lang=EN-GB>Italy</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>For any
information about this medicine, please contact the local representative of the
Marketing Authorisation Holder:</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <tr>
  <td width=310 valign=top style='width:232.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-.1pt'><b><span lang=DE
  style='color:windowtext'>Belgi&euml;/Belgique/Belgien</span></b></p>
  <p class=MsoNormal><span lang=DE style='color:windowtext'>Takeda Belgium</span></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
  lang=DE style='color:windowtext'>T&eacute;l/Tel: +32 2 464 06 11</span></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
  lang=EN-GB style='color:windowtext'>takeda-belgium@takeda.com</span><span
  lang=EN-GB style='color:windowtext'> </span></p>
  <p class=MsoNormal><span lang=EN-GB style='color:windowtext'>&nbsp;</span></p>
  </td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
  lang=FI style='color:windowtext'>Lietuva</span></b></p>
  <p class=MsoNormal><span lang=FI style='color:windowtext'>Takeda, UAB</span></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
  lang=FI style='color:windowtext'>Tel: +370 521 09 070</span></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
  lang=FI style='color:windowtext'>lt-info@takeda.com</span></p>
  <p class=MsoNormal><span lang=FI style='color:windowtext'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=310 valign=top style='width:232.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
  style='color:windowtext'>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoPlainText><span lang=EN-GB style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>&#1058;&#1072;&#1082;&#1077;&#1076;&#1072;
  &#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></p>
  <p class=MsoPlainText><span lang=EN-GB style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>&#1058;&#1077;&#1083;.: + 359 2 958 27 36</span></p>
  <p class=MsoNormal><span lang=EN-GB style='color:windowtext'>&nbsp;</span></p>
  </td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE style='color:windowtext'>Luxembourg</span></b><b><span
  lang=DE style='color:windowtext'>/Luxemburg</span></b></p>
  <p class=MsoNormal><span lang=DE style='color:windowtext'>Takeda Belgium</span></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
  lang=DE style='color:windowtext'>T&eacute;l:/Tel: +32 2 464 06 11</span></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
  lang=EN-GB style='color:windowtext'>takeda-belgium@takeda.com<span
  class=MsoHyperlink><span style='color:windowtext'> </span></span></span></p>
  <p class=MsoNormal><span lang=EN-GB style='color:windowtext'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=310 valign=top style='width:232.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
  lang=EN-GB style='color:windowtext'>&#268;esk&aacute; republika</span></b></p>
  <p class=MsoNormal><span lang=EN-GB style='color:windowtext'>Takeda
  Pharmaceuticals </span></p>
  <p class=MsoNormal><span lang=EN-GB style='color:windowtext'>Czech Republic
  s.r.o.</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:windowtext'>Tel: + 420 23<span style='letter-spacing:1.9pt'>4</span>72<span
  style='letter-spacing:1.9pt'>2</span>722 </span></p>
  <p class=MsoNormal><span lang=EN-GB style='color:windowtext'>&nbsp;</span></p>
  </td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
  lang=EN-GB style='color:windowtext'>Magyarorsz&aacute;g</span></b></p>
  <p class=MsoPlainText><span lang=EN-GB style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Takeda Pharma Kft.</span></p>
  <p class=MsoPlainText><span lang=EN-GB style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Tel.: +361 2707030</span></p>
  <p class=MsoNormal><span lang=EN-GB style='color:windowtext'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=310 valign=top style='width:232.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
  lang=EN-GB style='color:windowtext'>Danmark</span></b></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
  lang=EN-GB style='color:windowtext'>Takeda Pharma A/S</span></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
  lang=EN-GB style='color:windowtext'>Tlf: +45 46 77 11 11</span></p>
  <p class=MsoNormal><span lang=EN-GB style='color:windowtext'>&nbsp;</span></p>
  </td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
  lang=FI style='color:windowtext'>Malta</span></b></p>
  <p class=MsoPlainText><span lang=FI style='font-size:11.0pt;font-family:"Times New Roman",serif'>Takeda
  Italia S.p.A.</span></p>
  <p class=MsoPlainText><span lang=EN-GB style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Tel: +39 06 502601</span></p>
  <p class=MsoNormal><span lang=EN-GB style='color:windowtext'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=310 valign=top style='width:232.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  page-break-after:avoid'><b><span lang=DE style='color:windowtext'>Deutschland</span></b></p>
  <p class=MsoPlainText><span lang=DE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Takeda
  GmbH</span></p>
  <p class=MsoPlainText><span lang=DE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Tel:
  +49 (0) 800 825 3325</span></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
  lang=DE style='color:windowtext'>medinfo@takeda.de</span></p>
  <p class=MsoNormal><span lang=DE style='color:windowtext'>&nbsp;</span></p>
  </td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
  lang=SV style='color:windowtext'>Nederland</span></b></p>
  <p class=MsoPlainText><span lang=SV style='font-size:11.0pt;font-family:"Times New Roman",serif'>Takeda
  Nederland bv</span></p>
  <p class=MsoPlainText><span lang=SV style='font-size:11.0pt;font-family:"Times New Roman",serif'>Tel:
  +31 23 56 68 777</span></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
  lang=SV style='color:windowtext'>nl.medical.info@takeda.com</span></p>
  <p class=MsoNormal><span lang=SV style='color:windowtext'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=310 valign=top style='width:232.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
  lang=PT-BR style='color:windowtext'>Eesti</span></b></p>
  <p class=MsoNormal><span lang=PT-BR style='color:windowtext'>Takeda Pharma AS</span></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
  lang=PT-BR style='color:windowtext'>Tel: +372 6177 669</span></p>
  <p class=MsoNormal><span lang=PT-BR style='color:windowtext'>&nbsp;</span></p>
  </td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
  lang=NO-NYN style='color:windowtext'>Norge</span></b></p>
  <p class=MsoNormal><span lang=NO-NYN style='color:windowtext'>Takeda AS</span></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
  lang=NO-NYN style='color:windowtext'>Tlf: +47 6676 3030</span></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
  lang=NO-NYN style='color:windowtext'>infonorge@takeda.com</span></p>
  <p class=MsoNormal><span lang=NO-NYN style='color:windowtext'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=310 valign=top style='width:232.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
  lang=EN-GB style='color:windowtext'>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal><span lang=NO-NYN style='color:windowtext'>TAKEDA </span><span
  lang=EN-GB style='color:windowtext'>&#917;&#923;&#923;&#913;&#931;</span><span
  lang=EN-GB style='color:windowtext'> </span><span lang=EN-GB
  style='color:windowtext'>&#913;</span><span lang=NO-NYN style='color:windowtext'>.</span><span
  lang=EN-GB style='color:windowtext'>&#917;</span></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
  lang=NO-NYN style='color:windowtext'>T</span><span lang=EL style='color:windowtext'>&#951;&#955;</span><span
  lang=EN-GB style='color:windowtext'>: +30 210 6387800</span></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
  lang=DE style='color:windowtext'>gr.info@takeda.com</span></p>
  <p class=MsoNormal><span lang=DE style='color:windowtext'>&nbsp;</span></p>
  </td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
  lang=DE style='color:windowtext'>&Ouml;sterreich</span></b></p>
  <p class=Default><span lang=DE style='font-size:11.0pt;color:windowtext'>Takeda
  Pharma Ges.m.b.H. </span></p>
  <p class=MsoPlainText><span lang=EN-GB style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Tel: +43 (0) 800 20 80 50 </span></p>
  <p class=MsoNormal><span lang=EN-GB style='color:windowtext'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=310 valign=top style='width:232.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
  lang=ES style='color:windowtext'>Espa&ntilde;a</span></b></p>
  <p class=MsoNormal><span lang=ES style='color:windowtext'>Takeda
  Farmac&eacute;utica Espa&ntilde;a S.A</span></p>
  <p class=MsoPlainText><span lang=EN-GB style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Tel: +34 </span><span style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>917 90 42 22</span></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
  lang=EN-GB style='color:windowtext'>spain@takeda.com</span></p>
  <p class=MsoNormal><span lang=EN-GB style='color:windowtext'>&nbsp;</span></p>
  </td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
  lang=PL style='color:windowtext'>Polska</span></b></p>
  <p class=MsoNormal><span lang=PL style='color:windowtext'>Takeda Pharma sp. z
  o.o.</span></p>
  <p class=MsoNormal><span lang=FR style='color:windowtext'>Tel.: + 48 22 608
  13 00</span></p>
  <p class=MsoNormal><span lang=FR style='color:windowtext'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=310 valign=top style='width:232.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
  lang=FR style='color:windowtext'>France</span></b></p>
  <p class=MsoNormal><span lang=FR style='color:windowtext'>Takeda France </span></p>
  <p class=MsoNormal><span lang=EN-GB>T&eacute;l</span><span lang=EN-GB>:</span><span
  lang=FR style='color:windowtext'> +33 1 46 25 16 16</span></p>
  <p class=MsoNormal><span lang=FR style='color:windowtext'>&nbsp;</span></p>
  </td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
  lang=PT-BR style='color:windowtext'>Portugal</span></b></p>
  <p class=MsoPlainText><span lang=PT-BR style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Takeda Farmac&ecirc;uticos Portugal, Lda.</span></p>
  <p class=MsoNormal><span lang=FR style='color:windowtext'>Tel: + 351 21 120
  1457</span></p>
  <p class=MsoNormal><span lang=FR style='color:windowtext'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=310 valign=top style='width:232.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
  style='color:windowtext'>Hrvats</span></b><b><span lang=EN-GB
  style='color:windowtext'>ka</span></b></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
  lang=EN-GB style='color:windowtext'>Takeda Pharmaceuticals Croatia d.o.o.</span></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
  lang=EN-GB style='color:windowtext'>Tel: +385 1 377 88 96</span></p>
  <p class=MsoNormal><span lang=EN-GB style='color:windowtext'>&nbsp;</span></p>
  </td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='color:windowtext'>Rom&acirc;nia
  </span></b></p>
  <p class=MsoNormal><span lang=EN-GB style='color:windowtext'>Takeda
  Pharmaceuticals SRL</span></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
  lang=EN-GB style='color:windowtext'>Tel: +40 21 335 03 91</span></p>
  <p class=MsoNormal style='text-indent:28.35pt'><span lang=EN-GB
  style='color:windowtext'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=310 valign=top style='width:232.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
  lang=EN-GB style='color:windowtext'>Ireland</span></b></p>
  <p class=MsoNormal><span lang=EN-GB style='color:windowtext'>Takeda Products
  Ireland Limited</span></p>
  <p class=MsoNormal><span lang=EN-GB style='color:windowtext'>Tel: +44 (0)1628
  537 900</span></p>
  <p class=MsoNormal><span lang=EN-GB style='color:windowtext'>&nbsp;</span></p>
  </td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
  lang=NO-NYN style='color:windowtext'>Slovenija</span></b></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
  lang=NO-NYN style='color:windowtext'>Takeda GmbH, Podru&#382;nica Slovenija</span></p>
  <p class=MsoNormal><span lang=NO-NYN style='color:windowtext'>Tel: + 386 (0)
  59 082 480</span></p>
  </td>
 </tr>
 <tr>
  <td width=310 valign=top style='width:232.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
  lang=EN-GB style='color:windowtext'>&Iacute;sland</span></b></p>
  <p class=MsoNormal><span lang=EN-GB style='color:windowtext'>Vistor hf. </span></p>
  <p class=MsoNormal><span lang=EN-GB>S&iacute;mi:</span><span lang=EN-GB
  style='color:windowtext'> +354 535 7000</span></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
  lang=EN-GB style='color:windowtext'>vistor@vistor.is</span></p>
  <p class=MsoNormal style='text-indent:28.35pt'><span lang=EN-GB
  style='color:windowtext'>&nbsp;</span></p>
  </td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
  lang=EN-GB style='color:windowtext'>Slovensk&aacute; republika</span></b></p>
  <p class=MsoNormal><span lang=EN-GB style='color:windowtext'>Takeda
  Pharmaceuticals Slovakia s.r.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='color:windowtext'>Tel: +421 (2) 20
  602 600</span></p>
  <p class=MsoNormal><span lang=EN-GB style='color:windowtext'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='color:windowtext'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=310 valign=top style='width:232.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoPlainText style='page-break-after:avoid'><b><span lang=ES
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Italia </span></b></p>
  <p class=MsoPlainText><span lang=ES style='font-size:11.0pt;font-family:"Times New Roman",serif'>Takeda
  Italia S.p.A.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='color:windowtext'>Tel: +39 06
  502601</span></p>
  </td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
  lang=SV style='color:windowtext'>Suomi/Finland</span></b></p>
  <p class=MsoNormal><span lang=SV style='color:windowtext'>Takeda Oy</span></p>
  <p class=MsoNormal><span lang=SV>Puh/Tel:</span><span lang=SV
  style='color:windowtext'> +358 20 746 5000</span></p>
  <p class=MsoNormal><span lang=EN-GB style='color:windowtext'>infoposti@takeda.com</span></p>
  <p class=MsoNormal><span lang=EN-GB style='color:windowtext'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=310 valign=top style='width:232.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
  lang=EN-GB style='color:windowtext'>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:windowtext'>A. POTAMITIS MEDICARE LTD</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:windowtext'>T&#951;&#955;: +357 22583333</span></p>
  <p class=MsoNormal><span lang=LV style='color:windowtext'>info@potamitismedicare.com</span></p>
  <p class=MsoNormal><span lang=LV style='color:windowtext'><a
  href="mailto:info@potamitismedicare.com"></a></span></p>
  <p class=MsoNormal><span lang=EN-GB style='color:windowtext'>&nbsp;</span></p>
  </td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
  lang=SV style='color:windowtext'>Sverige</span></b></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
  lang=SV style='color:windowtext'>Takeda Pharma AB</span></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
  lang=SV style='color:windowtext'>Tel: +46 8 731 28 00</span></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
  lang=EN-GB style='color:windowtext'>infosweden@takeda.com</span></p>
  <p class=MsoNormal style='text-indent:28.35pt'><span lang=EN-GB
  style='color:windowtext'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=310 valign=top style='width:232.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  page-break-after:avoid'><b><span lang=FI style='color:windowtext'>Latvija</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=FI
  style='color:windowtext'>Takeda Latvia SIA</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=FI
  style='color:windowtext'>Tel: +371 67840082</span></p>
  <p class=MsoNormal style='text-indent:28.35pt;page-break-after:avoid'><span
  lang=FI style='color:windowtext'>&nbsp;</span></p>
  </td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  page-break-after:avoid'><b><span lang=EN-GB style='color:windowtext'>United
  Kingdom</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:windowtext'>Takeda UK Ltd</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:windowtext'>Tel: +44 (0)1628 537 900</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:windowtext'>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>This
leaflet was last revised in</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>This medicine
has been given &#8216;conditional approval&#8217;. This means that there is
more evidence to come about this medicine.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>The European
Medicines Agency will review new information on this medicine at least every
year and this leaflet will be updated as necessary.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Detailed information on this medicine is
available on the European Medicines Agency website: </span><u><span lang=EN-GB
style='color:blue'>http://www.ema.europa.eu/</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>----------------------------------------------------------------------------------------------------------------------</span></p>

<p class=MsoNormal><span lang=EN-GB>The following information is intended for
healthcare professionals only:</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Traceability</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>In order to
improve the traceability of biological medicinal products, the name and the
batch number of the administered product should be clearly recorded.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Disposal </span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Adcetris is for single use only. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Any unused product or waste material should
be disposed of in accordance with local requirements.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Instructions
for reconstitution </span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each single use vial must be reconstituted
with 10.5&nbsp;mL of water for injections to a final concentration of
5&nbsp;mg/mL. Each vial contains a 10% overfill giving 55&nbsp;mg of Adcetris
per vial and a total reconstituted volume of 11&nbsp;mL.</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Direct the stream toward the wall of the vial
and not directly at the cake or powder. </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Gently swirl the vial to aid dissolution. DO NOT
SHAKE. </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The reconstituted solution in the vial is a
clear to slightly opalescent, colourless solution with a final pH of 6.6. </span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The reconstituted solution should be inspected
visually for any foreign particulate matter and/or discolouration. In the event
of either being observed, discard the medicinal product.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Preparation
of Infusion Solution</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The appropriate amount of reconstituted
Adcetris must be withdrawn from the vial(s) and added to an infusion bag
containing sodium chloride 9&nbsp;mg/mL (0.9%) solution for injection in order
to achieve a final concentration of 0.4&#8209;1.2&nbsp;mg/mL Adcetris. The
recommended diluent volume is 150&nbsp;mL. The already reconstituted Adcetris
can also be diluted into 5% dextrose for injection or Lactated Ringer's for
injection. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Gently invert the bag to mix the solution
containing Adcetris. DO NOT SHAKE. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Any portion left in the vial, after
withdrawal of the volume to be diluted, must be disposed of in accordance with
local requirements. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not add other medicinal products to the
prepared Adcetris infusion solution or intravenous infusion set. The infusion
line should be flushed following administration with sodium chloride
9&nbsp;mg/mL (0.9%) solution for injection, 5% dextrose for injection, or
Lactated Ringer's for injection. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Following dilution, infuse the Adcetris
solution immediately at the recommended infusion rate. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Total storage time of the solution from
reconstitution to infusion should not exceed 24&nbsp;hours.</span></p>

</div>

</body>

</html>
